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7 Thesis Abstract 
Introduction 
The concept of this thesis was driven by stagnation within the Irish healthcare system. 
Multiple reports from pharmacy organisations had outlined possible future directions 
for the profession but progress was minimal, especially in comparison with other 
countries.  The author’s directive was to evaluate the economic impact of a series of 
clinical pharmacy services (CPS) in hospital and community settings.  
Methods 
A systematic review of economic evaluations of clinical pharmacy services in hospital 
patients was undertaken to gain insight into recent research in the field. Eligible studies 
were evaluated using the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS), to establish the quality, consistency and transparency of 
relevant research.  
A retrospective analysis of an internal hospital pharmacy interventions database was 
conducted. A method first described by Nesbit et al. was implemented to estimate the 
level of cost avoidance achieved.  
A cost-effectiveness analysis based on data from a randomised controlled trial of a 
pharmacist-supervised patient self-testing (PST) of warfarin therapy is presented. 
Outcome measure was the incremental cost associated with six months of intervention 
management.  
A similar cost-effectiveness analysis based on previously published RCT data was 
used to evaluate a novel structured pharmacist review of medication in older 
hospitalised patients. Cost-effectiveness analysis was presented in the form of an 
incremental cost-effectiveness ratio (ICER). An ICER is an additional cost per unit 
xv 
 
effect, in the case of this study, the cost of preventing an additional non-trivial ADR 
in hospital. 
A method described by Preaud et al. was adapted to estimate the clinical and economic 
benefit gained from vaccination of patients by a community pharmacist in Ireland in 
2013/14. Sample demographic data was obtained from a national chain of community 
pharmacies and applied to overall national vaccination data.  
Results 
Systematic review identified twenty studies which were eligible for inclusion. Overall, 
pharmacist interventions had a positive impact on hospital budgets. Only three studies 
(15%) were deemed to be “good-quality” studies. No ‘novel’ clinical pharmacist 
intervention was identified during the course of this review.   
 
Analysis of internal hospital database identified 4,257 interventions documented on 
2,147 individual patients over a 12 month period.  Substantial cost avoidance of 
€710,000 was generated over a 1 year period from the perspective of the health care 
provider. Mean cost avoidance of €166 per intervention was generated. The cost of 
providing these interventions was €82,000. Substantial net cost-benefits of €626,279 
and a cost-benefit ratio of 8.64 : 1 were generated based on this evaluation of 
pharmacist interventions. 
 
Results from an evaluation of a novel pharmacist-led form of warfarin management 
indicated indicated that on a per patient basis, PST was slightly more expensive than 
established anticoagulant management. On a per patient basis over a six month period, 
PST resulted in an incremental cost of €59.08 in comparison with routine care. Overall 
cost of managing a patient through pharmacist-supervised PST for a six month period 
xvi 
 
is €226.45. However, for this increase in cost a clinically significant improvement in 
care was provided. Patients achieved a significantly higher time in therapeutic range 
during the PST arm in comparison with routine care, (72 ± 19.7% vs 59 ± 13.5%).     
Difference in overall cost was minimal and PST was the dominant strategy in some 
scenarios examined during sensitivity analysis. 
 
Structured pharmacist review of medication was determined to be dominant in 
comparison to usual pharmaceutical care. Even if the healthcare payer was unwilling 
to pay any money for the prevention of an ADR, the intervention strategy is still likely 
to be cost-effective (probability of being determined cost-effective = 0.707).  
 
Implementation of pharmacist-led influenza vaccination has resulted in substantial 
clinical and economic benefits to the healthcare system. The majority of patients 
(64.9%) who availed of this service had identifiable influenza-related risk factors. Of 
patients with influenza-related risk factors, age ≥65 year was the most commonly cited 
risk factor. Pharmacist vaccination services averted a total of  848 influenza cases 
across all age groups during the 2013/2014 influenza season. Due to receipt of 
vaccination in a pharmacy setting, 444 influenza-related GP visits were prevented. In 
terms of more serious influenza-associated events, 11 hospitalisations and five 
influenza-related deaths were averted. Costs averted were approximately €305,000. 
These were principally wider societal-related costs associated with lost productivity. 
Conclusion 
Overall, clinical pharmacy services are adding value to the Irish healthcare system in 
both hospital and community settings, but provision of additional funding for new 
services would enable them to offer a great deal more. 
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1 - Chapter 1: Thesis Introduction 
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1.1 Introduction 
This concept of this thesis was driven by stagnation within the Irish healthcare system. 
Multiple reports and pharmacy organisations had outlined possible future directions 
for the profession but progress was minimal, especially in comparison with other 
countries.  The author’s directive was to evaluate the economic impact of a series of 
clinical pharmacy services (CPS). The economic focus of this thesis had two primary 
stimuli. In essence, these proposed services had clinical evidence to support them but 
policy decisions in a modern healthcare service require economic evaluation. 
Furthermore, the Irish healthcare system and pharmacy services in particular had been 
the target of significant reductions in expenditure in the years directly preceding the 
commencement of this thesis. Therefore, resources are scarce and any potential 
services require a comprehensive economic evaluation to inform decisions 
surrounding their adoption.  
 
This research focused on providing evidence for policy makers on a range of CPS 
which had been proposed for introduction or recently introduced as a pharmacy service 
at a national level. Due to the nature of the question, the research has a quantitative 
focus consisting of a systematic review and four separate service evaluations.  Service 
evaluations were in both community and hospital pharmacy settings. Three of the 
chapters had a hospital setting for the research. A systematic review focusing on 
economic outcomes of pharmacist interventions on hospital inpatients acts as an 
introduction for chapters investigating the impact of  pharmacist clinical interventions 
on hospital inpatients. The remaining chapters of the thesis are composed of economic 
evaluations of community pharmacy based services namely pharmacist-led warfarin 
monitoring and influenza vaccination services.   
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This chapter will provide some background and context to the current status of 
pharmacy services in Ireland. An overview of the Irish healthcare service, its current 
status and future issues, will also be described. In addition, the state of pharmacy 
services at an international level will be furnished to inform the reader of the overall 
state of CPS and the extent and limitations of its scope. The development of health 
economics and its importance in setting health policy will be discussed. Finally, this 
chapter will describe why we feel this research is worth undertaking and outline the 
aims and objectives associated with this thesis.  
 
1.2 Background 
1.2.1 Clinical Pharmacy Services 
Pharmacy is currently undergoing a paradigm shift from a “product focused to a 
patient focused” profession [1]. The traditional focus of a pharmacist was ensuring the 
patient receives the correct medication prescribed by a physician. While this role 
remains an integral part of pharmacy practice, advances in global healthcare systems 
are such that the primary focus of modern pharmacists should be directed towards 
medication optimisation. It is more of a broader focus than the traditional role, a role 
which should benefit the patient while also being more rewarding for the professional. 
Whilst the concept that pharmacists should perform a role outside of preparing and 
dispensing medications has been promoted for over 40 years [2], transformation of the 
profession is far from complete.  
The concept of clinical pharmacy originated in the United States (US) in the mid-20th 
century. Initial developments included the gradual increase in number of pharmacists 
employed by hospitals, the establishment of drug information centres, clinical 
pharmacokinetic monitoring and early methods of drug therapy management [2]. 
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Developments in Ireland have been largely influenced by progress in the United 
Kingdom (UK) and US and we are still striving to compare with pharmacy systems in 
place in these countries.   
 
Due to the organic development of the concept of clinical pharmacy, there is no 
universal definition as to what clinical pharmacy entails. Numerous pharmacy 
representative bodies have tried to develop an all-encompassing definition but the true 
meaning of the term is still debated. The  American College of Clinical Pharmacy 
(ACCP) definition of clinical pharmacy has proposed the following unabridged 
definition [3],  
“Clinical pharmacy is defined as that area of pharmacy concerned with the science 
and practice of rational medication use.” 
As all interventions assessed in this thesis have been carried in a European setting, the  
European Society of  Clinical Pharmacy (ESCP) [4] definition will be employed 
during the course of this thesis, unless otherwise stated. This group defines clinical 
pharmacy as the following, 
“It is a health specialty, which describes the activities and services of the clinical 
pharmacist to develop and promote the rational and appropriate use of medicinal 
products and devices. 
Clinical Pharmacy includes all the services performed by pharmacists practising in 
hospitals, community pharmacies, nursing homes, home-based care services, clinics 
and any other setting where medicines are prescribed and used.” 
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The confusion is compounded by the existence of another related concept, 
“pharmaceutical care”. Pharmaceutical care as defined by Hepler and Strand is the 
responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a patient's quality of life [5]. Unfortunately, they have almost become 
rival theories when in fact they should be viewed as complementary methods of patient 
management. Neither definition fully articulates the potential of a pharmacist but the 
two interlinking concepts provide a useful starting point in the description. During the 
course of this thesis, the author will predominantly use the term clinical pharmacy as 
it is the most widely established term [6].  
Bodies may differ in terms of their definition of clinical pharmacy; however objectives 
associated with it are shared. Exponents of clinical pharmacy attempt to combine a 
caring orientation with therapeutic expertise, experience and clinical judgement for 
the overall benefit of their patients. In addition to optimising patient therapy, clinical 
pharmacists should also have a public health role in the promotion of health wellness 
and disease prevention [3]. The term ‘clinical’ does not entail that the practice is 
confined to a hospital setting. Clinical pharmacy is equally as vital in primary care.  
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1.2.2 Clinical Pharmacy Services in Ireland 
Since its foundation in 2003, School of Pharmacy, University College Cork (UCC) 
has been prominent in the development of clinical pharmacy services from an Irish 
and global perspective. It has proven the valuable clinical impact that pharmacist 
interventions can have on a diverse range of healthcare outcomes in both community 
and hospital settings [7, 8]. However, despite proving the clinical benefit of additional 
pharmacy services, these services have not yet been implemented on a widespread 
basis. Transformation within a complex health system is never straightforward; but 
the adoption of clinical pharmacy services within the Irish healthcare system is slow.  
In order to facilitate the more widespread adoption of additional clinical pharmacy 
services, economic data is a fundamental requirement. Services such as medication 
use reviews (MUR) and minor ailments schemes (MAS) have been established in 
England, Scotland and even Northern Ireland [9, 10]. However, similar services have 
not been implemented in Ireland.  
 
Previously, the development of pharmacy as a profession in Ireland was hampered by 
a shortage of qualified professionals [9]. The formation of two additional Schools of 
Pharmacy in the State in 2002 and 2003 has created a critical mass of newly qualified 
pharmacy graduates available to implement additional clinical pharmacy services in 
all sectors. Furthermore, the emergence of a number of postgraduate training courses 
has further enhanced the overall knowledge and capabilities of Irish pharmacists.  
 
The landmark “Pharmacy 2020” report published in 2008 outlined the vision of the 
Pharmaceutical Society of Ireland (PSI) for the development of pharmacy services in 
Ireland [9]. The services outlined in this report are easily achievable and have been 
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implemented in many other settings but almost a decade later, the majority of the 
objectives in the report have yet to be realised.  
However, it must be acknowledged from the outset that the production of this report 
approximately coincided with a major financial crisis in Ireland [11]. Between 2008 
and 2015, public expenditure on health was reduced by 9%. These savings were 
achieved through reductions in pharmaceuticals and human resources, increased 
productivity and health system revision [11]. During this period of austerity and 
declining healthcare budgets, the Irish public health system was required to cope with 
additional demands due to a growing, ageing population with a higher burden of 
chronic disease [12] Therefore, any improvement in pharmacy services since the onset 
of the financial crash in Ireland would have been difficult to achieve.  
 
In order to provide initial employment and a viable and progressive career path for the 
graduates of the three Schools of Pharmacy, it is imperative that the additional 
pharmacy services outlined in the “Pharmacy 2020” report are finally implemented. 
Furthermore, the development of pharmacy services in Ireland, can help the 
government achieve its stated goal of providing a healthcare system which is more 
focused on providing care in a community setting  [13].    
1.2.3 Current status of hospital pharmacy in Ireland 
Despite being at the forefront of the development of clinical pharmacy services, 
hospital pharmacy remains fastened to a “production-based culture” rather than a 
“patient-based culture” [14]; this is still the situation for many hospitals in Ireland. 
The traditional dispensary based functions account for a large part of a pharmacist’s 
working day. Clinical services remain very much secondary to dispensing functions.  
The International Pharmaceutical Federation (FIP) has developed the Basel 
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Statements, which outline the goals and objectives for the future development of 
hospital pharmacy. The primary aim of the statements is to ensure that hospital 
pharmacists are in a position to optimize patient outcomes through the judicious, safe, 
efficacious, appropriate and cost-effective use of medicines [15]. The implementation 
of these goals in Ireland is variable. 
 
A study on the status of hospital pharmacy commissioned by the PSI was published in 
2012 [16]. This baseline study gives an accurate reflection of the workings of hospital 
pharmacy in Ireland at the time when this thesis was commenced. An overview of the 
workforce, systems, services, potential and limitations demonstrated throughout the 
country is described. On the surface, Irish hospital pharmacy appears to be in a 
robustly healthy state. It is only when one delves deeper into the report that the 
problems within the system become apparent.  
 
Pharmacist staff numbers in hospital compare favourably to most other European 
countries. Approximately 1.8 pharmacists are employed for every 100 hospital beds. 
In terms of this indicator Ireland is ahead of the majority of European countries 
(average 0.9 pharmacists/100 beds) [17]. However, it is still lower than US and UK 
staffing levels [17]. A Health Service Executive (HSE) (primary provider of health 
services in Ireland), recruitment embargo has placed additionally pressure on 
resources, due to a disproportionately high number of staff who have taken maternity 
leave during the embargo period [16]. This embargo was as a result of financial 
pressures in due to a series of austerity budgets outlined previously. Pharmacy staff 
employed at hospital level are highly qualified; more than 40% of the workforce has 
completed Masters level postgraduate qualifications. As an overall workforce, they 
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have significant experience; over 70% have five years or more experience in a hospital 
setting [16]. Pharmacists surveyed had positive views on their relationship with other 
members of the hospital team and feel they are appreciated by other professions. 
 
All hospitals surveyed performed core dispensary services [16]. Most operate a 
centralised dispensary service, however individualised patient dispensing still occurs. 
Pharmacists felt that clinical pharmacy services could be improved with additional 
resources. While many hospitals had established medicines reconciliation and ward 
based interventions, they were largely confined to specific wards within a hospital 
rather than being a universal service [16].  
 
Considering the knowledge accrued of the system due to their lengthy employment 
within a hospital setting and post-graduate qualifications of the current cohort of 
hospital pharmacists, if additional roles were opened up, training requirements or 
education would be minimal. As the vast majority of pharmacists in the Irish system 
have greater than five years of employment (71.3%), it would be a considerable 
setback if this expertise was to be lost [16]. Enhanced roles which hospital pharmacists 
feel they could adequately fulfil include medicines reconciliation, outpatient 
antimicrobial treatment, structured patient medication review and discharge, 
specialising in a therapeutic area and integration into a multidisciplinary team. 
 
1.2.4 Current status of community pharmacy in Ireland 
The pivotal Health Act (1970) ended the antiquated dispensary based system and was 
the foundation of the current primary care system in Ireland, which is principally based 
on General Practitioners (GPs) and community pharmacists. The General Medical 
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Services (GMS) scheme followed in 1972, providing vulnerable members of society 
with free access to primary care services. The GMS scheme is the national public (tax-
funded) health insurance programme [13]. Eligibility is primarily determined on the 
basis of income based means testing. Most people who qualify are low-income, and 
due to differing means thresholds, the majority of people aged over 70 years also 
qualify. Altogether, approximately 40% of the Irish population qualifies for the GMS 
scheme. Because everyone in the state is entitled to free or subsidised hospital care, 
the main benefit of the GMS scheme is free primary care inclusive of GP visits and 
access to prescription medicines (subject to minimal co-payments). Prior to 1970, a 
system was in place whereby district doctors were responsible for both prescribing 
and dispensing medication to patients. The onset of the GMS scheme and the 
significant increase in new medications from the pharmaceutical industry, transformed 
the everyday practice of pharmacy in Ireland.  
 
A barrier to the development of clinical pharmacy services in recent years has been 
the deterioration of the relationship of pharmacists and representative bodies with the 
state to the point where it has almost become adversarial. The community pharmacy 
– state network is a complex one. Although community pharmacies in Ireland are 
independent businesses, they in effect have a single customer, the HSE. Without a 
contract to provide medication under state schemes, it would be exceptionally 
difficult for a business to remain viable [18]. 
 
Community pharmacists derive the vast majority of their income from reimbursement 
for items dispensed under state run drug schemes, €345 million in 2011 [19]. 
Therefore, the HSE has a transcendent influence on the operation of community 
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pharmacy in Ireland. A series of unilateral reductions in reimbursement fees and 
medicine prices has threatened the continued viability of the community pharmacy 
sector in Ireland. Reductions to pharmacy income can be summarised as follows: 
Table  
Date Reason for reduction Influence on pharmacy 
income 
July 2009 Financial Emergency 
Measures in the Public 
Interest (FEMPI) 
8.8% due to a reduction in 
professional fees to 
healthcare professionals. 
February 2010 Framework agreement 
between the Irish 
Pharmacuetical 
Healthcare Association  
(IPHA) and the DOH 
and HSE on the supply, 
terms, conditions and 
prices of medicines 
4.3%, reduction in cost 
price of medications 
October 2010 Association of 
Pharmaceutical 
Manufacturers of 
Ireland (APMI) 
agreement 
6.2% reduction in cost 
price of generic 
medications 
June 2011 FEMPI 2011 1.3%, reduction in 
retail/wholesale mark ups 
and reduction in patient 
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care fees for items 
dispensed under High Tech 
schemes. 
 
June 2013 FEMPI 2013 2.4%, removal of mark-up 
on Drugs Payment Scheme 
(DPS) and Long-Term 
Illness (LTI) schemes. 
 
 
 
Competition between pharmacies has also increased. In 2001 the number of 
pharmacies in Ireland was approximately 1200 [18]. By December 2014, this number 
had increased to 1848 [20]. Ireland has the fourth highest number of pharmacies per 
head of capita amongst Organisation for Economic Co-operation and Development 
(OECD) countries [21]. Average net profit is reported at 6% in 2012 [22], making the 
viability of a number of businesses questionable especially if new services are not 
implemented. Regardless, consolidation within the pharmacy sector is probably 
inevitable, but remaining pharmacies should be stronger, better staffed and better able 
to implement additional clinical pharmacy services.  
 
Pharmacists have a desire to broaden the range of services provided but are realistic 
regarding what can be achieved. At present, enhanced services in an Irish setting are 
very much provided on an ad-hoc basis and generally only to private patients who are 
able to afford to pay for the cost of services. Considering in 2014, 39% of the 
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population were considered eligible for a medical card under the GMS [23]; this 
considerably reduces the number of patients who can avail of these services. 
Furthermore, medical card patients have a higher proportion of older and more 
vulnerable patients and would have most to gain from the provision of additional 
services [24]. 
 
Similar to the discussion on hospital pharmacy, the PSI commissioned a report on the 
status of community pharmacy in Ireland at the outset of this thesis [25]. The majority 
(76%) of community pharmacists would like to see enhanced services in a community 
setting. Services which pharmacists favoured included; health promotion programmes, 
screening, diagnostic and monitoring services, blood sugar / cholesterol testing and 
international normalized ratio (INR) monitoring [25]. Some pharmacists did not want 
to facilitate these services and were of the opinion that core pharmacy services 
(dispensing and counselling) are the staple work of a community pharmacist and 
should retain priority focus. However, a consensus was visible based on pharmacists 
interviewed as part of the PSI report indicating that two key services would be 
worthwhile pursuing; namely medicine use reviews  and a minor ailment scheme  [25].  
 
There is no clear vision for the future of pharmacy in Ireland. Under-appreciation and 
underutilisation is a common theme for both community and hospital pharmacists.  
Despite some advances in the provision of clinical pharmacy services over the past 
few years, the perception remains that these have been isolated events and there is no 
overall plan for how pharmacy should be developed and where it should fit within the 
delivery of healthcare services to patients [25].  
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One of the few clinical pharmacy services which received support from the state, the 
influenza vaccination scheme, was implemented around the same time as the HSE 
significantly reduced fees they paid to GPs for administering flu vaccinations [26]. 
The timing of this event provides further evidence to claims that pharmacists are seen 
by the HSE as a means of cutting costs rather than provide solutions. The impact of 
this service is investigated in Chapter 6.  
 
Another example of an additional pharmacy service implemented in Ireland, was the 
switching of emergency hormonal contraception (EHC) from a prescription only 
medicine (POM) to one which is available from a pharmacy (P medicine). POM 
medication is only provided on receipt of a prescription written by a registered medical 
doctor, whereas P medications can be provided under the supervision of a pharmacist. 
Instead of the initial implementation being in the form of collaboration between 
pharmacist representatives and the HSE / Department of Health (DoH), it was forced 
through as a patient group directive (PGD) by an individual pharmacy group [27]. This 
PGD was subsequently replicated by additional pharmacies. While the service has 
proved to be a success, it has received no support from state bodies and is only 
available to private patients, which subsequently limits the availability of the service 
to patients [28].  
 
POM to P switching is an area of community pharmacy which has seen limited 
development, but overall has not reached its full potential. Since the publication of the 
“Pharmacy 2020” report, a number of substances have been reclassified from POM to 
P but they have largely been medications which had adequate alternatives already 
available [29].  It has largely been a missed opportunity; suitable medications for the 
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treatment of self-limiting conditions such as conjunctivitis, minor urinary tract 
infections and minor skin infections have remained under POM classification. The 
potential of developing a new category of medication, “pharmacy prescribed” or a 
minor ailment scheme has been ignored. Potential medications which could be 
included in this scheme include simvastatin and oral contraceptives. These medicines 
have been prescribed under similar schemes in other jurisdictions [30, 31].  Based on 
a recent postal survey of Irish GPs, this is likely to be met with strong resistance [32].  
 
A novel area which pharmacists could use their skills for the greater benefit of the 
population is connected health. Connected health is a step away from directly 
providing care to a ‘passive’ patient. Instead it facilitates the patient, in a form of self-
management collaborative care, generally through telemedicine [33]. It helps the 
patient take ownership of their condition; instead of only addressing it when it needs 
attention i.e. GP or hospital visit. Connected healthcare is a multidisciplinary approach 
to healthcare provision. Despite community pharmacists being in an ideal position to 
act as a facilitator for empowered patient management, policy on connected healthcare 
has failed to integrate pharmacists into future plans. Public support for pharmacist 
involvement in connected health programmes is strong [34]. It is still a nascent area 
of care which requires substantial development. Infrastructure deficits within the 
healthcare system may counter long-term savings [33]. However, it is an area which 
deserves consideration as a means of relieving pressures on acute care facilities. 
Chapter 4, investigates an example of connected healthcare, pharmacist expanded role 
in managing patient oral anticoagulation. 
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1.3 Pharmacy and the Irish healthcare system 
Pharmacists are the third largest group of healthcare professionals [34]. However, 
pharmacists as a profession are traditionally poor to lobby or network at higher levels 
of power. Groups such as the Irish Pharmaceutical Union (IPU), Hospital Pharmacists 
Association of Ireland (HPAI) and Pharmacists in Industry, Education and Regulatory 
(PIER) have started to realise this and are beginning to advocate for the role of 
pharmacists. However, the small and fragmented nature of pharmacy representative 
groups pales into insignificance when compared with powerful medical and nursing 
lobby groups.  
 
There is currently no Chief Pharmacist assigned to the Department of Health in Ireland 
[35]. This is a major problem, which has been unresolved for a number of years. The 
Chief Pharmacist would have direct access to the Minister for Health and would help 
influence the future progression of our profession. While academic evidence is an 
important part in overall service redesign, advocates interacting with high level 
decision makers are important to make sure all parties are made aware of all available 
evidence.    
 
Successive governments have all released documents describing their vision for a 
better healthcare system. The potential impact of pharmacy has generally been ignored 
in previous strategies: 
1994 - Shaping a healthier future. Astrategy for effective healthcare in the 
1990's. Brief mention of plans for pharmacy during the government’s lifetime, 
including plans for a new Pharmacy Act . Unfortunately, none of these plans 
were implemented during the course of the document’s implementation. It was 
2007 before a revised Pharmacy Act was produced [36].  
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2001 – Quality and Fairness.  A Health System for You. No mention of 
pharmacy. The steering group involved in this programme had multiple 
representatives from medical and nursing professions, but no pharmacist input 
[37]. 
2007 – Transformation Programme. This was a policy document representing 
a commitment to advance primary, community and continuing care in order to 
relieve pressure on the hospital system. Again pharmacies are omitted from 
any consideration in the entire document [38].  
2013 – Healthy Ireland. Anational health strategy devised by the Fine-Gael 
Labour coalition government (at time of writing February 2016). Despite a 
change in the make-up of the government, only a brief mention of pharmacy 
was included in the document. No details were given on what role they would 
have in a strategy which was very much primary care orientated and offered a 
perfect platform to outline the plans for the pharmacy over the coming years 
[39].  
  
These reports represent the health strategies of all administrations over the past 20 
years, not one has considered the positive contribution that pharmacy could make to 
Ireland’s on-going health resource issues.  
The evidence over the past decade has indicated that the only way in which pharmacy 
is viewed by state bodies is an area where costs can be cut, rather than a profession 
which can offer viable solutions to problems within our healthcare system.  
 
Realistically, since the onset of the financial crisis, the HSE has had limited scope to 
invest in further services. Drastic cutbacks to its budget have been implemented over 
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a prolonged period of time. A 17% reduction in overall healthcare spending was 
implemented between 2010 and 2012 [40]. Many of them were passed on to the 
pharmacy sector. Numerous Ministers for Health have referred to the development of 
pharmacy services but as already stated it lacks a strategic approach.  
 
The HSE has never published a strategy or publication outlining the intended direction 
of pharmacy. A potential reason for this may be the high level of expenditure 
associated with on pharmaceuticals in the community (€1.92 billion - 2014) [23]. 
Therefore, focus at a national level was on reduction of this expenditure rather than 
addition of new services. However, only €379 million of this funding goes to 
community pharmacies [23].  
A policy of publishing pharmacy strategies and following up on implementation has 
long been established in the UK and Northern Ireland.[41-43].  Furthermore in the 
UK, individual trusts within the National Health Service (NHS) have published 
prospective strategic documents which outline direction of pharmacy for the next 5 
years [44]. It must be acknowledged however, that the NHS system in the UK is 
considerably different to the current Irish model. NHS Trusts are well-established and 
have considerable autonomy so it is in their own interests to have pharmacy specific 
policy documents. Pharmacy is also given consideration in national frameworks which 
provide guidelines and quality indicators which drive improvement in pharmacy 
services at an individual trust level. While these measurements have their critics, they 
do foster a more progressive environment; unfortunately they have not yet become 
standard practice within the Irish healthcare system.  
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Up until now, the HSE has not invested in additional pharmacy services to any great 
extent. A review of the most recent HSE service plans 2014 and 2015 revealed that 
only one hospital pharmacy (Letterkenny) was to receive capital investment [45] [46]. 
A subsequent update for 2016 saw additional capital funding for new pharmacy in 
Ennis general hospital and development of an ePharmacy program as part of the 
overall eHealth Vision for Ireland [47, 48]. This project aims to deploy digital 
solutions across different care settings to make the delivery of pharmacy services safer 
and more efficient.  
Only one additional pharmacy service, a needle exchange programme was being 
formally considered for evaluation [46]. This program was driven by social inclusion 
policies rather than a primary care or pharmacy orientated policy.  
 
The current government (at time of writing February 2016) has outlined their plans for 
a primary care orientated healthcare system in but anticipated pharmacy input is 
minimal [39]. Evidence generated in this thesis will inform HSE strategists on the 
value for money (or lack of) to be gained from clinical pharmacy services.  
 
If consideration has not yet been given to the benefits that pharmacists can provide, 
future projections have highlighted its importance. Irelands ageing population ensures 
that investment in preventative and public health measures is imperative in order to 
prevent our tertiary care systems collapsing. In 2011 it was estimated that 532,000 
people in Ireland were aged 65 or older. By 2026 that figure is expected to be closer 
to 850,000 [49]. An inevitable consequence of an ageing population is an increase in 
age related illnesses. When this is combined with current and expected increases in 
chronic conditions caused by factors such as obesity, smoking and dietary deficiencies 
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it is reasonable to expect demands on Ireland’s healthcare to multiply over the coming 
years. 
   
1.4 Community pharmacy worldwide 
As in Ireland, traditionally community pharmacists in other countries around the world 
have worked in isolation, with a focus on retailing and dispensing of medications. 
However, countries around the world are beginning to recognize this untapped 
potential and are beginning to integrate community pharmacists into their primary care 
strategy.  
A recent systematic review has identified a range of community pharmacy services 
which are remunerated [50]. The majority of funding is obtained from government 
agencies, with the remainder of funding coming from private insurance companies, 
generally in the US. The most prevalent service identified was medication reviews 
with or without care plan development (n = 18). Other services identified which 
received support from a healthcare provider included contacting prescribers regarding 
drug therapy problems, smoking cessation counselling (n = 9), diabetes management 
(n = 5), emergency hormonal contraception counselling (n = 2) and inhaler device 
training (n = 2). Minor ailment schemes are operated in Scotland, Northern Ireland 
and isolated Canadian provinces [50] .  
1.4.1 Pharmacy in the UK  
Arguably the most progressive jurisdiction in the context of primary care pharmacy 
reform has been the UK. The development of pharmacy has received ongoing support 
from the state. The framework for the development of pharmacy service was outlined 
for England in the “Pharmacy in the Future” (2000) report [41]. The impetus for 
expansion in Scotland came from the publication of the “Right Medicine” report in 
2002 [43]. Enhanced services provided include [34]:  
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• Provision of emergency prescription refills 
• Renewal or extension of prescriptions 
• Responsibility for adjustment of medication dosage or formulation 
• Initiation of prescription drug therapy 
• Minor ailment prescribing 
• Therapeutic substituition 
• Ordering and interpreting lab tests 
 
Accredited  pharmacists in England  and Scotland have been allowed to independently 
prescribe since 2006 [51]. While this service was originally met with considerable 
resistance from the medical fraternity, it has remained in place and in 2012 was 
expanded to include prescription of certain controlled drugs [34].   
Transfer of patients between tertiary and community care settings is a changeover 
which is fraught with danger and associated with exacerbations in patient conditions. 
This has been recognized by the NHS in Wales. Pharmacists are reimbursed for the 
provision of a structured Discharge Medicines Review Service [52]. 
 
Since 2011, a New Medicines Service has been provided in English pharmacies [53]. 
This service is also been made available to patients in Northern Ireland under the most 
recent pharmacy contract. Patients who receive a newly prescribed medication for a 
number of chronic conditions receive three consultation with a pharmacist during the 
first month of receiving their new therapy. 
 
Scotland is perhaps the most advanced country in terms of a community pharmacy 
input into the primary care system. Smoking cessation is widely recognised as one of 
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the most cost-effective public health interventions and regularly provided as part of a 
pharmacist service in many countries. However, smoking cessation counselling is 
financially supported in Scottish pharmacies [54]. In addition, to recognised services 
such as medicine use reviews and minor ailment schemes, more novel services such 
as a community pharmacy heart failure programs are also supported in some Scottish 
districts [55].   
 
1.4.2 Pharmacy in Europe 
Community pharmacy services in Europe are less developed in comparison with the 
services available in the UK. A recent systematic review has only identified two 
enhanced pharmacy services which are eligible for reimbursement [50]. Danish 
community pharmacies provide inhaler assessment and training for asthma and 
chronic obstructive pulmonary disorder (COPD) patients [56]. Patients in Switzerland 
on ≥ 4 medication for more than 3 months can avail of a polymedications check [57]. 
This is a modified form of medication use review which focuses on medications 
management, adherence issues and other drug related problems. Efforts to reform the 
Dutch pharmacy system are progressing. Recently legislation has been passed which 
will allow pharmacists to access laboratory test results and prescribing indications 
[34].  
 
1.4.3 Pharmacy in Australia and Asia 
There is a history of engagement between healthcare payers and pharmacist 
representatives on the provision of pharmacy services. Since 1990, there have been 
regular agreements between the Australian government and the Pharmacy Guild of 
Australia. Originally, these specifically governed pharmacist reimbursement and 
regulations regarding the opening of pharmacy businesses. Over time, these 
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agreements have begun to incorporate designated funding for the provision of clinical 
pharmacy services [58]. These agreements provide an example of a coherent primary 
care strategy in which an agreed level of pharmacist services are reimbursed over a 
significant period of time. Up to $1.26 billion in funding will be available under the 
most recent agreement (6th version) for evidence-based, patient-focused professional 
pharmacy programmes and services. Pharmacists are provided reimbursement in the 
form of patient care fees or annual stipends for offering clinical pharmacy services 
targeting medication adherence, medication management and rural support projects. 
Another interesting funded provision is the “Pharmacy Trials Programme” which 
provides funding for new initiatives which seek to expand the role of pharmacy and 
improve patient outcomes [58].   
 
Along with Scotland, New Zealand is oft cited as an example of a country with a 
similar population level to Ireland which has significantly developed its community 
pharmacy services. Since 2007, patients have been offered a medication use review 
and adherence support service [59]. Pharmacists receive a payment of $86.38 for an 
initial patient consultation, along with a fee of $21.60 for follow-up visits. Multi-
disciplinary teams including community pharmacists are also encouraged to generate 
care plans for patients under a Medicines therapy assessment scheme.  
However, despite these considerable incentives, uptake is disappointing. Only half of 
pharmacists who are qualified to perform medication use reviews regularly do so [60]. 
1.4.4 Pharmacy in North America 
The development of community pharmacy services in the US is primarily influenced 
by the Medicare Prescription Drug Benefit Act which came into effect in 2006. This 
introduced a Medication Therapy Management (MTM) service, a variation of 
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medicine use review programs established in the UK. The objective of MTM is to 
prevent adverse drug events and improve adherence for Medicare beneficiaries. 
Studies analysing the impact of the program, concluded it was associated with 
improved clinical outcomes and cost savings [61]. Pharmacist-estimated cost savings 
in a large integrated healthcare system over the 10-year period were $2,913,850 ($86 
per encounter). The total cost of providing this service was $2,258,302 ($67 per 
encounter) [61]. Further evidence from a meta-analysis comparing direct pharmacy 
care over comparative services indicated favourable therapeutic and safety outcomes 
for haemoglobin A1c, low-density lipoprotein cholesterol, blood pressure and adverse 
drug events were significant (P<0.05) [62].  
 
There is considerable interstate variation in the availability of various community 
pharmacy services. Collaborative Drug Therapy Management agreements are in place 
in 33 states, which allow pharmacists to provide clinical services such as initiating and 
modification of drug therapy. They are also permitted to order laboratory tests in 31 
states [34].  
 
Canadian practice demonstrates considerable interprovincial variation. Pharmacists 
are independently allowed to prescribe in 70% of provinces [33].Alberta is the most 
advanced province in terms of additional dispensing functions. Accredited 
pharmacists are entitled to initiate and manage drug therapy[33].   
 
Minor ailments schemes which include POMs are supported and reimbursed in 4 
provinces. However remainder of provinces (9), limit scheme to non-prescription 
medication and do not provide financial incentives to provide the scheme. 
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1.5 Hospital pharmacy worldwide 
Hospital pharmacy practice varies from country to country; however, challenges are 
similar regardless of population, location or wealth [63]. These barriers include 
shortage of qualified experienced staff, inadequate IT infrastructure and inability to 
monitor patient outcomes [63].   
1.5.1 Hospital pharmacy practice UK 
As with many pharmacy matters, hospital pharmacies in the UK were to the forefront 
of adopting of clinical pharmacy services. Even 10 years ago, a published survey 
indicated that clinical pharmacy was regarded as a core service in hospitals  (94% of 
hospital provided clinical pharmacy services) [64].  As well as providing services at 
ward level, UK hospital pharmacists had significant involvement in the direction of 
drugs and therapeutic committees at NHS Trust or Directorate level [64]. Full-time 
specialist pharmacist positions have become the norm in many clinical wards 
including emergency departments [65]. 
 
1.5.2 Hospital pharmacy practice in Europe 
Overall, clinical pharmacy services provided in the EU trail behind the level of service 
demonstrated in the US. A total of 34% US hospitals, employ pharmacists to work full 
time exclusively at ward level. The same level of care is not provided in Europe; only 
6% of pharmacies have pharmacists spending at least 50% of their time on the ward. 
Developments in clinical pharmacy have been minimal over the past 10 years. A 
comparable survey conducted by the European Association of Hospital Pharmacists 
in 2005 and 2010 demonstrate minimal changes in the provision of clinical pharmacy 
services amongst hospital pharmacies. Despite the recognised dangers associated with 
transfer of patients from hospitals to other care settings, hospital pharmacies have not 
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become systematically involved in the discharge planning process, only 16.9% of 
pharmacies offer this service on admission and 22.1% at discharge [17]. 
 
1.6 Health Economic Evaluations 
1.6.1 Introduction to Health Economics 
Healthcare and government agencies must decide how to allocate their resources for a 
wide range of different medical interventions.  Costs and outcomes of different 
healthcare interventions require evaluation to ensure the optimum health gain from 
any given budget. Economic evaluation is now a widely accepted tool for the appraisal 
of health care and this is reflected by the increasing number of research papers in this 
area in the medical literature. Economic evaluation of heath care programs has become 
increasingly important as resource constraints necessitate decisions regarding the 
allocation of heath care funding. Economic evaluation assesses the costs and benefits 
associated with an intervention or technology and only when this information is 
available should decisions be made regarding the availability of new services.   
 
The application of the principles of economics are necessary to design health services 
that produce the best health care outcomes for society based on available resources. 
This is particularly applicable to pharmaceutical spending which in 2012 accounted 
for 20% of all health expenditure across European Union (EU) member states, with 
Ireland’s ranked as third highest in terms of expenditure per capita.  
Ireland’s expenditure on healthcare will be €13.3 billion in 2014, and this accounts for 
27% of total government expenditure [66]. Despite the high expenditure, resources are 
still limited. An aging population, in addition to an increase in expensive health 
technologies will continue to raise healthcare related expenditure. We will never 
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inhabit a utopian society with unlimited resources available to fund all healthcare 
requirements; therefore tough decisions on healthcare usage will have to be made.  
 
Insufficient healthcare funding results in trade-offs between different potential 
healthcare interventions. These trade-offs result in an opportunity-cost; this refers to 
the benefits lost when potential therapy is foregone due to the choice of an alternative 
[67]. The decision on whether to provide funding for a particular healthcare 
intervention can be a painful and sensitive issue. It can also be politically contentious 
and the available evidence is not the only item taken into account. Health economics 
can help decision makers make informed decisions on complex and often emotive 
matters.   
The influence of health economics is becoming pervasive in all areas of healthcare 
provision. Economic considerations have a significant influence on drug development, 
medication availability, clinician prescribing and service provision [67]. Historically, 
clinicians would have resisted the notion that cost would have an influence on patient 
treatment decision. In fact, some healthcare professionals would have initially 
regarded health economics as a marketing tool by pharmaceutical companies [68] 
however, the realities of the modern healthcare system have largely eradicated 
suspicions surrounding health economics.  
 
Regardless of whether they are conducted in the health services sector or an alternative 
industry, two features characterise an economic analysis. An economic analysis 
accounts for both the inputs and outputs of a service, often called the costs and 
consequences of a proposed activity. Additionally, an economic analysis considers the 
alternative choices available. Therefore, an economic evaluation can be defined as the 
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comparative analysis of alternative courses of action in terms of both costs and 
consequences [69]. An economic evaluation will attempt to identify, measure, value 
and compare costs and consequence of a number of alternative initiatives.  
 
Another important factor to account for when developing a health economic 
evaluation is the perspective or point of view from which the study will be conducted 
[70]. The two most common perspectives employed are the healthcare perspective or 
the societal perspective. The healthcare perspective only includes direct costs which 
are incurred by the relevant health service. The societal perspective takes a broader 
viewpoint and includes indirect costs such as loss of productivity and travelling 
expenses, in addition to direct healthcare costs. It also enables decision makers to be 
more informed regarding potential “shifting of costs” from one health area to another 
[71]. Government departments and hospital managers tend to favour a narrower 
perspective, although many health economic guidelines recommend utilisation of the 
broadest perspective available [70].  
 
Health economic evaluation remains a relatively contemporary field of study. 
Although its origins can be traced back to the 17th century [72], it has really only risen 
to prominence in the past 30 years. Improvements in the methodologies applied and 
increased confidence in outcomes associated with research in the field has helped 
health economics become more acceptable to all stakeholders [73].  
 
1.6.2 Health Economics in Ireland 
As early as 1989 it was recognised that health economic evaluation was being ignored 
within the Irish Healthcare system [74]. Early attempts at economic evaluation of 
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services were very much isolated accountancy driven efforts [75, 76] and were  
retrospective in nature. The ethos of prospective health economic evaluation did not 
become ingrained within the Irish healthcare system until the establishment of the 
Health Information and Quality Authority (HIQA). The direction for health economic 
evaluation remains under the remit of HIQA. It provides guidance on economic 
evaluation on all health technology assessments including pharmaceuticals, 
procedures, medical devices, broader public interventions and service delivery models 
[77]. While these guidelines can be used across multiple settings, they are 
predominantly used to inform pharmaceutical reimbursement.   
 
Economic evaluation for service provision within the Irish healthcare system is a less 
transparent process. A clear pathway and decision making process is available for 
economic evaluation of pharmaceuticals. Marketing authorisation holders can make 
their submission to the National Centre for Pharmacoeconomics (NCPE).  The NCPE 
assess evidence for comparative effectiveness and cost-effectiveness of technologies 
for use by patients in Ireland. Their predominant focus is on pharmaceuticals. They 
then make a recommendation as to whether the drug should be reimbursed within the 
Irish healthcare system. There are guidelines in place regarding timelines and 
thresholds for reimbursement. Unfortunately, this does not yet exist for medical 
devices or services.  
 
Published economic evaluations of services conducted by HIQA have focused on 
national screening and vaccination policies rather than individual services provided by 
healthcare professionals [78]. There are issues regarding the generalizability of 
pharmacoeconomic evaluations between different healthcare systems [79]. 
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Interventions or technologies which prove cost-effective in one country could result 
in an unwanted outcome when applied to another healthcare system [80]. Therefore, 
localised research into the economic impact of healthcare interventions is sometimes 
required.  
 
Economic evaluations of clinical pharmacy services in Ireland are minimal. While 
there have been significant publications detailing the clinical impact of pharmacists in 
the Irish healthcare system, these publications have variable relevance to those 
responsible for allocating resources within the healthcare system [81].  
 
Research has shown conflicting evidence regarding the utility of economic evaluations 
on determining healthcare policy [73]. Health policy decision making is a complex 
multi-faceted process which should never be reliant on a single study or input to have 
an overriding influence on the final decision.  However, as previously discussed, the 
establishment of bodies such as HIQA and NCPE have established a formal input for 
economic evaluations within the decision making process.  
 
One of the fundamental tenets of health economics is that funding priority is given to 
interventions that have the greatest effect at the lowest cost [69]. However, despite the 
acknowledged importance of economic evaluations they are not always used in 
decision making [82]. An important aspect of the influence of health economic 
evaluation is accessibility for decision makers. Research needs to be made available 
to decision makers in an accessible format [83]. Suggestions have been made to 
produce simplified summaries of research for non-health economists or alternatively 
provide health economic training to relevant stakeholders [84]. Other decision makers 
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have indicated their reluctance to engage with health economic research for reasons of 
scientific, institutional and ethical acceptability [85]. Indeed, one of the main outcome 
measures used within UK and Irish health economic research the quality adjusted life 
year has been rejected for use within evaluations in the German health system  [86].  
 
1.7  Aims and Objectives  
The primary aim of this doctoral thesis was to generate an evidence base for making 
future policy decisions in relation to the funding of pharmacy services and defining 
the role of the pharmacist within the Irish healthcare system. A secondary aim was to 
analyse a number of novel clinical pharmacy services in a more general manner, in 
order to provide evidence at an international level. The author of this thesis was the 
primary investigator for all research presented in this thesis. The author was 
responsible for devising research strategy and implementing methodologies required 
to complete research work. The five chapters described below, provide the main 
evidence for this thesis. The conclusions and recommendations forthcoming from this 
thesis are based on the findings of chapters 2 – 6 (inclusive). Chapter 2 – 6  have are 
all published or under review for publication in academic peer reviewed journals. The 
author of this thesis is listed as the lead author on all external publications generated 
from work presented in this thesis manuscript.  
 
The specific objectives for each chapter were:  
 
Chapter 2 - Systematic review of clinical pharmacist interventions on hospital 
inpatients 
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i) Systematically review and summarise the literature concerning clinical pharmacy 
services directed at hospital inpatients with an associated economic outcome.  
ii) Identify any changing trends in the status of hospital-based clinical pharmacy 
services 
iii) Utilise the Consolidated Health Economic Evaluation Reporting Standards to 
identify whether the economic evaluations of clinical pharmacy services were of an 
acceptable quality from a health economic perspective.   
 
Chapter 3 - Cost-outcome description of clinical pharmacist interventions in a 
university teaching hospital 
 
i) Identify the number and type of interventions made by hospital pharmacists on 
hospital inpatients in a major Irish teaching hospital 
ii) Determine the cost avoidance associated with these interventions 
iii) Determine the cost of providing this service from a healthcare payer perspective 
 
Chapter 4 - Economic Evaluation of a randomised controlled trial of pharmacist- 
supervised patient self-testing of warfarin therapy 
i) Determine whether a pharmacist-supervised model of warfarin testing is cost-
effective.  
ii) Perform additional analysis using multiple scenarios and perspectives 
 
Chapter 5 - Structured pharmacist review of medication in older hospitalized 
patients: A cost-effectiveness analysis 
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i) Perform a cost-effectiveness analysis comparing the impact of the novel structured 
pharmacist review with usual care 
ii) Use a multi-level mixed effect regression model to control for variables 
iii) Construction of a cost-effectiveness acceptability curve based on a number of 
hypothetical thresholds 
 
Chapter 6 - Clinical and economic benefits of a community pharmacy vaccination 
strategy 
 
i) Evaluate the impact of a pharmacist-led vaccination campaign on a national scale 
ii) Calculate the economic and health benefits associated with the vaccination 
campaign. 
 
Chapter 7 - Systematic Review Update 
 
i) Provide an update on any recent evidence not incorporated in chapter 2.  
 
Chapter 8 - Discussion 
 
i) Critically examine findings of previous chapters in terms of known information and 
consideration of new evidence generated by this research. 
ii) Examine the strengths and limitations of the major research findings 
iii) Outline the implications of this research at a societal level  
 
Summary 
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Clinical pharmacy services have the potential to have a positive impact within the Irish 
healthcare system. Existing evidence indicates that a number of novel and newly 
established services have demonstrated positive clinical based outcomes. However, 
evaluations of the impact of these services from a health economic perspective are 
lacking. This thesis will attempt to address this knowledge gap. Output from thesis 
will help ensure decision makers can make informed decisions on the future direction 
of both hospital and community pharmacy in Ireland.  
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2 - Chapter 2: Systematic review of 
clinical pharmacist interventions on 
hospital inpatients 
 
 
The work of this chapter has been published as Gallagher J, McCarthy S, Byrne S. 
Economic evaluations of clinical pharmacist interventions on hospital inpatients: a 
systematic review of recent literature. Int J Clin Pharm. 2014 Dec;36(6):1101-14. doi: 
10.1007/s11096-014-0008-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
2.1 Abstract 
Background 
Clinical and cost-effectiveness evidence are needed to justify the existence or 
extension of routine clinical pharmacy services in hospital settings. Previous reviews 
have indicated that clinical pharmacist interventions are likely to have a positive 
economic impact on hospital budgets but highlighted issues relating to the quality of 
studies.   
Aim of the review  
The primary aim of this review was to feature economic evaluations of clinical 
pharmacy services which targeted hospital inpatients. The review focused on the 
current cost-effectiveness status of different services, in addition to evaluating the 
quality of individual studies. Results of this systematic review were compared with 
cost-effectiveness and quality related findings of reviews which considered earlier 
time frames and alternative settings.  
Methods  
A systematic review of the literature included a review of the following databases: 
Academic Search Complete, Cochrane Library, EconLit, Embase Elsevier, NHS 
Economic Evaluation Database and PubMed.  Only studies with an economic 
assessment of a clinical pharmacy service provided in a hospital setting were included. 
Data relating to the cost-effectiveness was extracted from eligible studies. 
Methodologies employed and overall quality of the studies was also reviewed. A 
grading system was applied to determine the quality of studies.  Consolidated Health 
Economic Evaluation Reporting Standards statement was employed to determine 
which aspects of a high quality health economic study were employed. 
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Results  
Twenty studies were deemed eligible for inclusion. Overall, pharmacist interventions 
had a positive impact on hospital budgets. Only three studies (15%) were deemed to 
be “good-quality” studies. No ‘novel’ clinical pharmacist intervention was identified 
during the course of this review.   
Conclusions  
Clinical pharmacy interventions continue to provide cost savings. However, the 
standard of studies published has stagnated or even deteriorated in comparison with 
those included in previous reviews. Utilisation of published guidelines at initial stages 
of future studies may help improve the overall quality of studies. 
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2.2 Introduction 
The pharmacy profession has transformed from a dispensary-based role to one centred 
on the provision of clinical services. While still ensuring that medicines are sourced 
and dispensed to a high standard, hospital pharmacists have expanded their scope of 
practice [87], and pharmacy interventions include integral components of the 
enhanced role which pharmacists offer [88-90]. 
 
A pharmacist intervention is defined as the following “any action taken by a 
pharmacist that aims to change patient management or therapy” [91]. Clinical 
pharmacy services (CPS) employ the pharmacotherapeutic expertise of the pharmacist 
to ensure optimal patient outcomes [92, 93] and can improve the quality, safety and 
efficiency of care. Various pharmacist interventions including interaction with other 
healthcare teams, patient interviews, medication reconciliation and patient discharge 
counselling demonstrated improvements in patient outcomes [87].  
 
In addition to clinical benefits, clinical pharmacist intervention have also 
demonstrated positive outcomes when measured using health-related quality of life 
assessments (HRQoL) [94]. This involves a multidimensional assessment of a 
patient’s physical, functional, emotional and social well-being. Pharmacist 
interventions targeting specific conditions including asthma, hypertension and chronic 
heart failure have tended to show noticeable improvements in HRQoL [94].  
However, there is an omnipresent danger that previous gains made by pharmacists will 
be eroded due to increased pressure on healthcare resources [1]. In order to vindicate 
the provision of additional pharmacy services, it is no longer sufficient to provide a 
justification exclusively based on clinical benefits. Cost-effectiveness data is also 
required [81]. 
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Previous review articles have broadly reached the same conclusion, the operation of 
additional clinical pharmacy services results in cost savings to the healthcare payer 
[80, 81, 95-97]. However, many published studies have been of poor quality [95, 97], 
limiting the strength of any conclusions presented in previous reviews. Due to the 
previously highlighted quality concerns, it was decided to conduct a quality 
assessment of economic evaluations.  
 
2.2.1 Aim of the Review 
This systematic review will examine economic evaluations of clinical pharmacy 
interventions made on hospital inpatients published between 2008 and 2012. The 
review will focus on assessing the economic outcomes of eligible studies. 
Additionally, it aims to provide a description of the quality of included studies. There 
has been no previously published systematic review which has exclusively focused on 
services specifically targeted to hospital inpatients covering the stated time period. 
This systematic review will provide evidence to healthcare decision makers regarding 
the cost-effectiveness of various services. Additionally, it will highlight to academics 
and clinical practitioners study areas which have been poorly designed and could be 
improved upon in the future. 
2.3 Method 
2.3.1 Search strategy 
This review of the literature was undertaken in April 2013. Searches were conducted 
of the following databases: Academic Search Complete, Cochrane Library, EconLit, 
Embase Elsevier, NHS Economic Evaluation Database and PubMed. The publication 
dates of articles included in search strategy ranged from January 2008 to December 
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2012. All authors were involved in the development of PubMed search strategy and 
appropriate Medical Subject Headings (MeSH) terminology was utilised. The 
following MeSH terms were employed: “drug information services”, “medication 
therapy management”, “drug toxicity”, “prescriptions”, “drug therapy”, “pharmacy 
services hospital” combined with “cost and cost analysis”, “economics, 
pharmaceutical”. Similar search strategies, with MeSH terms mapped to appropriate 
key words were used for additional databases. The full search strategy is detailed in 
Appendix 10.3. Search results from multiple databases were transferred to a reference 
manager, EndNote X6. Due to the broad remit of the search strategy, a ‘title review’ 
stage was conducted to remove obviously non-pertinent studies. This was conducted 
by the primary author. Studies were removed in a cautious manner. Abstract review 
was then performed.  If a study clearly did not meet inclusion criteria it was excluded. 
Studies which had not been excluded following abstract review stage underwent full-
text review. Full-text review was performed by the primary author. Studies selected 
for inclusion in the systematic review were reviewed by the co-authors to ensure they 
met eligibility criteria.  
2.3.2 Review criteria and data extraction 
Studies were required to meet multiple criteria specified in Table 2.1. 
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Table 2.1 Inclusion and exclusion criteria for systematic review 
Inclusion criteria Exclusion criteria 
Published peer reviewed full-text articles Non-peer reviewed literature e.g. 
government documents, technical 
reports, newspaper articles, letters to 
the editor, media releases 
Study assessed an intervention performed 
by a pharmacist or team of pharmacists 
Studies based on modelling effect of 
an intervention 
Intervention must conform to the 
unabridged American College of Clinical 
Pharmacists (ACCP) definition of clinical 
pharmacy [3] 
 
Study must include an economic assessment 
(Measurement of costs to provide the 
service, outcomes expressed in monetary 
terms or both) 
 
Interventions must be conducted on 
inpatients in a hospital setting 
Studies conducted in outpatient 
clinics, nursing homes, veteran’s 
affairs clinics and any form of 
community level care 
Study published in English language  
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The references of eligible studies and previously published systematic reviews were 
systematically searched to ensure that they did not contain further relevant research. 
The heterogeneity of health economic studies prevented a meta-analysis being 
undertaken. Grey literature (e.g. government documents, technical reports etc,) was 
excluded.  
 
Studies which met inclusion criteria were analysed with the aid of a data collection 
form (Appendix 10.4). Information collected included details of authors, type of 
intervention, study setting, study sample size, economic method, study period, 
outcome measures and results and multiple quality assessment related data. Completed 
data collection forms were reviewed by all listed authors. 
 
2.3.3 Quality assessment 
An established quality assessment of the economic methods employed was conducted 
[95]. Assessment comprised of a simple three question assessment, i) Was a 
comparator used? ii) Were program costs evaluated and described?  iii) Were program 
outcomes evaluated and described? Studies were determined to be “good-quality” 
studies if they complied with all three criteria. Studies which lacked a comparator or 
had multiple flaws were labelled as “poor-quality”. Studies which included a 
comparator but which did not evaluate either program costs or program outcomes were 
labelled as “fair-quality”.  This quality assessment was included as it provided a clear 
distinction on the standard of studies from a health economic perspective. 
Furthermore, it had been utilised in previous systematic reviews which enabled 
comparisons to be drawn with earlier time periods [95].  
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In addition to the previously described quality assessment, the authors decided it 
would be worthwhile to conduct a more comprehensive quality appraisal of included 
studies to provide an in depth analysis of study areas. The Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) statement [98] ,was applied to  
eligible studies. The CHEERS statement contains a checklist detailing aspects of 
health economic methodologies which should be considered for inclusion in a study 
(Appendix 10.5). As The CHEERS statement was designed for use across all types of 
health economic evaluations, only items on the statement checklist relevant to studies 
under review will be examined in this review.  
  
Descriptive statistics were used to summarise type of intervention, economic analysis, 
model, perspective and sensitivity analysis. A data collection form was initially 
completed by the primary author and then independently reviewed by another named 
author.  
2.4 Results 
Following elimination of duplicate titles, the search strategy yielded 6,815 titles for 
review. Reasons for exclusion are outlined in Figure 2.1. Twenty-two texts were 
considered eligible for inclusion in the systematic review. Studies were conducted in 
Asia [8], USA [8], Europe [5] and South America [1]. All studies were published in 
health related journals. Table 2.2 contains a summary of studies which met inclusion 
criteria.  
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Figure 2.1 Literature search method and screening results 
 
  
At title review stage, 6396 
articles were excluded. Reasons 
for exclusion: 
- 2,581, drug evaluations 
- 1,490, disease evaluations 
- 719, Duplicate papers not 
recognised as such by EndNote 
- 515, exclusively economic 
paper 
- 489, no intervention 
- 300, non-hospital setting 
- 186, miscellaneous 
- 116, intervention by other HCP 
 
 
 
 
 
After searching databases and removal 
of duplicates, 6,815 articles were 
reviewed 
419 papers underwent abstract review 
At abstract review stage, 350 were 
excluded. Reasons for exclusion:  
- 97, no intervention 
- 79, non-pharmacist intervention 
- 72, non-hospital setting 
- 40, no cost outcome 
- 20, outpatient service 
-17, drug study 
-13, source abstract 
- 6, disease 
- 6, methodological reasons 
 
69 papers underwent full text review 
47 papers were excluded 
following review of full text of 
paper. Reasons for exclusion: 
- 16, case studies / commentaries 
/ review 
- 11, no economic outcome 
- 7, multidisciplinary team 
- 5, formulary interventions 
- 3, modelling of an intervention 
- 3, non-hospital setting 
- 2, no results 
 
22 papers were eligible for inclusion in 
systematic review 
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Table 2.2  Description of studies eligible for inclusion in this review 
First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of 
study 
Wallerstedt 
et al. 
(2012) 
A cost-
effectiveness 
analysis of an in-
hospital clinical 
pharmacist 
service 
Composite 
intervention of 
medication 
reviews, drug 
treatment 
discussion with 
the patient at 
discharge and 
medication 
report. 
Two 
internal 
medicine 
wards in 
University 
Hospital in 
Sweden 
181 control 
patients and 164 
intervention 
patients 
Cost-
utility 
Analysis.  
2007 - 2008. 6 
month follow 
up on patient. 
Effectiveness 
measured in 
gain in quality 
adjusted life 
years (QALY) 
as measured 
by EQ-5D.  
Unlikely to be cost 
effective. Cost per 
QALY of €316243. 
No significant 
difference in total 
healthcare costs 
between study 
groups. 
Good Randomised 
controlled 
trial.   
Magedanz 
et al. 
(2012) 
Impact of the 
pharmacist on a 
multidisciplinary 
team 
in an 
antimicrobial 
stewardship 
program: 
a quasi-
experimental 
study 
Impact of a 
pharmacist on 
an antimicrobial 
stewardship 
program (ASP) 
Cardiology 
hospital, 
Brazil 
Not provided Cost 
analysis 
Pharmacy 
responsible for 
ASP: 19 
months. ID 
Physician 
responsible for 
ASP: 21 
months. Pre-
implementation 
of ASP 
(Control): 30 
months.  
Mean monthly 
antibiotic costs 
The mean monthly 
antibiotic cost, during 
the control stage, was 
US$30,727, US$ in 
the ID physician led 
ASP period and 
US$9623 in the 
pharmacist-led ASP 
period of study.  
Fair 
(Missing 
cost of 
service) 
Quasi-
experimental 
study 
Dunn et al 
(2011) 
Implementing a 
pharmacist-led 
sequential 
antimicrobial 
therapy strategy: 
controlled before 
and after study 
Intervention 
group consisted 
of application of 
stickers and 
implementation 
of criteria 
for switch to 
oral therapy 
Control was 
routine 
pharmacist care.  
753 bed 
academic 
hospital in 
Ireland.  
72 patients in 
intervention 
group and 44 in 
control group.  
Cost 
analysis 
Three data 
collection 
periods of 10 
consecutive 
days 
Direct cost 
savings were 
measured but 
it was not 
primary 
outcome 
Antimicrobial costs 
reduced by a mean 
€6.41 per patient.  
Fair 
(Missing 
cost of 
service) 
Prospective, 
controlled 
before-and-
after study 
design 
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Table 2.2 (continued) Description of studies eligible for inclusion in this review   
First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of 
study 
Shen et 
al. (2011) 
Pharmacist 
interventions on 
antibiotic use in 
inpatients with 
respiratory tract 
infections in a 
Chinese hospital 
Pharmacist 
making 
recommendations 
to clinical team of 
nurses and 
physicians. 
Control was 
absence of 
pharmacist 
involvement. 
Respiratory 
wards in 
tertiary 
hospital in 
China 
178 patients 
(control group), 
176 patients 
(intervention 
group). 
Cost 
analysis 
July 2009 
- April 
2010 
Total costs of 
hospitalisation 
and cost of 
antibiotics 
The total costs of 
hospitalization in the 
intervention group 
were significant 
lower compared to 
the control group 
($1442.3 ± 684.9 vs. 
$1729.6 ± 
773.7).Cost of 
antibiotics ($832.0 ± 
373.0 vs. $943.9 ± 
412.0) 
Fair 
(Missing 
cost of 
service) 
Randomised 
controlled 
trial. 
Winger et 
al. (2011) 
Cost savings from 
dose rounding of 
biologic 
anticancer agents 
in adults 
Cost savings from 
dose rounding of 
biologic agents 
US 33 dose 
adjustments 
Cost 
description 
January 1 - 
March 1 
2005 
Direct cost 
savings 
$15922, direct cost 
savings 
Poor (No 
comparator, 
missing 
cost of 
service) 
Retrospective 
database 
review 
Steinberg 
et al. 
(2008) 
Impact of 
Pharmacy 
Generated 
Recommendations 
on Antibiotic 
Therapy in 
Community 
Hospital 
Pharmacist 
initiated antibiotic 
review service.   
550 bed 
community 
hospital. 
Only 
undertaken 
in selected 
wards. USA 
122 patients.  Cost 
analysis 
10 weeks. 
Dec 2005 
to Feb 
2006 
Total money 
saved based on 
interventions 
generated. 
Total 
antibiotic cost 
per patient 
Overall savings of 
$12313.22. No 
significant difference 
in cost per patient 
between control and 
intervention groups.  
Fair 
(Missing 
cost of 
service) 
Pre and post 
intervention 
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Table 2.2 (continued) Description of studies eligible for inclusion in this review   
First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of 
study 
Moffett 
et al. 
(2008) 
 
 
 
Medication 
dosing and renal 
insufficiency in 
a paediatric 
cardiac 
intensive care 
unit: Impact of 
pharmacist 
consultation 
Pharmacist made 
recommendation 
to renal team 
regarding 
appropriateness 
of medication 
Paediatric 
cardiac 
ICU, 
Houston, 
Texas, 
USA. 
131 patients 
admitted during 
study period. 37 
patient 
admissions 
required 
adjustment.  
Cost 
description 
January 
through 
March 2006 
3 months 
Monetary 
impact of 
pharmacist 
interventions 
was 
determined by 
calculating the 
number of 
doses saved  
Cost savings of 
$12482.54.  
Poor (No 
comparator, 
missing 
cost of 
service) 
Retrospective 
analysis 
Gillespie 
et al. 
(2009) 
A 
comprehensive 
pharmacist 
intervention to 
reduce 
morbidity in 
patients 80 
years or older 
Compilation of 
meds on 
admission. Drug 
review. Patient 
education and 
discharge 
counseling. 
Contacted 
primary care 
physician.  
 2 acute 
medicine 
wards 
University 
Hospital of 
Uppsala, 
Sweden. 
199 patients in 
intervention 
group. 201 
patients in 
control group.  
Cost 
analysis 
October 1 
2005 - June 
30 2006 (9 
months) 
Secondary 
outcome was 
cost of hospital 
care 
Total direct cost of 
secondary care 
during follow up 
year was $400 per 
patient in the 
intervention group 
vs. the control group. 
$230 per patient 
overall cost savings. 
Good Randomised 
controlled 
trial. 
Mac 
Laren et 
al. (2009) 
Effects of 
pharmacist 
participation in 
intensive care 
units on clinical 
and economic 
outcomes of 
critically ill 
patients with 
thromboembolic 
or infarction-
related events 
Direct patient 
care services 
provided by a 
pharmacist 
specifically 
devoted to an 
intensive care 
unit.  
Multiple 
US 
hospitals 
141,079 
Medicare 
patients who 
experienced a 
thromboembolic 
or infarction 
related event.   
77,857 were in 
hospitals with 
critical 
pharmacist care. 
Cost 
analysis 
Retrospective 
database 
review 
(01/09/04 - 
31/08/05) 
Medicare 
charges, drug 
charges and 
laboratory 
charges 
Additional charges 
for control group in 
comparison with 
pharmacist group 
$215,397,354 in 
Medicare charges, 
$26,363,674 in drug 
charges, no 
difference in 
laboratory charges.  
Fair 
(Missing 
cost of 
service) 
Retrospective 
database 
review 
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Table 2.2 (continued) Description of studies eligible for inclusion in this review   
 
First 
Author 
(Year) 
 
Title 
Pharmacist 
Intervention 
 
Setting 
 
 
No of patients 
/ Interventions 
Economic 
Method 
 
Period 
Outcome 
Measures 
 
Results 
 
Quality 
 
Type of 
study 
Hassan et 
al. (2009) 
Impact of 
renal drug 
dosing service 
on dose 
adjustment in 
hospitalized 
patients with 
chronic 
kidney 
disease 
Pre and post 
intervention 
period 
comparison. 
Pharmacist 
participation in 
nephrology team 
rounds.  
35 bed 
nephrology 
unit, Penang 
General 
Hospital, 
Malaysia 
Each phase had 
a random 
sample of 300 
patients.  
Cost 
analysis 
4 months. 
Beginning 
of Feb to 
end of May 
2007. 
Drug cost 
savings of 
original 
physician 
regimen in 
comparison with 
pharmacist 
regimen 
$2250 US for study. 
For all patients 
admitted to unit over 1 
year, 13500 US$. 
Fair 
(Missing 
cost of 
service) 
Pre and post 
intervention 
Campbell 
et al. 
(2011) 
Analysis of 
cost 
avoidance 
from 
pharmacy 
students' 
clinical 
intervention 
at a 
psychiatric 
hospital 
Retrospective 
database review 
of interventions 
made by 
pharmacy 
students.  
Adult inpatient 
state 
psychiatric 
hospital, 
Missouri. 120 
beds  
320 
interventions 
by 15 
pharmacy 
students  
Cost 
description 
1 year. June 
1, 2008 - 
May 31, 
2009. 
Estimated cost 
avoidance based 
on MediTrend 
values for 
adverse drug 
events and 
literature 
review.  
Cost avoidance of 
$23000 (Literature 
calculation) or $4000 
(MediTrend 
calculation) 
Poor (No 
comparator, 
missing 
cost of 
service) 
Retrospective 
database 
review 
Ijo et al. 
(2011) 
Pharmacy 
intervention 
on 
antimicrobial 
management 
of critically ill 
patients  
Prospective 
pharmacy driven 
antimicrobial 
stewardship in the 
intensive care 
unit. 
31 bed 
medical-
surgical and 
cardiac ICU. 
US 
70 patients.  Cost 
description 
November 
2009 - 
February 
2010 (3 
months) 
Financial 
outcomes from 
drug 
discontinuation, 
streamlining, iv-
po conversion, 
dose 
optimization, 
addition and 
substitution. 
Service resulted in an 
additional cost of 
$192 to the pharmacy 
Poor (No 
comparator, 
missing 
cost of 
service) 
Prospective 
audit. 
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Table 2.2 (continued) Description of studies eligible for inclusion in this review   
First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients 
/ 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of 
study 
Zhang et 
al. (2012) 
Clinical 
pharmacists 
on medical 
care of 
pediatric 
inpatients 
Clinical 
pharmacist 
active 
participation 
in paediatric 
ward rounds. 
Control 
consisted of 
no clinical 
pharmacist 
participation. 
West 
China 
Second 
University 
Hospital 
80 patients in 
each group.  
Cost 
analysis 
4 Months, 
Dec 1 2010 
- March 31, 
2011 
Cost of drugs 
and cost of 
hospitalisation. 
This was a 
secondary 
outcome. 
No statistical difference in 
costs of drugs and cost of 
hospitalisation.  
Poor 
(Multiple 
flaws) 
Randomised 
controlled 
trial 
Wilkinson 
et al. 
(2011) 
Impacting 
readmission 
rates and 
patient 
satisfaction: 
Results of a 
discharge 
pharmacist 
pilot 
program 
Pharmacist 
driven 
discharge 
program for 
high risk 
patients. No 
control 
University 
of Kansas 
Hospital. 
525 beds 
average 
daily 
census.  
229 patients 
received 
pharmacist 
evaluation.  
Cost 
description 
3 month 
study period 
beginning in 
Sept 2009 
Cost 
avoidance 
calculated 
using Veterans 
affairs model. 
Total cost avoidance €378,899 Poor (No 
comparator, 
missing 
cost of 
service) 
Prospective, 
cohort, non-
randomized 
trial. 
Jing et al. 
(2009) 
The impact 
of 
pharmacist 
intervention 
on the use of 
activated 
Vitamin D in 
a tertiary 
referral 
hospital in 
Malaysia 
Retrospective 
review of 
activated 
Vitamin D 
use. 
Pharmacists 
discontinued 
unnecesary 
use.  
University 
Malaya 
Medical 
Centre 
557 patients Cost 
analysis 
1 year prior 
to 
intervention 
and 1 year 
post 
intervention.  
Cost of Vit D 
in pre and post 
intervention 
periods. 
Decease of 
RM400616.80(US$111,282.40) 
annually. P=0.002 
Fair 
(Missing 
cost of 
service) 
Pre and post 
intervention 
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Table 2.2 (continued)  Description of studies eligible for inclusion in this review   
First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of 
patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of 
study 
Nasser 
et al. 
(2010) 
Cost reduction 
associated with 
restriction 
policy on 
dispensing 
intraveneous 
esomeprazole in 
Lebanon 
Impact of pharmacist 
intervention on cost 
following 
implementation of 
restriction on 
esomeprazole iv 
dispensing. Physicians 
fill a form and 
pharmacists review 
prior to approval.  
Inpatients 
of a 
Lebanese 
hospital 
Not given Cost 
analysis 
12 months 
pre 
restrictions 
and 12 
months post 
restrictions. 
Measured reduction 
in IV vials 
dispensed, and 
calculated 
associated cost 
Reduction of 
$21,233 per 
month.  
Fair 
(Missing 
cost of 
service) 
Pre and post 
intervention 
Hou et 
al. 
(2011) 
Retrospective 
evaluation of 
the outcomes of 
applying the 
renal dosing 
monitoring 
system in a 
medical centre 
Computerised dosing 
system modifies dosing 
for patients with renal 
impairment. Pharmacist 
then decides whether to 
make recommendations. 
Retrospective analysis 
of outcomes. 
Inpatients 
in a 
Taiwanese 
hospital. 
12,057 cases 
reviewed. 
Pharmacists 
made 
recommendati
on in 202 
cases and 173 
suggestions 
were 
accepted. 
Cost 
descriptio
n 
April 2007 - 
March 2008 
Cost savings due to 
dosage adjustments 
US$5377 Poor (No 
comparator, 
missing 
cost of 
service) 
Retrospective 
evaluation 
Klopoto
wska et 
al. 
(2010) 
On-ward 
participation of 
a hospital 
pharmacist in a 
Dutch ICU 
reduces 
prescribing 
errors and 
related patient 
harm: an 
intervention 
study 
ICU hospital pharmacist 
reviewed medications 
for ICU patients and 
noted issues for 
discussion with ICU 
physician. If consensus 
reached issues were 
scored as prescribing 
errors.  
Adult 
medical 
and 
surgical 
ICU, in a 
1,002 bed 
tertiary 
care 
academic 
hospital in 
Amsterda
m 
All patients 
admitted to 
ICU during 
study period. 
Cost 
analysis 
8 months 
(Intervention 
period). 3 
weeks, 
(Baseline 
period). 3rd 
Oct 2005 
and 30th 
June 2006. 
Estimate of cost 
avoidance. 
Secondary outcome. 
Cost savings of 
€26 -40 per 
patient per day. 
Good A 
prospective 
baseline vs 
intervention 
period study 
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Table 2.2 (continued) Description of studies eligible for inclusion in this review   
First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of 
study 
Chan et 
al. (2009) 
Pharmacist 
intervention in 
activated protein 
C therapy for 
severe sepsis: 
influence on 
health and 
economic 
outcomes 
Clinical 
pharmacists 
determine the 
appropriateness 
of prescribing 
activated protein 
C to a patient 
Taiwanese 
hospital. 
Inpatiens. 
No further 
info given. 
19 patients in 
each group.  
Cost 
analysis 
2 years pre 
intervention. 
2 years post 
intervention. 
Jan 2003 to 
Dec 2007. 
Total direct 
medical costs 
for both groups.  
Intervention group 
US$20,632.3 vs 
control group 
US$24,785.8. 
Converted to US 
dollars from 
taiwanese currency 
but no conversion 
date give. 
Fair 
(Missing 
cost of 
service) 
Retrospective 
comparison 
Yen et al. 
(2012) 
Clinical and 
economic impact 
of a pharmacist-
managed iv to po 
conversion 
service for 
levofloxacin in 
Taiwan 
Pharmacist 
managed iv to po 
conversion 
programme for 
levofloxacin 
Inpatients 
in a 
Taiwanese 
hospital. 
Tertiary 
hospital 
with 732 
beds 
37 patients in 
each group.  
Cost 
analysis 
Pre 
intervention 
1/07/08 - 
31/08/08 (2 
months). 
Intervention 
period 
01/10/08 - 
31/12/08 (3 
months). 
Two cost 
outcomes, total 
inpatient 
expenditure and 
cost of 
antibiotics for 
both groups. 
Antibiotics: Pre- 
intervention 
US$568.9 vs 449.0. 
Total inpatient 
expenditure:Pre-
intervention 
US$6096.5 vs 
3649.6. Converted 
to US Dollars but no 
conversion date. 
Fair 
(Missing 
cost of 
service) 
Retrospective 
comparison 
pre and post 
intervention 
Swoboda 
et al. 
(2009) 
Implementation 
of Practice 
Guidelines for  
Antifungal 
Therapy in a 
Surgical 
Intensive 
Care Unit and Its 
Impact on Use 
and Costs  
Implementation 
of practice 
guidelines for 
antifungal 
therapy by a 
clinical 
pharmacist.  
Surgical 
intensive 
care unit of 
the 
University 
Hospital of 
Heidelberg, 
Germany 
372 patients in 
control period. 
379 patients in 
intervention 
period.  
Cost 
analysis 
Control 
period 
January 
2005 – June 
2006 (18 
months). 
Intervention 
period July 
2006 – 
December 
2007 (18 
months) 
Costs for 
antifungal 
agents during a 
period of 18 
months before 
and after 
implementation.  
Total of €557110 
was spent on 
antifungal agents 
during the control 
period. Total of 
€258806 was spent 
on antifungal agents 
during the 
intervention period.  
Fair 
(Missing 
cost of 
service) 
Pre and post 
intervention 
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Table 2.2 (continued) Description of studies eligible for inclusion in this review   
First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients 
/ 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of 
study 
Weant 
et al. 
(2009) 
Cost effectiveness of 
a clinical pharmacist on 
a neurosurgical team 
 
Monitoring 
and evaluating 
patients, 
participating in 
team rounds.  
Neurosurgical 
service in a 
US hospital 
1077 patients 
in control 
group. 1079 
patients in 
intervention 
group.  
Cost 
analysis 
2 years pre 
implementation 
period and 2 
years post 
implementation 
period.  
Average 
pharmacy 
and 
intravenous 
cost of 
therapy per 
patient 
The average 
pharmacy and 
intravenous 
therapy costper 
patient between the 
pre- and 
postimplementation 
groups decreased 
from $4833 to 
$3239 
Fair 
(Missing 
cost of 
service) 
Pre and post 
intervention 
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Type of economic evaluation  
Only one of the studies was determined to be a full cost-utility analysis [99]. Fifteen 
of the studies included were labelled as cost-analysis [100-114] . While a further six 
were simple cost-description studies [115-120].  
Clinical pharmacy interventions 
Interventions were in the following areas antimicrobial management [100-103, 112, 
118], targeted drug programmes [108, 109, 115, 121], multi-dimensional clinical 
pharmacy service [99, 104, 119], paediatric programmes [116, 122], renal specialist 
[106, 120], pharmacotherapeutic optimisation [110, 123], intensive care service [113, 
124] and neurosurgery [114]. All intervention types have been identified in previous 
reviews of the literature [80, 81, 95, 96].  
 
Antimicrobial management 
Six antimicrobial interventions were identified. Five of the studies included a 
comparator, either in the form of a randomised controlled trial [102] or a pre- and post- 
intervention comparison [100, 101, 103, 112]. One study was a prospective audit 
[118]. Two studies evaluated antimicrobial stewardship programmes. A stewardship 
programme set in a Brazilian cardiology hospital, reported a reduction in mean 
antibiotic costs (Pharmacist present - US$9623.73 v No pharmacist - US$18034.89) 
when a pharmacist was included as part of a multidisciplinary team [100]. The study 
lacked information on the number of patients or interventions. An alternative 
antimicrobial stewardship programme was conducted in a US intensive care unit 
(ICU) [118]. On a sample of seventy patients, improved clinical outcomes were 
reported but associated antibiotic costs increased by US$192. An Irish study, 
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attempted to reduce antibiotic costs through pharmacists highlighting interventions to 
switch from the intravenous (iv) to the oral (po) routes of administration [101]. 
Antimicrobial costs were reduced by €6.21 per patient. A study focusing on iv to po 
switching of levofloxacin in Taiwan, reported a reduction in total inpatient expenditure 
of US$2446.9 [112]. Pharmacist provided antibiotic review services, showed overall 
cost savings in a US hospital but did not result in any significant reductions in cost per 
patient between control and intervention groups [103]. A similar programme in a 
Chinese hospital resulted in a reduction in total costs of hospitalization in the 
intervention group versus control group (US$1442.3 ± 684.9 vs. US$1729.6 ± 773.7) 
[102]. Antibiotic costs (US$832.0 ± 373.0 vs. US$943.9 ± 412.0) were also reduced. 
No study relating to antimicrobial management adequately assessed the costs of 
providing the service. 
 
Targeted drug programmes 
Four studies described cost outcomes associated with intervention on specific drugs 
or classes of drugs. Thirty-three interventions on biologic agents provided savings of 
US$15922 in a US hospital [115]. Pharmacists simply rounded the dose of anticancer 
agents to reduce medication waste. Pharmacists discontinued unnecessary vitamin D 
supplements over a 1 year period, resulting in cost savings of US$111,282.40 [108]. 
A group of hospital pharmacists reviewed the appropriateness of prescribing iv 
esomeprazole resulting in savings of US$21233 per month [109]. Pharmacists in 
Taiwan reviewing the appropriateness of activated protein C therapy in septic patients 
over a 2 year period, demonstrated a reduction in total direct medical costs [121]. 
Service costs were omitted in the above studies. 
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Multi-dimensional clinical pharmacy service 
A multi-faceted pharmacist intervention programme incorporating medication 
reviews, patient counselling and discharge was reported as being unlikely to be cost-
effective. This was based on a cost of €316243 per increase in quality adjusted life 
year (QALY) [99]. A similar study, also conducted in Sweden reported that the total 
cost of secondary care per patient was US$230 lower than in intervention group over 
a 12 month follow up period [104]. Significantly, both of these studies adequately 
described associated costs of providing a service.  
 
A pharmacist-led discharge programme, consisting of patient counselling, medicines 
reconciliation and overall medication support resulted in cost avoidance of $378899 
for a group of 229 patients [119]. Cost of service was not stated. 
  
Paediatric programmes 
Pharmacists review of medication appropriateness in a paediatric cardiac ICU resulted 
in cost savings of $12482 from 131 patients [116]. However, the study lacked a 
comparator and didn’t assess cost of service. Pharmacists participated in ward rounds 
in a Chinese paediatric hospital. Intervention and control group showed no significant 
differences in terms of cost of drugs or cost of hospitalisation [122].  
 
Renal specialist  
Pharmacist participation in renal team ward rounds resulted in cost savings of 
US$2250 in comparison with control group [106]. The study size was 300 patients per 
group. Pharmacist recommendations on dosage adjustments for patients with renal 
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impairment resulted in savings of $5377 [120]. Savings were generated from 173 
accepted interventions.  Neither evaluation considered cost of providing the service.  
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Pharmacotherapeutic optimisation  
Pharmacy students identified 320 interventions, resulting in a cost avoidance of 
$23000 due to the prevention of potential adverse drug events [123]. A study 
evaluating the participation of pharmacists in a Dutch ICU ward reported savings of 
$26 – 40 per monitored patient-day. Cost of providing the service was estimated [110]. 
  
Intensive care programme 
A retrospective review of hospital databases indicated, presence of ICU specialist 
pharmacists resulted in improved clinical and economic outcomes in patients with 
thromboembolic events. Examining a total population of 141,079, patients who did 
not receive specific pharmacist care had additional Medicare costs of $215 million and 
drug charges of $26 million [124]. Implementation of antifungal practice guidelines 
by a clinical pharmacist member of an ICU team resulted in a 50% cost reduction in 
expenditure on antifungal agents [113].  
 
Neurosurgery 
A dedicated clinical pharmacist integrated as part of a neurosurgery team, resulted in 
total savings of  US$1,718,260 from 11250 interventions implemented over the 2 year 
study period [114].  
 
Quality appraisal 
Three studies [99, 104, 110], achieved good-quality ratings. Twelve studies were 
described as being of fair-quality as they did not include the cost of providing the 
service or intervention as part of the evaluation. Seven studies were considered to be 
of ‘poor-quality’. 
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The relevant criteria identified from the CHEERS statement are listed in Table 2.3; 
the number of studies which successfully addressed individual criteria is also detailed. 
Only one study accommodated all relevant criteria [99]. The most common items to 
be included in studies were details of patient demographics (77%) and a comparator 
(68%).  Statements on discount rates (measure of reduction in value of future costs 
and outcomes), horizon (period over which costs and outcomes were evaluated) and 
the perspective of the study were excluded in almost every study.  
 
Table 2.3 Quality assessment of eligible studies 
Item from CHEERS checklist % of studies included (n = 22) 
Demographics 77 (n = 17) 
Comparator 68 (n = 15) 
Estimating resources and costs 36 (n = 8) 
Study parameter 32 (n = 7) 
Incremental Cost-Effectiveness ratio 23 (n = 5) 
Analysis of uncertainty 23 (n = 5) 
Currency 18 (n = 4) 
Perspective  9 (n = 2) 
Horizon 4 (n = 1) 
Discount 4 (n = 1) 
 
2.5 Discussion 
 
Based on the studies examined in this review, clinical pharmacist interventions remain 
economically beneficial. The majority of studies included in this review demonstrated 
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some degree of cost savings; however the disparate nature of evaluated interventions 
and outcome measures makes it impossible to determine the most beneficial 
intervention type. Furthermore, the methods used to calculate and report outcomes do 
not facilitate inter-disciplinary comparison.  
Significant savings were generated through the prevention of ADEs; this concurs with 
findings of previous reviews which estimated that ADE prevention resulted in the 
highest cost-benefit ratio [81]. However, cost avoidance based results should be 
interpreted with caution, as it is difficult to predict the extent to which they will be 
reflected in real practice  [80].  
 
Clinical pharmacy services which targeted complex high cost environments such as 
ICUs, neurosurgery or biologic agents demonstrated promising results. While 
specialist training and experience is advantageous in this care area[125], interventions 
conducted in these settings have potentially a greater financial impact in comparison 
with interventions implemented in general wards. Furthermore, interventions deliver 
immediate savings which can be easily presented to administrators. Demands for 
critical care services are expected to increase [126].  Pharmacy education programmes 
should adapt accordingly to ensure graduates are suitably qualified for employment in 
these areas [127].  
 
Multiple health technology assessment bodies have tended to favour cost-utility based 
evaluations which include measurements such as QALYs [128]. QALYs measure 
health as a combination of HRQoL and the expected duration of a patient’s life, 
facilitating comparison between interventions in diverse healthcare settings [129]. 
QALYs were only used as the primary outcome in one included study [99]. This made 
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the comparison of outcomes between interventions impracticable. Other outcome 
measures which could be utilised to a greater extent are reductions in hospitalisations 
or mortality rates. These measures are more generalisable and facilitate inter 
disciplinary comparison.   
 
The established trend in systematic reviews of economic analyses is the identification 
of a low number of ‘good quality’ studies [95, 97]. This issue is replicated in this 
review. The quality of studies from a health economic perspective has deteriorated in 
comparison with previous reviews. Perez et al. review established that 27% of studies 
were of good quality [95]. Only 13% of studies included in this review were labelled 
as good quality studies. The majority of studies did not make any attempt to calculate 
input costs for the study. When input costs are not appropriately estimated, it is 
impossible to make an informed decision on the true value of a service. Savings or 
associated benefits can be overestimated. Quality issues seem to be particularly 
prevalent in hospital studies. A recent systematic review which included community 
pharmacy, noted an improvement in standards of economic evaluations of clinical 
pharmacy services [96].  
 
The application of the CHEERS checklist on eligible studies highlights the poor 
reporting standards from a health economic viewpoint. Basic components of a high 
quality economic evaluation such as estimation of resources and costs, uncertainty 
analysis and discount rates were absent from the majority of studies. The primary 
outcome of the majority of included studies was clinically orientated. This is reflected 
in the manner in which they were reported. Stating the perspective of the study, would 
be expected in a good quality health economic publication. However, this was only 
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quoted in two studies. It is expected that health economic studies would account for 
the uncertainty surrounding evidence used and some methodological assumptions 
[130]. The most basic way to address this issue is by conducting a sensitivity analysis. 
However, the issue of uncertainty was not considered in the vast majority of the 
studies.  
 
The highest quality evaluation included in this study concluded that a composite 
clinical pharmacist intervention consisting of medication review, patient education 
and provision of a medication report, was unlikely to prove cost-effective.  Wallerstedt 
et al. used the EQ-5D questionnaire which is a generic preference measure used to 
calculate QALYs [131]. For mild impairments, which most pharmacy interventions 
would be directed towards, condition specific preference measures have proven to be 
more sensitive (45). Despite their widespread use, QALYs are far from the perfect 
outcome measure and may exclude important health consequences (46). In addition, 
to issues around sensitivity mentioned previsously there are additional factors which 
increase the uncertainty surrounding their practicality[132]. Some researchers have 
questioned the validity of the underlying assumptions of a QALY based approach 
[133].   The QALY approach assumes that the value of being in a health state, for two 
years is twice that of being in the health state for one year [134]. Another assumption 
questioned, is that the value of a health state is independent of where a health state 
occurs in a sequence of health events [134].   On the contrary, the advantages of QALY 
based cost-effectiveness analysis are that they allow comparison across disparate 
therapy areas [129]. The widespread use of QALY based measurements has resulted 
in the availability of mapped algorithms to generate QALY values from disease 
specific questionnaires [129].  
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There were no new types of clinical pharmacist interventions highlighted in this 
review. This is a worrying finding for the future of pharmacy. While the profession 
has evolved, a constant stream of novel services will ensure that the profession does 
not stagnate. The lack of developments in economic evaluations of clinical pharmacy 
services is not just confined to a hospital setting. A recent review which included 
community, ambulatory and long-term care facilities did not unearth any ‘novel’ 
clinical pharmacy intervention [96].  
 
A surprising aspect of this review was the increase in the number of studies reporting 
data from Asian healthcare systems. A number of these studies cited an 
underutilisation of pharmacy services in their jurisdiction. Production of economic 
evidence to augment clinical evidence is an excellent strategy to precipitate a change 
in mind-set within these countries.  
 
There is an English language bias in this review. This is particularly important in 
health economic evaluations as the cost-effectiveness of a study is affected by the 
jurisdiction in which it is performed. The review may also be subject to a publication 
bias as grey literature was not evaluated.  
As previously discussed, the lack of standardisation in reporting outcomes and poor 
quality of studies reduced the ability for comparisons between interventions. 
 
2.6 Conclusion 
Clinical pharmacy interventions continue to provide cost savings. However, the 
number of studies examining the subject has decreased and there is a dearth of good 
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quality studies.  There was no novel clinical pharmacy service included in this review. 
The standard of studies published has stagnated or even deteriorated in comparison 
with those included in previous reviews. A number of reasons have been proposed to 
account for this, including lack of interest from academic journals due to the decline 
in ‘novel’ clinical pharmacy services. Alternatively, judgement may have been 
reached that established clinical pharmacy services are in general cost-effective and 
further research into them is unlikely to be necessary.  Pharmacist interventions in 
complex high-cost healthcare settings have been supported by multiple studies 
included in this review and are an area of care which pharmacy research and education 
could be directed towards in the future. Economic analysis was not the main outcome 
measure in majority of studies and was added almost as an afterthought to the primary 
results. In order to increase their relevance, future economic evaluations should at the 
very least present the cost of providing a service in addition to economic and clinical 
outcomes in comparison with an alternative option. Utilisation of a checklist like the 
CHEERS statement has the potential to improve quality of studies; however previous 
published guidelines have not had a lasting impact.  
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3 - Chapter 3: Cost-outcome 
description of clinical pharmacist 
interventions in a university teaching 
hospital 
 
 
The work of this chapter has been published as Gallagher J, Byrne S, Woods 
N, Lynch D, McCarthy S. Cost-outcome description of clinical pharmacist 
interventions in a university teaching hospital.  BMC Health Serv Res. 2014 Apr 
17;14:177. doi: 10.1186/1472-6963-14-177. 
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3.1 Abstract 
Introduction 
Pharmacist interventions are one of the pivotal parts of a clinical pharmacy service 
within a hospital. This study estimates the cost avoidance generated by pharmacist 
interventions due to the prevention of adverse drug events (ADE). The types of 
interventions identified are also analysed. 
Methods 
Interventions recorded by a team of hospital pharmacists over a one year time period 
were included in the study. Interventions were assigned a rating score, determined by 
the probability that an ADE would have occurred in the absence of an intervention. 
These scores were then used to calculate cost avoidance. Net cost-benefit and cost-
benefit ratio were the primary outcomes. Categories of interventions were also 
analysed.  
Results 
A total cost avoidance of €708,221 was generated. Input costs were calculated at 
€81,942. This resulted in a net cost-benefit of €626,279 and a cost-benefit ratio of 
8.64: 1. The most common type of intervention was the identification of medication 
omissions, followed by dosage adjustments and requests to review therapies. 
Conclusion 
This study provides further evidence that pharmacist interventions provide substantial 
cost avoidance to the healthcare payer. There is a serious issue of patient’s regular 
medication being omitted on transfer to an inpatient setting in Irish hospitals. 
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3.2 Introduction 
The traditional role of a pharmacist predominantly involved the dispensing of 
medications in both hospital and community settings; consequently the pharmacist 
was quite detached from other healthcare professionals. The profession has since 
evolved to become recognised as an essential part of the healthcare team [135]. While 
still ensuring that medicines are sourced and dispensed to the highest possible 
standards, pharmacists have diversified into alternative areas of care in hospital 
practice [87]. Interventions are integral components of the new enhanced role which 
pharmacists offer in a clinical setting [88-90, 102, 110, 136]. 
 
A pharmacist intervention is defined as any action taken by a pharmacist that aims to 
change patient management or therapy [91]. A pharmacist’s expertise in 
pharmacology, pharmacotherapy and pharmaceutics ensures they have the requisite 
capabilities to offer suggestions to other healthcare staff on possible alterations to a 
patient’s therapy [92]. This helps to ensure optimal patient outcomes, which has the 
potential to have an add-on economic benefit to the healthcare institution. 
 
A myriad of studies have described the high rate of potential inappropriate prescribing 
and potential adverse drug events (ADE) in multiple healthcare systems [137-141]. 
An ADE is defined by the International Conference for Harmonisation as “any 
untoward medical occurrence in a patient administered a medicinal product which 
does not necessarily have to have a causal relationship with treatment”. These issues 
cause repercussions in the form of increased resource utilisation [142]. Evidence of 
the clinical benefit and reduction in ADEs associated with enhanced roles for 
pharmacists in a hospital setting, are documented in the literature [80, 87, 88, 143]. 
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Healthcare systems worldwide are coming under increasing pressure due to a 
combination of aging populations and the proliferation of new expensive technologies 
[67]. All healthcare services need to show that they provide value for money for the 
investment made in their provision [144][21]. Despite early scepticism, health 
economic evaluations are required for the establishment and continued provision of 
services and technologies [67]. 
 
The provision of a clinical pharmacy service in a hospital setting is an investment 
which utilises costs which could be used elsewhere in the health system. Economic 
evaluations of clinical pharmacy services will help policy makers make informed 
decisions on whether they are a worthwhile investment. Studies in other jurisdictions 
have indicated that they are cost-effective, however these findings are not 
generalisable [145, 146]. 
 
This paper will analyse the interventions made by a team of pharmacists in a university 
teaching hospital and evaluate the cost avoidance achieved through the prevention of 
an ADE. For the purposes of this study, cost avoidance refers to an intervention that 
reduces or eliminates additional expenditure that otherwise may have been incurred in 
the absence of the intervention [117]. It is a different measure to cost saving 
interventions, which refer to reductions in current spending due to changes in the 
expenditure on a patients treatment [147]. Cost avoidance interventions contain and 
control costs and over a longer period of time they can result in cost savings. 
 
The study was based in an Irish university teaching hospital / tertiary referral centre 
setting over a period of one year. Similar studies have been performed, examining 
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shorter time periods or focusing on specific interventions [88-90, 110, 136, 147]. 
However, information which helps to evaluate the economic impact of pharmacist 
interventions over a longer period of time and covering an entire hospital domain is 
lacking. The authors have been unable to find a study where cost avoidance generated 
by a full department of clinical pharmacists in a full calendar year has been calculated. 
3.3  Methods 
3.3.1 Setting 
This was a retrospective study based on a 1 year time period from 01/01/2012 to 
31/12/2012 inclusive. Cork University Hospital (CUH) and the Cork University 
Maternity Hospital is a combined 850-bed hospital site. The hospital serves a 
population of over 620,000. In addition, it is a tertiary referral centre for over 1 million 
people, in the southern region of the Republic of Ireland. Approximately 32,000 
inpatient admissions were recorded for 2012. All patients who were in receipt of a 
pharmacist intervention on their drug therapy were included in this study. There were 
no additional exclusion criteria. The Pharmacy Department consists of 15.8 whole 
time equivalent (WTE) pharmacists. As two WTEs are employed in managerial and 
administrative capacities, 13.8 WTE are available to document interventions as part 
of the daily pharmaceutical service. Interventions performed in all areas of the 
hospital, including the maternity unit, were included in this study. 
3.3.2  Intervention analysis 
Clinical pharmacist interventions are provided by many basic and senior grade 
pharmacists at CUH. Clinical pharmacist interventions are carried out at patient 
admission, during pharmacist-led patient chart review or at the request of another 
healthcare professional. As previously discussed, the primary goal of a clinical 
pharmacist intervention is to ameliorate patient therapy. 
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Interventions made by pharmacists were recorded on a duplicate paper form. One form 
is kept by the pharmacist and one is passed on to the attending physician who has the 
final decision on whether to accept or reject the intervention. 
 
In addition to producing a paper record of the intervention, the pharmacist 
retrospectively enters the proposed intervention into the ‘eClinical Pharmacy Suite’. 
The ‘eClinical Pharmacy Suite’ is a browser-based application, aimed at supporting 
clinical pharmacists to record, grade and report medication related interventions or 
errors. Interventions were assigned by the clinical pharmacist to the most appropriate 
category in the application. Due to time constraints, not all recorded intervention had 
been entered on the computerised database. The primary researcher inputted any 
outstanding interventions and verified data which had been previously entered by 
hospital pharmacists. Intervention categories were developed based on the 
recommendations of an advisory group of clinical pharmacists from Ireland. 
3.3.3  Cost analysis 
The cost of providing this service was calculated based on the average time it took to 
carry out an intervention and the hourly cost of employing a hospital pharmacist. The 
average time of an intervention was based on a previously published study, which 
showed that the majority of pharmacist interventions in a university hospital setting 
took between 15 – 30 minutes to complete [90]The hourly rate of employing a 
pharmacist at the mid-point of the salary scale was calculated based on an annual 
salary of €49,425 (Point 6 of 2010 salary scale) [148] This underwent upward revision 
to account for employer related costs and hospital overheads based on guidance for 
conducting an economic analysis within the Irish healthcare system [149-151]. Base 
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case scenario was calculated using the hourly cost of employing a basic level 
pharmacist at the mid-point of the salary scale and an average intervention time of 
22.5 minutes. 
 
Cost avoidance was calculated based on the probability that an ADE would have 
occurred in the absence of the proposed pharmacist intervention. Interventions were 
analysed by the primary author and a score was assigned based on the probability of a 
patient experiencing harm directly or indirectly from their prescribed/administered 
medicines, and also the potential of omission of regular medication, sub-therapeutic 
dosing or an ill-advised choice of therapy. Determination of the probability that a 
patient would experience harm in the absence of an action by a pharmacist was based 
on the methodology described by Nesbit et al. [147], description provided in Table 
3.1. The cost avoidance for each individual intervention was determined as per 
equation 1 and total cost avoidance was accordingly calculated through summation of 
the individual interventions. A random sample of the interventions (n = 100) were 
reviewed by two academic pharmacists with hospital pharmacy experience and inter-
rater reliability was calculated for the sample. 
Equation 1 
𝑪𝑪𝑪𝑪𝑪𝑪𝑪𝑪 𝒂𝒂𝒂𝒂𝑪𝑪𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂 𝒇𝒇𝑪𝑪𝒇𝒇 𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒂𝒊𝒊𝒂𝒂𝒊𝒊 𝒂𝒂𝒂𝒂𝑪𝑪𝒂𝒂𝒇𝒇𝒂𝒂𝒂𝒂𝒂𝒂𝑪𝑪𝒂𝒂𝑪𝑪𝒂𝒂 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑃𝑃𝑜𝑜 𝐴𝐴𝐴𝐴𝐴𝐴 𝑃𝑃𝑜𝑜𝑜𝑜𝑜𝑜𝑃𝑃𝑃𝑃𝑜𝑜𝑜𝑜 𝑥𝑥 𝐶𝐶𝑃𝑃𝐶𝐶𝑃𝑃 𝑃𝑃𝑜𝑜 𝐴𝐴𝐴𝐴𝐴𝐴 
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Table 3.1 Nesbit method for calculating indirect cost-benefit 
Probability of an 
ADE occurring 
Probability 
score 
Example 
No harm expected 0.00 Pharmacist suggests changing patient from 
esomeprazole to omeprazole exclusively for 
economic reasons. 
Very low 0.01 Patient regularly takes a bisphosphonate, but 
medication omitted from hospital kardex 
Low 0.10 Patient takes an antibiotic twice daily, when 
recommended dose would be three times daily. 
Medium 0.40 Metformin dose not reduced despite patient 
demonstrating renal impairment. 
High 0.60 Patient prescribed amiodarone while currently 
taking digoxin without any reduction in digoxin 
dose. 
Source Nesbit, T.W. et al.: Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice 
model. American journal of health-system pharmacy 58(9), 784–790 (2001)[147] 
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The authors were unable to find an estimated cost of an ADE, calculated based on data 
from the Irish healthcare system. The additional cost of treating an inpatient that 
experienced an ADE was taken from a recent study which utilised a micro-costing 
approach based on data from German hospitals [152]. This study also included a range 
of previously published ADE estimates (€934 – 5783). The majority of previously 
published studies which calculate cost avoidance used a cost of ADE determined by 
Bates et al. [88, 90, 117, 147]. Rottenkolber ADE valuation was deemed to be more 
appropriate for this study as it was published in 2012 while Bates study was published 
in 1997 using US data [153]. This removed the need to account for currency 
differentials and inflation. Purchasing power parities between Germany and Ireland 
were used to further minimise differentials between the two countries. Cost of an ADE 
used in base case scenario was €1057.  
A micro-costing approach, assigns a valuation to each individual unit of resource 
consumed and is considered the most robust costing method [154]. Diagnosis related 
group (DRG) costs for toxic side effects of drugs based on Irish hospital data were 
available but were not chosen as the cost of an ADE. The DRG estimate exclusively 
measured toxic side effects of drugs [155], furthermore DRG costs are generally less 
accurate in comparison to micro-costing estimates [154]. DRG costs for toxic side 
effects for drugs (€887) were included in sensitivity analysis calculations. 
 
Following estimation of the cost of carrying out the pharmacist interventions and the 
resulting cost avoidance, net cost-benefit and cost-benefit ratio for providing the 
service were calculated. Analysis was calculated from the perspective of the healthcare 
institution. Discounting was excluded as events were all considered to have taken 
place in a 1 year time period. 
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3.3.4  Sensitivity analysis 
One-way deterministic sensitivity analysis was performed. Published ranges and 
confidence intervals where available determined the extent of the parameters. 
Sensitivity analysis was also performed using alternative published costs of an ADE 
[153], Irish DRG data and with various intervention acceptance rates. 
3.3.5 Data analysis 
Reports generated from the eClinical Pharmacy Suite database were in Microsoft 
ExcelTM format. Summary statistics were calculated through Microsoft Excel 2010 
(Microsoft Corp., Redmond, Washington). All other advanced analysis was conducted 
through IBM SPSS Statistics Version 18. 
3.3.6 Ethical approval 
Approval was obtained from the Clinical Research Ethics Committee of the Cork 
Teaching Hospitals, University College Cork, Ireland. 
3.4 Results 
A total of 4,257 interventions were documented on 2,147 individual patients (Table 
3.2). The majority of the interventions were judged to have prevented potential ADEs 
(n = 3,417). The remaining interventions had no discernible impact on therapy or 
patient outcomes, based on the judgement of the primary author. Additional 
interventions required entry under multiple categories on the database, but were only 
evaluated once for potential prevention of an ADE. 
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Table 3.2  Intervention analysis 
 Number of interventions 
Total number of patients who received intervention 2147 patients 
Total number of interventions 4257 
Mean number of interventions per patient (St. dev.) 1.98 (1.60) 
Median number of interventions per patient  1  
Range of interventions per patient 1 - 18 
Interventions accepted by physicians (%) 1275 (29.92) 
Interventions rejected by physicians (%) 61 (1.43) 
Interventions with unknown acceptance outcome 
(%) 
2921 (68.81) 
 
Recorded acceptance rate by physicians was 29.92% (n = 1275). Only 1.43% (n = 61) 
interventions were recorded as being rejected by a physician. However, the rate of 
interventions with an unknown acceptance outcome was high, 68.81% (n = 2921). 
Substantial cost avoidance of €710,000 was generated over a 1 year period from the 
perspective of the health care provider. Mean cost avoidance of €166 per 
intervention was generated. The cost of providing these interventions was €82,000. 
Substantial net cost-benefits of €626,279 and a cost-benefit ratio of 8.64 were 
generated based on this evaluation of pharmacist interventions as shown in Table 
3.3. 
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Table 3.3  Cost analysis of pharmacist interventions 
 Description Base case (Range) 
1. Cost avoidance €708221 (625808–3874783) 
2. Cost of Service  
 - Pharmacist Wages €81942 (22402 –110389) 
 
a 3 = (1–2) Net Cost-Benefit €626279 (567173–3764394) 
b 4 = (1/2) Cost-Benefit Ratio  
 
8.64 : 1 
a (Cost avoidance – Cost of Pharmacy Services) 
b (Net Cost-Benefit ÷ Cost of Service) 
The number of interventions that potentially avoided ADEs were as follows: 119 
(2.8% of all interventions) of the interventions were associated with a probability score 
of 0.6 (high likelihood of preventing an adverse event), 1101 interventions (25.86%) 
were associated with a probability score of 0.4 (medium), 1514 interventions (35.56%) 
were associated with a probability score of 0.1 (low), 683 interventions (16.04%) were 
associated with a probability score of 0.01 (very low) and 840 interventions (19.73%) 
were associated with a probability score of 0 (no harm expected). Results are presented 
in table 3.4 
 
 
Table 3.4 Cost avoidance associated with intervention probability  
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Probability of an ADE 
occurring 
Example No of 
interventions 
assigned to 
category  
Cost avoidance 
generated (€) 
No harm expected Pharmacist 
suggests changing 
patient from 
esomeprazole to 
omeprazole 
exclusively for 
economic reasons. 
840 0 
Very low Patient regularly 
takes a 
bisphosphonate, 
but medication 
omitted from 
hospital kardex 
683 7219.31 
Low Patient takes an 
antibiotic twice 
daily, when 
recommended 
dose would be 
three times daily. 
1514 160029.8 
Medium Metformin dose 
not reduced 
despite patient 
demonstrating 
renal impairment. 
1101 465502.8 
High Patient prescribed 
amiodarone while 
currently taking 
digoxin without 
any reduction in 
digoxin dose. 
119 75469.8 
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The most prevalent type of intervention was the identification of omissions of patient’s 
regular pre-admission medication, followed by requests to change the dose of 
medications and requests for the physician to consider whether it was appropriate to 
continue with a medication (Table 3.5). The most common categories of medications 
to require interventions were proton pump inhibitors (n = 259), statins (n = 208), beta-
blockers (n = 165), corticosteroids (n = 161) and penicillins (n = 157). 
 
Table 3.5  Intervention categorisation 
Category of intervention N (%) 
Drug 2759 (64.81%) 
- Drug, Omissions 1820 (65.93% of Drug Category) 
- Drug, Review Therapy 421 (15.24% of Drug Category) 
- Drug, Interaction 124 (4.56% of Drug Category) 
- Drug, Other 394 (14.27% of Drug Category) 
Doses 920 (21.61%) 
Frequencies 354 (8.32%) 
Routes 125 (2.94%) 
Duration 47 (1.10%) 
Other 27 (0.63%) 
Date/Time 20 (0.47%) 
Rates 5 (0.12%) 
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Inter-rater reliability indicated an acceptable level of agreement, based on a random 
sample of 100 interventions. Average agreement between 3 raters was 0.744. 
Individual pairwise agreement was over the significant level of 0.7 for all 3 
comparisons: Primary Rater (PR) – Academic Pharmacist (AP) 1 = 0.763, PR – AP 2 
= 0.761, AP 1 – AP 2 = 0.709. 
 
In all scenarios examined, the cost-benefit ratio remained positive as outlined in Table 
3.6. All known variables underwent a one-way sensitivity analysis based on known 
ranges or using variations used in previously published sensitivity analysis on the 
topic. Nesbit et al. conducted a sensitivity analysis where the ADE probability 
underwent an each way variation of 50%, an identical variation was undertaken in this 
paper [25]. The greatest variance in cost-benefit ratio was displayed in the cost 
assigned to an ADE. . 
Table 3.6  Sensitivity analysis for cost-benefit ratios 
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Variable Lower limit (Cost-Benefit 
Ratio) 
Upper limit (Cost-Benefit 
Ratio) 
Time 30 minutes per intervention 15 minutes per intervention 
6.48 12.96 
ADE Probability −50% Probability score +50% Probability score 
4.32 12.96 
Salary Highest point on senior 
pharmacist scale 
Lowest point on basic 
pharmacist scale 
6.42 12.07 
ADE CostA Lowest point on range Highest point on range 
7.63 47.28 
Intervention 
acceptance 
50% Acceptance Known Acceptance (29.92%) 
4.32 2.59 
A ADE range taken from a review of selected international studies regarding the economic consequences of ADEs 
which reported additional mean costs in the range of €934 to €5783 per case  [156]. 
Two additional ADE cost estimates were investigated during the course of sensitivity 
analysis (Table 3.7). The estimated cost of an ADE calculated by Bates and adjusted 
due to change in setting and year resulted in a considerable increase in the cost-benefit 
ratio. 
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Table 3.7  Sensitivity analysis using alternative ADE estimates 
Alternative ADE estimate Cost-benefit ratio 
DRG Toxic Side Effects [33] 7.25 
Bates ADE Costing [31] 49.49 
 
3.5  Discussion 
Substantial cost avoidance was demonstrated in this study. Cost-benefit ratio and net 
cost-benefit remained positive under all conditions examined. To the authors’ 
knowledge, this study is the first that has attempted to estimate the cost avoidance 
achieved in a total hospital environment over such an extended period of time. Direct 
comparison of savings generated in this study with previously published studies is 
difficult. Calculation of cost avoidance will have inter study variations in the cost 
assigned to an ADE, methodologies, healthcare settings, duration of study and number 
of pharmacists employed. 
 
The original study which implemented the cost avoidance method used in this paper 
generated a net benefit of $392,660 [147]. This was over a similar 12 month period 
but only included 3 WTE pharmacists operating on three specific hospital wards. 
Study location was in a US hospital. These pharmacists had undergone specialist 
training and were to a large extent exclusively performing interventions during their 
participation in the study. Cost-benefit ratio of 3.1:1 was considerably smaller in the 
Nesbit study. Cost-benefit ratio was influenced significantly by the method used to 
calculate the cost of the service. The complete pharmacist salary was used to calculate 
the cost of providing the intervention rather than apportioning part of the salary based 
on the time pharmacist spent enacting the interventions. 
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A study by Olson et al. conducted in a 360 bed US hospital has the greatest 
methodological agreement with this paper [90]. This was conducted over a 3 month 
period and estimated the cost-benefit ratio to be 1.2. Only 5 pharmacists provided 
interventions in this study. Although, substantial savings ($84,631) was generated 
from a small number of interventions, the cost-benefit ratio was lower than expected. 
As with the Nesbit study, cost-benefit ratio was reduced as full pharmacist salary was 
used to calculate the cost of providing the service. The results in this study provides 
evidence that the positive cost-benefit ratio of clinical pharmacists’ interventions is 
maintained over a longer period of time, with additional pharmacists and in a wider 
hospital setting. 
 
Cost avoidances are impacted significantly if they are focused in specific departments. 
Cost avoidance per intervention generated in our study was decidedly lower in 
comparison to a study conducted in an intensive care unit. The addition of a single 
critical care pharmacist to a 16 bed intensive care unit produced an average cost 
avoidance of $1596.27 - $1615.67 per intervention [88]. Input costs were omitted in 
this study so further comparison was not feasible. 
 
While the cost-benefit ratio in this study was positive, it needs to be reiterated that this 
ratio was based on estimates of time and avoidance of cost rather than actual monetary 
valuations. Therefore, the ratio could potentially be an overestimate. Furthermore, an 
evaluation of a clinical pharmacy service is strengthened when it also includes an 
assessment of the clinical and humanistic outcomes involved [81].  
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This high degree of omissions of patient’s regular pre-admission medications (43% of 
all interventions) highlights the need for a dedicated system of medicines 
reconciliation at a tertiary healthcare level in Ireland. A pilot study of pharmacist-led 
medication reconciliation in two university teaching hospitals, elsewhere in Ireland, 
also identified omission of a pre-admission medication as the most common 
discrepancy [157]. These findings are replicated in other healthcare settings [158]. 
Medication omissions can have potentially serious consequences for patients 
depending on the nature of the drug omitted [159]. 
 
An argument could be presented not to include medication omissions as an ADE, 
based on a strict interpretation of the definition, as the patient did not receive the drug 
[160]. However, the decision was taken to include them in this study. Similar studies 
in the past have included the identification of medication omissions as a potential ADE 
[90, 161]. The probability of a patient incurring harm is increased if they do not receive 
their regular medication, resulting in a related increase in hospital resource utilisation 
[162]. 
 
Medium and low scores were the most frequent probabilities assigned to the 
interventions. This reflects findings obtained in the majority of previous studies which 
implemented the same method of calculating cost avoidance [88, 147, 161]. The 
frequency of these scores were influenced by the number of medication omissions 
(39% of omissions were assigned a medium probability score and 37% assigned a low 
probability score.) Interventions designated with a high probability of preventing an 
ADE were largely composed of omissions of essential medications (e.g. anti-epileptic 
drugs) or known serious drug interactions. 
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The most common medication classifications requiring intervention were 
unsurprising. Proton pump inhibitors (PPI) were the medication classification 
requiring the most frequent intervention. Interventions on PPIs were largely 
suggestions to change to lower cost equivalents, highlighting therapeutic duplication, 
excess of therapy or suggestion for switching from intravenous to oral administration. 
The majority of these interventions resulted in cost savings to the healthcare provider. 
Inappropriate prescribing of PPIs is a significant issue in the Irish healthcare system 
and a significant drain on resources [163, 164]. This demonstrates the pivotal role can 
play as cost containers in the healthcare system. 
 
Another method of increasing the number of interventions would be the provision of 
further training for clinical pharmacists which would enable them to become 
specialists in various areas of patient care. This practice is common in other countries 
and has been shown to provide substantial monetary savings from interventions 
enacted by specialist pharmacists [88]. Specialised anti-microbial pharmacists have 
been shown to be of value and are now established in many hospitals in Ireland [164, 
165]. 
 
A significant level of agreement was found between three of the listed authors. 
Assignment of probabilities is subjective; therefore a high level of agreement is 
unlikely. On review of samples, almost all were within 1 score of each other, further 
indicating that probabilities were assigned by the primary author in a manner 
consistent with fellow professionals. Although, inter-rater reliability was not 
examined for all interventions, the clinical background of the primary rater and the 
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significant agreement level demonstrated in the sample indicate the ADE probabilities 
were assigned in an appropriate and consistent manner. 
 
There was a high rate of interventions where the outcome was unknown at time of 
analysis. However, review of interventions where status was determined indicated that 
only a small minority of pharmacist interventions were rejected. This indicates that 
other healthcare professionals are receptive to pharmacist interventions on patient 
medication. The high level of unknown outcomes was most likely due to time 
constraints on the pharmacist. Following acceptance or rejection, system requires 
manual updating. It is understandable that an administrative task such as this may be 
neglected. 
 
The importance of an accurate estimation of ADE cost was emphasized from the 
dramatic increase in cost-benefit ratio if Bates et al. estimate of ADE was used. As 
previously stated, there is an absence of data on ADE costs in Ireland. The validity of 
estimated cost avoidance would be improved through application of local data on 
excess costs associated with ADE. Until this issue has been addressed, imperfect data 
is the only viable option. Sensitivity analysis undertaken in this study was 
deterministic in nature; performing probability sensitivity analysis would have been a 
more robust method to determine whether pharmacist interventions would have 
maintained a positive cost-benefit ratio. 
 
The primary limitation was the limited availability of additional patient information 
(medical record, medical history, outcome of intervention etc.) when assigning 
adverse drug event probabilities. As this study contained a large number of patient 
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interventions, it was not feasible to retrospectively retrieve this information from 
medical notes. 
 
Another major limitation was the exclusion of some potential input costs. In order to 
conduct an intervention, problems must be located which takes up pharmacist time 
and therefore has an associated cost. Screening of a patient’s medication may not be 
exclusively for the purpose of discovering interventions but it is one possible outcome 
from it. Additionally, other healthcare professionals are required to spend time 
reviewing suggested pharmacist interventions. This was also excluded from analysis. 
 
Utilisation of a scoring system which also accounts for the severity of the potential 
ADE would significantly enhance this study. Such scoring systems exist but they do 
not assign a cost with the scoring outcome generated. There is no ideal system for 
assigning probabilities to adverse events but the widespread adaptation of one system 
would add to the ability to compare studies across jurisdictions. The classification of 
interventions is subjective. Generation of local guidelines on the classification of 
interventions would help reduce this variation. 
 
While the interventions included in the study represented the majority of work 
conducted by clinical pharmacists, it is possible that some interventions were not 
inputted on to the eClinical System. Therefore, the current data may under-represent 
the cost avoidance produced. The overall return on investment associated with clinical 
pharmacist interventions could potentially be increased if some interventions were 
omitted from entry into eClinical System.  
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The interventions were assigned scores by an individual rater. While sample of 
interventions examined for inter-rater reliability indicated that the primary author was 
assigning probability scores in a manner consistent with other pharmacists, review of 
complete dataset by additional pharmacists and other medical professionals would 
have enhanced the study. 
3.6 Conclusion 
Previous reviews have indicated that pharmacist interventions generate significant 
cost avoidance when measured under certain criteria and conditions [18]. This study 
has confirmed previous opinions and supplemented the body of evidence that the 
provision of clinical pharmacy services in an entire hospital provides value for money 
to the healthcare payer. An excessive amount of omissions of regular medications has 
been highlighted by this study. The estimation of cost avoidance would be improved 
by the development of a method which incorporated the potential severity of an ADE 
into the evaluation and an evaluation of excess costs associated with ADEs in an Irish 
healthcare setting. 
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4 - Chapter 4: Economic Evaluation of a 
randomised controlled trial of 
pharmacist-supervised patient self-
testing of warfarin therapy 
 
The work of this chapter has been published as Gallagher J, McCarthy S, Woods 
N, Ryan F, O' Shea S, Byrne S. Economic evaluation of a randomized controlled trial 
of pharmacist-supervized patient self-testing of warfarin therapy. 
J Clin Pharm Ther. 2015 Feb;40(1):14-9. doi: 10.1111/jcpt.12215. 
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4.1 Abstract 
Introduction 
The increase in numbers of patients requiring oral anti-coagulation testing in 
outpatient clinics has focused attention on alternative flexible systems of anti-
coagulation management. One option is pharmacist-led patient self-testing (PST) of 
international normalised ratio (INR) levels. PST has demonstrated improvements in 
anti-coagulation control, but its cost-effectiveness is inconclusive. This study reports 
the first cost-effectiveness evaluation of a randomized controlled trial of an automated 
direct-to-patient expert system, enabling remote and effective management of patients 
on oral anti-coagulation therapy. 
Method 
We conducted an economic evaluation alongside a randomised controlled trial 
investigating a pharmacist-led PST method. The primary outcome was to determine 
the cost effectiveness of PST in comparison with usual care (management in a 
hospital-based anti-coagulation clinic). Long term anti-coagulation patients were 
recruited to a 6 month cross over study between PST and routine care in an anti-
coagulation clinic. Economic evaluation was from the healthcare payer perspective. 
Result 
On a per patient basis over a 6 month period, PST resulted in an incremental cost of 
€59.08 in comparison with routine care. Patients achieved a significantly higher time 
in therapeutic range (TTR) during the PST arm in comparison with routine care, (72 
± 19.7% vs. 59 ± 13.5%). Overall cost of managing a patient through pharmacist-
supervised PST for a 6 month period is €226.45. Additional analysis of strategies from 
a societal perspective indicated that PST was the dominant strategy. 
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Conclusion 
Pharmacist-led patient self-testing is a viable method of management. It provides 
significant increases in anti-coagulation control for a minimal increase in cost. 
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4.2 Introduction 
Despite the development of new oral anticoagulant agents (NOACs), warfarin remains 
an integral treatment option in anticoagulation management strategies. In Ireland in 
2010, 57,000 patients were in receipt of a prescription for warfarin [166]. This 
constitutes 1.7% of the population. The majority of patients (55%) required warfarin 
for treatment of atrial fibrillation [166].  
 
Warfarin is a well-established medication with a relatively low cost. However, 
unusually for an oral medication, it has significant expenses associated with the 
monitoring and management stage of the therapy. Warfarin is a medication with a 
narrow therapeutic index, requiring close management and regular dosage adjustments 
can be necessary. Currently in Ireland, the majority of management is provided by 
dedicated hospital-based anticoagulation clinics [166]. 
 
 There are documented limitations to hospital-based clinics, especially from a patient’s 
perspective which include the requirement to make regular and frequently, time 
consuming visits to the clinic [167]. Furthermore, previous studies have shown that 
alternative management strategies can improve anticoagulation control in comparison 
with hospital-based anticoagulation clinics [168]. The development of NOACs will 
decrease the overall proportion of patients’ dependent on warfarin as a long term 
anticoagulant, however some patients will remain on warfarin therapy and therefore 
require an anticoagulation management service [169].  
 
Patient self-testing (PST) of warfarin therapy is a concept which allows the 
management of warfarin therapy to move away from already overburdened hospital-
based clinics to management at a primary care level. The PST model involves the 
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patient measuring their international normalised ratio (INR) levels using a portable 
point-of-care (POC) device. There are clinical benefits associated with the application 
of PST over usual care in anticoagulation management. Evidence ranging from 
randomised controlled trials (RCT), meta-analysis and full systematic reviews 
indicates that PST is associated with improved outcomes [7, 170-174]. PST of oral 
anticoagulation is proven to be a safe option in all age groups [175].  
 
Input from healthcare professionals is still a fundamental requirement for the success 
of any PST strategy. Ryan et al. demonstrated that a single pharmacist could 
favourably oversee the management of a group of patients managing their INR using 
a PST strategy [7]. Pharmacists have a broad clinical and therapeutic knowledge and 
are using these skills to diversify into new areas of patient care [176]. With additional 
training in the area of anticoagulation management and accreditation of required 
standards, pharmacists have shown they are capable of providing an anticoagulation 
management service [177].  
 
The method by which results are communicated to the responsible professional is 
another crucial part of warfarin PST. Telephone-based communication has been 
proven as a viable method and is widely utilised in the US [178]. However, availing 
of technological developments can reduce the cost, time and risk of errors associated 
with verbal communication [179]. ‘Expert’ software systems have been developed to 
assist in patient management and data recording. The RCT examined in this evaluation 
utilises the CoagCare™ system (ZyCare Inc. Chapel Hill, NC, USA). CoagCare™ 
combines a direct-to-patient expert system accessed via the internet with PST to 
provide a novel model of pharmacist-supervised tele-health [7].  
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This study is the first cost-effectiveness evaluation of an internet based, direct-to-
patient expert system in anticoagulation management. The direct-to-patient expert 
system employs a rule-based algorithm to inform patients how to adjust warfarin 
therapy based on INR data which has been recorded and inputted by the patient [7]. 
Previous cost-effectiveness analysis has been inconclusive as to whether similar 
systems offer “value for money” to the healthcare payer [180].  
 
In this paper, a cost-effectiveness analysis was undertaken based on the outcomes and 
resource utilisation from a RCT of pharmacist-supervised PST of warfarin therapy 
using an internet based system [7]. The primary aim of this study was to determine the 
incremental cost-effectiveness of PST in comparison with usual care.   
4.3 Methods 
4.3.1 Trial protocol 
This cost-effectiveness analysis was based on data from an RCT which is documented 
elsewhere [7]. In summary, the trial was a prospective, randomized controlled 
crossover study. Patients were initially assigned to either six months of routine care or 
six months of PST. At the end of the six month period, the patient was transferred to 
the alternative arm. The crossover design of the study eliminated the potential for 
covariate disparities. The primary outcome was the difference in the time in 
therapeutic range (TTR) between the two arms. Overall TTR for each arm was 
calculated using the Rosendaal method [181]. For the purposes of this trial, TTR was 
defined as the time spent within 0.5 units of the targeted INR value [7]. Patients were 
required to have been on warfarin therapy for at least two months prior to the start of 
the study and expected to have a requirement for warfarin for the duration of the 12-
month study. Patients were excluded from the trial if they were unable to use a POC 
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device, if they missed attending more than two clinic appointments in a six month 
period prior to recruitment screening or if the patient was taking an additional 
anticoagulant other than warfarin. Furthermore, patients were excluded if they had 
experienced a haemorrhagic complication in the preceding six months, or if they were 
unable to attend the hospital clinic at short notice. Following recruitment, patients 
received comprehensive training from the research pharmacist.  
 
Initially INR levels were measured in the PST arm twice weekly. Following 
stabilisation of INR levels, intervals between tests were increased to a maximum of 
once every two weeks. Management of deviations from the targeted INR value or other 
patient issues were the responsibility of the research pharmacist, assisted by the 
CoagCare™ system. During the course of routine care, patients attended the 
anticoagulation   management service (AMS) for INR measurement every 4 - 6 weeks. 
Any necessary dosage adjustments were calculated by a doctor or nurse associated 
with the clinic.  
Ethical approval was obtained from the Clinical Research Ethics Committee of the 
Cork Teaching Hospitals, University College Cork, Ireland. 
 
4.3.2 RCT information 
Patient recruitment and provision of routine care was provided at the AMS of Cork 
University Hospital (CUH). Currently, the AMS has approximately 850 regular 
patients. Additionally, the clinic is responsible for short-term anticoagulation patients 
and the processing of INR tests which are taken at other locations. In 2012, 120,000 
INR tests were processed at the medical laboratory in CUH.  
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The total patient enrolment was one hundred and sixty-two patients, 132 of whom 
completed both the AMS and PST arms of the trial. Only patients who completed both 
arms of trial were included in final analysis. Mean age of the patient was 58.7 ± 14.3 
years. Indication for oral anticoagulation therapy consisted of prosthetic heart valve – 
49 (37.1%), atrial fibrillation – 43 (32.6%), deep vein thrombosis (DVT) / pulmonary 
embolism (PE) – 29 (22%) and other - 11 (8.3%). Patients withdrew from the trial for 
the following reasons: warfarin therapy discontinued (n = 8), patient found PST 
stressful (n = 5), left the AMS (n = 5), issues with internet access (n = 4), poor 
correlation between PST meter and laboratory INR results (n = 3), non-anticoagulant 
related death (n = 2), difficulty obtaining sample of blood using lancet (n = 1). 
4.3.3 Pharmacoeconomic analysis 
The analysis has a time horizon of six months which is the duration of the intervention 
arm.  Discounting of costs or outcomes was not required as the time horizon was less 
than one year. Base case analysis is from the narrower perspective of the healthcare 
payer. Base case analysis used mean values determined during the RCT. Resource 
utilisation was over a six-month time period. The effect measurement was TTR in both 
the routine care and intervention arms. The duration of the trial was unsuitable for the 
adequate measurement of patient orientated outcomes such as death and non-fatal 
thromboembolic events. However, TTR is a documented marker for haemorrhagic and 
thrombotic complications [182].  Kaatz reasons that TTR should be the standard 
quality indicator for anticoagulant control as there are pragmatic issues affecting the 
completeness and accuracy of adverse event gathering [183].    
 
Costs associated with the control and intervention groups are described in Table 4.1. 
The cost of processing an INR test at the CUH laboratory had previously been 
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calculated as part of an internal CUH evaluation. Costs of staff were calculated based 
on expert guidance from staff of CUH, internal CUH data and published HSE salary 
scales [184]. Patients received a 90 minute education and training session from the 
pharmacist. These were carried out in groups of one to three people; the pharmacist 
conducted 44 separate sessions [7]. Mean daily time required to manage a group of 80 
patients was 23.2 minutes (± 9.5 minutes standard deviation). Therefore, an estimated 
20 hours per month would be required for management of 132 patients. A cost of €30 
per hour was applied to pharmacist time required for the study. The cost of the POC 
system was sourced from Roche Diagnostics, the manufacturer of the device used in 
the RCT.  
 
The cost of warfarin therapy was excluded from both arms as significant differences 
in usage between groups were not anticipated; furthermore warfarin is a relatively 
cheap medication.  Referenced unit cost prices are from 2012. Value added tax (VAT) 
was excluded from study costs based on recommendations for conducting health 
technology assessments in Ireland [185]. 
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Table 4.1 Costs associated with anticoagulation management   
Anticoagulation Management Service* € 
Cost per laboratory INR test  2.00 
Medical Staff ab 8.08 
Nursing ac 62.67 
Clerical Officer a 8.17 
Senior Medical Scientist a 9.43 
Phlebotomy a 52.51 
Healthcare Assistant a 5.11 
Patient self-testing group € 
Cost per Coaguchek strip 3.66 
Lancets (200) 12.62 
Pharmacist supervision a 27.27 
Cost of education session per patient  15.00 
Coaguchek® XS Meter (Purchase cost)  588.00 
CoagCare - 6 month license cost 2500 
* - Costs calculated based on internal CUH data and expert guidance 
a – Mean cost per patient per 6 month period 
b – Four senior house officer hours and three consultant haematologist hours per week 
c- One whole time equivalent (WTE) clinical nurse specialist and 2.5 WTE's staff nurse  
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4.3.4 Sensitivity analysis 
One-way sensitivity-analysis was conducted on all known variables. Standard 
deviations and confidence intervals were employed where possible. In the absence of 
any indication of variability, a ±50% variation was applied. Additional evaluations 
which were inclusive of societal benefits such as travel costs and patient time foregone 
through attendance at AMS were also included in a supplementary evaluation. An 
argument for evaluation from a societal perspective can be made as significant costs 
can be accrued due to patients’ requirement to attend an anticoagulation clinic. 
Societal benefits were calculated using resource consumption and patient data 
obtained in the RCT [7]. Cost per km travelled by car was calculated using 
recommended Irish reimbursement rate for a mid-sized car [186]. Working time 
sacrificed due to attendance at anticoagulation clinic was calculated using national 
average wage per hour (Q3 2013) [187]. Leisure time lost through attendance at clinic 
was valued at 35% of the local average gross wage. This methodology had been used 
in previously published attempts to calculate cost of attending an anticoagulation 
clinic [167]. The cost to the HSE for provision of POC devices to patients was also 
investigated. Machine costs were spread over a five year period using a straight line 
depreciation method. This was deemed acceptable as five years is recognised as the 
minimum lifespan of these machines [188]. The year one purchase cost of a CoagChek 
XS meter was included in this scenario.    
4.4 Results 
Patients achieved a significantly higher TTR during the PST arm in comparison with 
routine care, (72 ± 19.7% vs 59 ± 13.5%).   Increases in TTR were achieved for both 
patients who were initially randomized to PST group (16.6%) and AMS group 
(12.3%). The effect of order of management was non-significant (P = 0.412).  
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There was a substantial difference in the frequency of testing between the trial groups. 
The PST group tested their INR almost four times more frequently than the AMS 
group over a 6 month period as described in Table 4.2. The mean frequency of testing 
days for PST was 4.6 days, which was a considerably shorter time period than the 19.6 
days between each test in the control group.  
 
Table 4.2 Cost Effectiveness of 6 months of PST versus AMS (Usual Care) 
 
The base case cost-effectiveness analysis indicated that on a per patient basis, PST 
was slightly more expensive than AMS (Table 4.2). On a per patient basis over a six 
month period, PST resulted in an incremental cost of €59.08 in comparison with 
routine care. Overall cost of managing a patient through pharmacist-supervised PST 
for a six month period is €226.45.  Difference in overall cost was minimal and PST 
 Patient Self-Testing Anticoagulation 
Management Service 
Mean % TTR (95% CI) 72 (+/- 2.32%) 59 (+/- 3.36%) 
Median % TTR (IQR) 74 (64.6 – 81) 58.6 (45.5 – 73.1) 
Mean INR tests / patient 
± SD 
(Range) 
41.7 +/- 6.6 
(24 – 60) 
10.7 +/- 5.2 
(5 – 35) 
Cost of 6 months of 
patient management 
€226.45 €167.38 
Incremental cost of 6 
months of PST therapy 
versus AMS 
 
€59.08 
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was the dominant strategy in some scenarios examined during sensitivity analysis, 
specifically if analysis was conducted from a societal perspective or at the maximum 
estimate of the cost of AMS staff as demonstrated in Table 4.3. Unsurprisingly, the 
most expensive scenario evaluated was if full cost of POC meter was reimbursed by 
healthcare payer.  
Table 4.3 One-way sensitivity analysis  
 
  
1 Based on expert guidance, sensitivity analysis of +/- 50% was applied 
2 This scenario was both less costly and more effective in comparison with management at AMS. 
Therefore, PST is dominant over usual care. 
  
Testing frequency € 
- Minimum value 95% CI 34.92 
- Maximum value 95% CI 83.23 
Point of care device reimbursement  
- 5 Year Straight Line Depreciation 176.68 
AMS Staff   
- Minimum value (15% of workload) -13.91  (Dominant)1 
- Maximum value (5% of workload) 132.07 
Societal perspective -13.44  (Dominant)2 
Excluding pharmacist training 44.08 
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4.5 Discussion  
Based on the results of this study, on a per-test basis, PST is marginally more 
expensive in comparison to centralized laboratory testing. This is similar to the 
established trend of previous publications [189]. However, it does offer additional 
benefits to the healthcare payer in exchange for this extra cost. It is speculative to 
determine whether this strategy is cost-effective, as no threshold has previously been 
suggested for an increase in TTR. However, the relatively small value of the 
incremental cost increases the probability that a healthcare payer would surmise that 
it is a worthwhile strategy to finance. The fact that multiple scenarios examined in the 
sensitivity analysis, including an evaluation from a societal perspective concluded that 
PST was the dominant strategy, gives further credence to this prospect.  
 
The cost-effectiveness of PST is dependent on the method of evaluation used, choice 
of comparator and the setting. As far as the authors are aware, this is the first economic 
evaluation of a pharmacist-supervised direct-to-patient system.   Furthermore, this is 
the first evaluation of PST that has been undertaken in an Irish population.  
 
The strategy evaluated in this paper is favourable on a cost per patient basis to a 
number of other PST strategies which have undergone economic evaluation. Claes et 
al. evaluated a similar method which involved a CoaguChek device, dosing software 
and GP management in Belgian GP practices, however, this method was more 
expensive and achieved an inferior TTR level to our study. Perhaps the most 
comprehensive evaluation of PST strategies was a health technology assessment 
conducted in Canada. This concluded that PST was not cost-effective based on a 
threshold of €50000 (CAN) per Quality Adjusted Life Year (QALY).  However, when 
calculated from a societal perspective, PST was determined to be cost saving [190]. 
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While QALYs attempt to give an overall measurement of the impact of a therapy or 
intervention on a patient, they can lack sensitivity when used in the comparison of two 
similar treatment strategies, as is the case with PST and AMS. 
 
TTR is a reliable indicator of the performance of any method of anticoagulation 
management and therefore is a suitable effect measurement for this cost effectiveness 
analysis. The current study showed a difference of 13% between the means of both 
groups and a 15.4% difference between the two median values. The Stroke Prevention 
using oral thrombin inhibitor in atrial fibrillation (SPORTIF) III and SPORTIF V 
studies suggest that the incidence of death, major bleeding and stroke may be halved 
by a 15 % improvement in TTR [191]. Similar increases were obtained during the 
course of this study.  
 
Significantly, the TTR levels associated with this study were greater than the 70% 
range which would be considered a good level of control. A retrospective review of 
6108 patients with non-valvular atrial fibrillation showed that patients with INR 
control of 70% of time in range had a significantly reduced risk of stroke [192].  
The cost of managing a patient using PST based on our trial data was determined to 
be €226 for a six month period. In comparison, the net ingredient cost of six months 
of therapy of either of the two NOACs  currently licensed for the prophylaxis of 
thromboembolic events in Ireland is between €456.06 (Dabigatran 150mg x 60 tablets 
per month) and €384.66 (Rivaroxaban 20mg x 28 tablets per month) [193]. Previous 
studies indicate that these are cost-effective in comparison with conventional warfarin 
management [194]. However, the comparator used in both of these trials was 
conventional warfarin management which is associated with reduced TTR levels and 
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overall poorer patient outcomes. No significant effect has been shown between 
patients treated with dabigatran and those who are treated with warfarin and have TTR 
levels >65.5% [195]. The management strategy evaluated in this paper has an overall 
TTR of 72%. Improvements in warfarin control may force a reappraisal of the cost-
effectiveness of NOACs.  
 
Although, the increase in testing frequency has been hypothesised as the reason for 
the observed benefits of PST [196], it does not offer a comprehensive explanation. 
Similar testing frequencies in control and intervention groups resulted in better 
outcomes in the groups using POC monitoring [197, 198].  
 
Patient self-testing is not a suitable strategy for all patients. This is reflected in the 
reasons given by patients for dropping out of the trial. Thirteen patients did not 
complete the trial for reasons which could be attributed to difficulties with PST 
management. Future research should attempt to investigate which patient groups 
would benefit most from self-testing or self-monitoring strategies. Some studies have 
suggested focusing on those with mechanical heart valves or those under 55, however 
conclusive evidence is lacking [199]. 
 
The limited duration of the RCT restricts the utility of the data as initial costs such as 
patient training and purchase costs of the POC devices are loaded into a six month 
time period, even though they will have a longer term benefit to the patient which is 
not captured during this study. The duration and sample size did not allow for a 
significant level of haemorrhagic and thromboembolic complications to be detected.  
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Optimal management of warfarin therapy in the form of PST has a long-term benefit 
to the patient in terms of reduced thromboembolic events and deaths [170]. The benefit 
is not one that is conclusively detectable after six months data collection.   
Some of the costs calculated were based on expert guidance and internal hospital data. 
Workload of AMS staff was based on expert guidance from senior staff in the 
anticoagulation clinic at CUH; however variation of this estimate had the greatest 
effect on outcome. Wide variations were employed to any assumptions based on expert 
guidance during sensitivity analysis. Analysis based on micro-costing techniques, 
would considerably reduce uncertainty around outcomes. Additionally, there was a 
self-selective nature to patient recruitment. Therefore, the group studied may not be 
representative of the actual population. The estimated percentage of patients who are 
prescribed warfarin for atrial fibrillation was lower in this study compared to national 
levels. 
 
As with all economic evaluations based on a single RCT, there are considerable issues 
associated with the generalizability of the results reported. However, this has been 
partially addressed through the application of a sensitivity analysis.  
 
4.6 Conclusion 
PST provides a significant increase in anticoagulation control for a modest increase in 
expenditure. This is maintained in all situations evaluated in sensitivity analysis. The 
associated increase in INR control for a modest increase in expenditure demonstrated 
in this study provides further evidence that optimally managed warfarin therapy 
remains a viable strategy for anticoagulation management. Therefore, pharmacist-
supervised patient self-testing should be considered as an alternative to NOACs which 
are both more expensive and not established.  
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5 - Chapter 5: Structured pharmacist 
review of medication in older 
hospitalized patients: A cost-
effectiveness analysis 
 
 
The work of this chapter has been published as Gallagher J, O'Sullivan D, McCarthy 
S, Gillespie P, Woods N, O'Mahony D, Byrne S. Structured Pharmacist Review of 
Medication in Older Hospitalised Patients: A Cost-Effectiveness Analysis. 
Drugs Aging. 2016 Feb 9. [Epub ahead of print] 
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5.1 Abstract 
Introduction 
A recent cluster randomised controlled trial (RCT) conducted in an Irish hospital 
evaluating a structured pharmacist review of medication (SPRM), supported by 
computerised decision support software (CDSS), demonstrated positive outcomes in 
terms of reduction of adverse drug reactions (ADR). The aim of this study was to 
examine the cost-effectiveness of pharmacists applying a SPRM in conjunction with 
CDSS to older hospitalised patients compared to usual pharmaceutical care.  
Method 
Cost-effectiveness analysis was based on data from a cluster RCT. The trial was 
conducted in a tertiary hospital in the south of Ireland.  The intervention arm patients 
(n=361) received a multi-factorial intervention consisting of medicines reconciliation, 
deployment of CDSS and generation of a pharmaceutical care plan.   Control arm 
patients (n=376) received usual care from the hospital pharmacy team. Incremental 
cost-effectiveness was examined in terms of costs to the healthcare system and an 
outcome measure of ADRs during an inpatient hospital stay. Uncertainty in the 
analysis was explored using a cost-effectiveness acceptability curve (CEAC). 
Results 
On average, the intervention arm was the dominant strategy in terms of cost-
effectiveness. Compared to usual care (control), the intervention was associated with 
a decrease of €807 (95% Confidence intervals (CI) -3443, 1829) (p = 0.548) in mean 
healthcare cost and a decrease in the mean number of ADR events per patient of -
0.064 (95% CI -0.135, 0.008) (p = 0.081). The probability of the intervention being 
cost-effective at respective threshold values of €0, €250, €500, €750, €1000 and €5000 
was 0.707, 0.713, 0.716, 0.718, 0.722 and 0.784.  
Conclusions 
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Based on the evidence presented, SPRM/CDSS is likely to be determined to be cost-
effective in comparison with usual pharmaceutical care. However, neither incremental 
costs nor effects demonstrated a statistically significant difference so results of this 
single site study should be interpreted with caution. 
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5.2 Introduction 
Interventions targeting medication optimisation in older persons have the potential to 
significantly improve patient outcomes and reduce unnecessary expenditure [200, 
201]. Therefore, any potential improvements in prescribing and medication use in this 
expanding group could have a substantial positive impact on resource consumption. 
 
Multiple approaches have been proposed to minimise the prevalence of inappropriate 
prescribing and preventable adverse events in older patients. Methods include 
prescriber education initiatives, use of screening tools to highlight inappropriate 
medications, medication review by health professionals and structured protocols for 
medication review [202]. A recent clinical trial which incorporates a number of these 
elements into a structured medication review programme has demonstrated promising 
clinical outcomes [203]. 
 
Medication review in a hospital setting is generally conducted on an ad-hoc basis and 
can vary depending on the experience and ability of the professional conducting the 
review [204]. The structured medication review implemented by O’Sullivan et al. was 
designed with the aim of reducing inappropriate prescribing and adverse events in a 
geriatric population. It is based on the application of a clinical decision support system 
(CDSS), which incorporates patient data from multiple sources and clinical guidelines 
[205]. Application of CDSS in a hospital setting is associated with fewer patient 
complications, lower mortality rates and lower costs [206]. However, a review of the 
evidence highlighted that CDSS does not appear to reliably prevent adverse drug 
events (ADEs) and in some instances can have a negative influence on work practices 
[207]. 
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The evidence-based guidelines included in our unique CDSS system include the 
widely used STOPP/START (Screening Tool of Older Person’s Prescriptions / 
Screening Tool to Alert doctors to Right Treatment) criteria (version 1) [208]. 
STOPP/START attempts to optimise pharmacotherapy in older patients by identifying 
medications which may be inappropriate to use (STOPP) and suggesting medications 
which patients should be receiving according to current available evidence (START) 
[209]. A recent cluster randomised controlled trial (RCT) sought to apply a structured 
pharmacist review of medication (SPRM) which was supported by CDSS. The 
intervention has demonstrated improvements in terms of adverse drug reactions 
(ADR) [203] and medication appropriateness measures [210].  
 
Uncertainty still remains around the cost-effectiveness status of medication reviews 
[80, 97] Research examining net ingredient costs within health systems is simple to 
measure and often quoted. These studies simply provide a summary of the overall cost 
of drugs based on their list prices. However, they do not offer an accurate reflection 
of changes in patient outcomes. The cost of prescribing, dispensing and monitoring 
must also be taken into consideration [211]. There is also a potential that the outcome 
of a medication review will have negative consequences for a patient.  Effectiveness 
of medication reviews can be difficult to evaluate due to the overlapping effects of 
polypharmacy and the highly complex and transient health status of patients.   
 
Prior to recommending a general adoption of any intervention, investigation of the 
economic and budgetary impact of this method is a prerequisite. Despite some 
promising evidence [203, 210], a comprehensive economic evaluation of the 
implementation of the programme has not yet been conducted. The aim of this study 
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is to perform a cost-effectiveness evaluation of the SPRM/CDSS program based on its 
application in a RCT in an older population in order to reduce in-hospital ADRs. This 
is the first economic evaluation of a programme which is based on the application of 
STOPP/START.  
 
5.3 Methods 
5.3.1 SPRM/CDSS Intervention 
Comprehensive details of this trial have been published elsewhere [203]. In summary, 
the RCT was conducted in an 810 bed teaching hospital in Ireland between June 2011 
and June 2012. This trial was cluster-randomized with consultants from each speciality 
represented in each trial arm. Patients were randomised into either intervention or 
control group based on the consultant with primary responsibility for their care during 
their hospital stay. The intervention arm consisted of 361 patients. Patients in the 
control arm of this study received usual pharmaceutical care (n = 376). Usual 
pharmaceutical care consisted of ad-hoc pharmaceutical review from a hospital 
pharmacist employed at the study site. This involved hospital pharmacists performing 
an unstructured pharmaceutical review with communication of any suggested 
interventions to the attending medical team via hand written notes attached to the 
patient’s hospital Kardex. In some cases, medicines reconciliation was also performed. 
The baseline characteristics of the recruited patients are presented in Table 5.1. No 
significant differences existed between the groups in terms of age, sex, functional 
status, cognitive function or number of medications at entry to the study.  
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Table 5.1  Baseline characteristics of patients in the randomised controlled trial. 
Variable Measure Intervention (n = 
361) 
Control (n = 376) 
Age  Median (IQR) 77(71-83) 78 (72-84) 
Male n (%) 180 (49.9%) 190 (50.5%) 
Female  n (%)  181 (50.1%)  186 (49.5%)  
Length of hospital 
stay   
Median (IQR)  8 (5 – 13.5) 9 (5 – 16) 
Hospital mortality 
rate 
n (%) 17 (4.7%) 17 (4.5%) 
Key: IQR – Interquartile range 
 
The SPRM/CDSS intervention consisted of four elements. The first of these was direct 
contact with the patient’s community pharmacy and or general practitioner in order to 
reconcile the patient’s medication history, from available medical and pharmacy 
records.  
 
The second element was deployment of the CDSS to review the patient’s list of 
medications in order to identify any drug related problems, such as incorrect drug 
omission, dosage, frequency and formulation. The CDSS also identified problems 
with drug appropriateness, non-indication, drug-drug interactions, excessive doses for 
the level of renal or hepatic impairment, potential prescribing omissions as defined by 
the START criteria [208]and potentially inappropriate prescribing (PIP) as defined by 
the STOPP [208], Beers [212] and PRISCUS criteria [213]. Potential drug-drug 
interactions in the CDSS were informed using British National Formulary 61 [214]. 
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The CDSS allowed standardization of the data collection, medication review and ADR 
detection process. 
 
Thirdly, the intervention pharmacist then reviewed CDSS output and interpreted 
which potential interventions were clinically relevant. Clinical relevance was 
informed by accounting for clinical status, number of prescription drugs and the likely 
risk: benefit ratio of each recommendation. Finally, a written pharmaceutical care plan 
was presented to the attending medical team, which decided whether suggested 
alterations would be implemented.  
 
SPRM/CDSS was applied to patient profiles within 48 hours of admission. All patients 
aged ≥ 65 years admitted under the care of the medical or surgical services through 
the emergency department were eligible for inclusion. Additional exclusion criteria 
included  i) admission to psychiatric services, intensive care unit, specialist geriatric 
or clinical pharmacology services, ii) anticipated length of stay (LOS) <48 hours iii) 
elective admission.  
 
5.3.2 Economic evaluation  
This economic evaluation consisted of a trial-based analysis conducted alongside the 
RCT. The perspective of the healthcare provider (Health Service Executive – HSE) 
was adopted with respect to trial- related costs and outcomes. Evidence on resource 
use and patient health outcomes were collected by the intervention pharmacist during 
the course of the study and retrospective review of patient medical records. The time 
horizon for this evaluation was confined to patient discharge or 10 day follow-up, 
whichever came first. This was informed by average length of stay for elderly patient 
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in the Irish hospital system [215]. The average length of stay for patients aged 65 – 74 
years is 7.9 days and 10.4 days for patients aged 75 – 84 years. The study was not 
designed to measure the medium/long term impact of this intervention. Discounting 
of costs or outcomes was not required due to the limited follow-up period. Statistical 
analysis was conducted on an intention to treat (ITT) basis, in accordance with 
guidelines for conducting cost-effectiveness analysis alongside cluster RCTs [216]. 
Missing data were not an issue in this evaluation, as follow-up was facilitated by a 
unique hospital number identifier and confined to a single centre over a short time 
period.   
5.3.3 Cost analysis 
Multiple cost components were included in the analysis and are described in Table 
5.2. Costs are expressed in euros (€) using 2012 prices (unless otherwise stated). The 
primary component was the cost of employing and training a pharmacist to implement 
the programme. We took the mid-point of the HSE pharmacist scale (new entrant) and 
adjusted according to guidelines for conducting economic evaluation in Ireland [217, 
218]. Salary was adjusted for employers’ insurance cost, pension payments and 
general overheads. Based on discussion with the intervention pharmacist, it was 
agreed that one hour was an appropriate duration to assign for pharmacist time spent 
implementing the intervention.  
 
The second component consisted of the associated follow-up time for other healthcare 
professionals to implement the suggested interventions. Costs associated with 
physician and nurse review of pharmaceutical care plan were included. Expert 
guidance dictated that it would take approximately 5 minutes for both physician and 
nurses respectively to review written communication and approve or reject suggested 
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interventions. The mid-point on the specialist registrar scale was used in cost-analysis. 
Nursing salary was based on the cost of a senior staff nurse.  
 
The third major component was the cost of a hospital inpatient stay; this cost was 
obtained from aggregated national data [219]. In general, micro-costing estimates of 
patient estimates are preferable. However in the context of this piece of research a 
broader cost like the diagnosis-related group cost, is a justifiable choice as patients are 
admitted due to a diverse range of primary indications. The fourth component 
consisted of the support structures necessary to implement the intervention including 
software and training required to implement SPRM / CDSS. 
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Table 5.2  Costs associated with care of patients 
Cost Component Unit Cost Description  Reference 
Pharmacist  €40.00 Per application of 
SPRM/CDSS  
HSE Salary Scales 
[218] 
Non-consultant 
hospital doctor 
€5.06 Per review of 
pharmaceutical care plan 
HSE Salary Scales 
[218] 
Senior staff nurse €3.55 Per review of 
pharmaceutical care plan 
HSE Salary Scale 
[218] 
Inpatient day €850.00 Cost of care per hospital 
in patient day  
HSE Inpatient 
Ready Reckoner 
[155] 
Software costs €1000.00 One off installation of 
software programme 
Investigator 
estimate 
Training costs €2000.00 Training costs of trial 
pharmacist 
Investigator 
estimate 
Key: SPRM - Structured pharmacist review of medication; CDSS - Computerised decision support 
software; HSE – Health Service Executive 
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5.3.4 Effectiveness analysis 
It has been established that conducting economic evaluation based on data from RCTs 
is a suitable methodology [220]. ‘This approach has dual advantages; first, internal 
validity is maintained due to the comprehensive nature of data collection during the 
trial; second, there is a modest marginal cost associated with collecting required data 
alongside a trial which is predominantly clinically orientated [220].  
 
While a cost-utility analysis with a health-related outcome measure is recommended 
as the reference case in Ireland [217], it was not a realistic outcome measure for this 
study. The population under consideration has multiple co-morbidities and often an 
initially poor health status. Therefore health-related quality of life (HRQoL) is 
inappropriate in this case [221].  The primary outcome measure of this RCT was the 
difference in the proportion of patients in the two groups who experienced a non-trivial 
ADR during the course of their hospital stay. ADRs were identified by a trained 
clinical pharmacist and verified by a physician. A comprehensive description of ADR 
identification and outcomes is provided elsewhere [203]. 
 
5.3.5 Cost-effectiveness analysis 
Techniques were adopted to account for the effect of clustering and correlation of cost 
and effect data collected alongside cluster RCTs. Cost-effectiveness analysis was 
presented in the form of an incremental cost-effectiveness ratio (ICER). An ICER is 
an additional cost per unit effect, in the case of this study, the cost of preventing an 
additional non-trivial ADR in hospital. In an economic evaluation, one treatment or 
method is considered more cost-effective than its comparator if it meets one of the 
following conditions [69]; 
 a) Less costly and more effective; 
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 b) More costly but more effective, with an ICER which is considered acceptable by 
decision makers;  
c) Less costly and less effective, but the additional cost per unit of effect of its 
comparator is not considered worth paying by decision makers.  
 
While threshold ICER values exist for some generic measures of health (eg cost per 
quality-adjusted life year (QALY)), acceptable values for cost per ADR prevented 
have not yet been proposed. In this paper, we examine a number of hypothetical 
thresholds.  
 
Incremental analysis was undertaken using a multilevel mixed-effect regression model 
for both cost and effect data. The model was designed to control for treatment arm, 
age, sex, number of medications at admission and consultant (cluster group).  This 
form of regression analysis is appropriate for normal and non-normal distributional 
forms of clustered data [222]. Regression for total costs was estimated using multilevel 
mixed-effects linear regression models; while regression for ADR event used mixed 
effect logistic regression models.  
 
The estimated treatment arm effects represent the difference in means for control 
patients compared with intervention patients, with 95% confidence intervals and p-
values reported to examine the statistical significance of these coefficients based on 
standard errors estimated using the mixed command in STATA 13. 
 Uncertainty in the analysis was addressed by estimating confidence intervals and a 
cost-effectiveness acceptability curve (CEAC), which link the probability of a 
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treatment being cost-effective to a range of potential threshold values (λ) that the 
health system may be willing to pay for an additional unit of effect [223].  
 
Nonparametric bootstrapping with 1,000 replications was conducted on the difference 
in mean costs and mean ADR events to generate ICER replicates. The ICER replicates 
were used to generate a CEAC [224]. Analysis was performed using STATA (IBM 
SPSS Statistics 22) and Microsoft Excel (2010). A scenario analysis was performed 
which varied the time required by all healthcare professionals to complete intervention 
by +/- 50%. 
5.3.6 Guidelines and ethical considerations 
This manuscript followed the CHEERS guidelines for reporting health economic 
evaluations [98]. A completed CHEERS checklist details compliance with 
guidelines (Appendix 10.6). Original clinical cluster randomised trial conformed to 
Consolidated Standards of Reporting Trials (CONSORT) guidelines [216]. The 
biomedical ethics committee (institutional review board) of the University College 
Cork teaching hospital network approved the trial protocol and the trial was 
registered with the United States National Institutes of Health (NCT01467128 - 
http://clinicaltrials.gov/show/NCT01467128). Written consent was sought and 
obtained from all participating patients, prior to enrolment in the study. Approval for 
an ethical amendment submission was received for research presented in this 
manuscript from the Clinical Research Ethics Committee Of The Cork Teaching 
Hospitals.  
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5.4 Results 
There were no significant demographic differences between the two treatment arms. 
Fifty-six percent of patients in usual care received some form of pharmacist review of 
medication. Demographic analysis is presented in the original RCT paper [203]. 
SPRM/CDSS strategy was dominant in comparison to usual pharmaceutical care. It 
showed improved outcomes in terms of ADRs experienced, alongside a reduction in 
associated costs, see Table 5.3. The mean cost of caring for an intervention patient 
during a single admission was €13250 (standard deviation (SD) €15530). The control 
group showed a mean cost of care of €15465 (€19310). Median costs also favoured 
intervention arm (€8954) in comparison with usual care (€10029). Following 
application of a multi-level mixed effects model in STATA and accounting for 
baseline differences across groups, the adjusted incremental difference in costs of -
€807 was non-significant.  
 
The effectiveness measures similarly favoured the intervention strategy.  The odds 
ratio for experiencing an ADR was 0.655 when comparing SPRM/CDSS to usual care. 
This related to an adjusted difference in mean number of ADRs of -0.064, (95% CI = 
-0.135, 0.008, p = 0.081).  
 
As both mean health costs and outcomes scores favoured the intervention arm of trial, 
it was unnecessary to calculate an ICER. It can be stated that SPRM/CDSS was 
dominant to usual care during the course of this RCT. However, as with all attempts 
to calculate the cost-effectiveness of an intervention, there is a degree of uncertainty 
surrounding this outcome. Even if the healthcare payer was unwilling to pay any 
money for the prevention of an ADR, the intervention strategy is still likely to be cost-
effective (probability of being determined cost-effective = 0.707) (Table 5.4). 
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Table 5.3  Incremental cost effectiveness analysis 
 Intervention (n = 361) Control (n = 376) 
Cost analysis 
Total cost (€)   
    Mean (SD) 13,250 (15,530) 15,465 (19,310) 
    Median (IQR) 8,954 (5,618 – 
14,515) 
10,029 (5,572 – 17,830) 
 
Effectiveness analysis 
Total ADRs [n (%)] 50 (13.85) 78 (20.74) 
ADRs per patient [n (%)]   
    0 311 (86.15) 298 (79.26) 
    1 40 (11.08) 66 (17.55) 
    2 9 (2.49) 12 (3.19) 
    3 1 (0.28) 0 (0.00) 
ADRs per patient [mean 
(SD)] 
0.169 (0.456) 0.242 (0.503) 
 
Incremental analysis Intervention vs control 
Difference in mean total 
costs 
−807 (95% CI −3443, 1829); p = 0.548 
 Difference in odds ratio 
for ADR events 
0.655 (95% CI 0.431, 0.994); p = 0.047 
 Difference in mean 
ADR events (n)    
−0.064 (95% CI −0.135, 0.008); p = 0.081 
Notes:  
1. Reported estimates for incremental differences in costs and effects adjusted to account for baseline differences 
between groups. 
2. Regression for total costs estimated using multilevel mixed-effects linear regression models and controlling for 
treatment arm, age, sex, number of medications at admission and clustering. 
3. Regression for ADR event estimated using mixed effect logistic regression models and controlling for treatment 
arm, age, sex, number of medications at admission and clustering. 
 
Key: IQR = interquartile range; SD = standard deviation; ADR = adverse drug reaction; CI = confidence interval. 
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 Table 5.4  Threshold analysis of cost-effectiveness of intervention 
Threshold value (λ) per 
ADR averted (€) 
Probability that intervention is cost-effective 
             0 0.707 
         250 0.713 
         500 0.716 
         750 0.718 
      1,000 0.722 
      3,000 0.759 
      5,000 0.784 
    10,000 0.833 
    20,000 0.878 
    25,000  0.898 
    50,000 0.918 
1. Probabilities for cost-effectiveness estimated parametrically using net benefit regression models for analysis at 
each threshold value.  
Key: IQR = interquartile range; SD = standard deviation; ADR = adverse drug reaction; CI = confidence interval. 
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A graphical representation of the probability of the intervention being cost-effective 
is given in Figure 5.1. The majority of entries are in the south-east quadrant, indicating 
that the intervention group is likely to be considered cost-effective.  
 
 
Figure 5.1  Graphical representation of the incremental cost-effectiveness 
ratio of structured pharmaceutical review of medication / clinical decision 
support system in comparison with usual care.  
Key: ADR – Adverse drug reaction. 
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Scenario analysis demonstrated that if healthcare professional time associated with 
intervention was increased by 50% , SPRM/CDSS remained the dominant strategy as 
seen below in Table 5.5. 
Table 5.5  Scenario analysis 1:  50% increase in healthcare 
professional time 
 Incremental Analysis 
Intervention  versus Control 
Incremental Cost: Total Cost 
Difference in Mean (95% CI’s) (p-value) 
 
-760 (-3466, 1804) (0.537) 
Incremental Effect: No. of ADR Events 
Difference in Mean (95% CI’s) (p-value) 
 
-0.064 (-0.135, 0.008) (0.081)  
Incremental cost-effectiveness ratio SPRM/CDSS dominant 
 
SPRM remained dominant when healthcare profession time was reduced by 50%, see 
Table 5.6. 
Table 5.6 Scenario analysis 2:  50% decrease in healthcare professional 
time 
 Incremental Analysis 
Intervention  versus Control 
Incremental Cost: Total Cost 
Difference in Mean (95% CI’s) (p-value) 
 
-830 (-3466, 1804) (0.537) 
Incremental Effect: No. of ADR Events 
Difference in Mean (95% CI’s) (p-value) 
 
-0.064 (-0.135, 0.008) (0.081)  
Incremental cost-effectiveness ratio SPRM/CDSS dominant 
 
 
The overall cost of applying the intervention to a group of 361 patients was estimated 
to be approximately €20000 or €55 per patient. The majority of the SPRM/CDSS 
intervention costs were associated with the cost of the trial pharmacist’s time in 
conducting the intervention (€40 per patient). Length of stay in the hospital was 
responsible for the majority of the cost associated with management in both arms. The 
majority of the SPRM/CDSS intervention costs were associated with the cost of the 
trial pharmacist’s time in conducting the intervention (€40 per patient). 
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5.5 Discussion 
Combining a CDSS with a medication review incorporating STOPP/START is likely 
to be cost-effective. This is predominantly based on the premise that even at a €0 
threshold; the probability of the intervention being cost-effective is 0.707. The 
probability of the intervention being cost-effective, increases to 0.759 if a €3,000 
threshold is applied. The thresholds applied were arbitrary but when one considers that 
the mean cost associated with a single ADR event has been estimated at €2250 [225], 
the threshold values presented in Table 5.4 are a reasonable measure of what could be 
considered value for money. Similar increases in the cost of care could be imputed 
from this study, as patients who experienced a suspected ADR had their average length 
of stay increased by three days [203]. 
 
ICER results are not presented in the regular form of cost per additional unit of health. 
Our results show that SPRM / CDSS is likely to result in reduced costs and improved 
health outcomes. If it were to be plotted on an ICER plane, it would be located in the 
“south-east” quadrant. It is possible to represent this in ICER traditional terms; 
however it would be a “negative ICER”. This is ambiguous as a “negative ICER value” 
would also be possible with a method of care that cost more but resulted in reduced 
health outcomes, i.e. was plotted in the “north-west” quadrant. When a cost-
effectiveness analysis finds that option A is associated with decreased costs and 
increased health outcomes compared with option B, it is considered more practical to 
state that option A is dominant in comparison with option B.. Therefore, we have 
stated in our results section that SPRM/CDSS intervention was dominant in 
comparison to usual care in the context of this randomised controlled trial. 
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This is the first study to evaluate the economic impact of a novel SPRM/CDSS based 
intervention. The CDSS element of the intervention was highly influenced by the 
application of the STOPP/START criteria. We are unaware of any study which has 
included the practical application of the STOPP/START criteria as part of a 
comprehensive cost-effectiveness evaluation. Since their development in 2008, 
STOPP/ START criteria have become a widely used method of identifying and 
improving instances of potentially inappropriate prescribing. This study provides 
further evidence for the adoption of STOPP/START guidelines as a fundamental part 
of any healthcare review conducted by a healthcare professional in an older 
population.  
 
The principal barrier to the application of SPRM/CDSS at a wider level is capacity. 
This RCT demonstrated that a single pharmacist could recruit 3 trial patients each day; 
however it should be noted that the pharmacist in question was not employed on a full-
time basis applying SPRM/CDSS interventions to patients. If all older hospitalised 
patients are to receive this method of care, increased pharmacy staff numbers will be 
required. However, we believe that this will be a worthwhile investment, since 
healthcare payers will likely be rewarded in the form of substantial cost avoidance 
from a reduction in ADRs. Previous reviews have concluded that for every €1 invested 
in clinical pharmacy services, a saving of €4.80 is achieved [95]. Furthermore a 
correlation exists between increased clinical pharmacy services/pharmacy staff 
numbers and reduced mortality [145]. 
 
The results of this study are aligned with previous evaluation of clinical pharmacist 
services. Pharmacist interventions are generally considered to be cost-effective [226], 
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however a recent Cochrane review declared that it is difficult to make a generalised 
conclusion on the efficacy of pharmacist interventions due to the heterogeneity in 
study comparison groups, outcomes and measures evaluated [227]. Moreover, a recent 
systematic review highlighted issues with the general quality of economic evaluations 
of pharmacist interventions from a health economic perspective [226]. The present 
study has implemented recommendations from the CHEERS statement to ensure that 
this manuscript presents a transparent high quality evaluation.   
 
It has been established that conducting economic evaluation based on data from RCTs 
is a suitable methodology [220]. This approach has dual advantages; internal validity 
is maintained due to the comprehensive nature of data collection during the trial. 
Furthermore, there is a modest marginal cost associated with collecting required data 
alongside a trial which is predominantly clinically orientated [220]. While a cost-
utility analysis with a health-related outcome measure is recommended as the 
reference case in Ireland [217], it was not a realistic outcome measure for this study. 
The population under consideration has multiple co-morbidities and often an initially 
poor health status. Therefore health-related quality of life (HRQoL) is inappropriate 
in this case [221]. 
 
A very similar assessment to our study recently evaluated the Lund Integrated 
Medicines Management Model (LIMM), an alternative structured protocol designed 
to optimise drug treatment [228]. A modelled economic evaluation was determined to 
be dominant in comparison to usual care. The model estimated costs and utility loss 
from medication errors needing medical attention within a 3-month time period. 
Gillespie et al. evaluated a model of unstructured pharmaceutical care in older patients 
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on a hospital ward [104]. The total cost per patient in the intervention group was lower 
than the control group. Patient outcomes in terms of reduction in hospital visits and 
emergency department visits were also reported.   
 
Conversely a similar structured clinical pharmacy service in a Swedish hospital setting 
was labelled as unlikely to be cost-effective [99]. The study generated an ICER of 
€316,243 per unadjusted QALY. This highlights the effect which a small increase in 
QALY values can have on the cost-effectiveness status of an intervention or therapy. 
Reasons hypothesised for the negative verdict on cost-effectiveness included the 
previously mentioned lack of specificity associated with generic outcome measures, 
the conduct of the study in a pharmacist naïve environment with relatively 
inexperienced pharmacists and non-attendance of medical rounds by intervention 
pharmacist.  
 
It is likely that the intervention acceptance rates in our study were negatively affected 
by non-attendance of medical rounds by the research pharmacist. Similar intervention 
methods which included a pharmacist as a member of a multi-disciplinary team have 
demonstrated higher intervention acceptance rates [104, 229]. Other factors which 
have been proposed as having an influence on the acceptance rate of pharmacist 
interventions include ward type and pharmacist grade [230]. 
Methods used to investigate the economic evaluation were appropriate for the type of 
data available. Multi-level mixed effect models are a suitable method for estimating 
the incremental net benefits for a clinical trial of this nature. Clustered data can 
potentially lead to biased results [231]. Normal statistical analysis are generally 
unsuitable, however the methods employed for our analysis overcome this issue [222]. 
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These techniques account for both the clustering and correlation of cost and effect 
data.  
 
There are several limitations to the present cost-effectiveness analysis, predominantly 
relating to the extrapolation of the findings to routine clinical practice. Training costs 
and software costs were not recorded at time of event and were solely informed by 
investigator estimate It is likely that some costs associated with this intervention were 
overestimated. For example, the 1-hour period allocated to conducting the intervention 
included time required to obtain the patient’s consent to participate in the intervention. 
Since minimal time would be required to obtain patient consent for a medication 
review (if indeed this was in fact considered necessary at all), the time spent with each 
patient is likely to be less in routine practice than was estimated for this analysis.. A 
time in motion study which gathered data on healthcare professional time required to 
complete the intervention, would have reduced uncertainty surrounding this input. In 
addition, as healthcare professionals become more familiar with the application of the 
SPRM/CDSS programme, they will be able to apply it more efficiently and come to 
quicker decisions regarding the relevance of a suggested intervention. 
 
This study is based on the work of one pharmacist in a single centre. Aspects of the 
intervention which would be variable between settings include the ability of the 
pharmacist involved and the extent of the uptake of interventions by the associated 
medical team. The fact that the trial pharmacist was singularly responsible for 
determining whether an intervention is clinically relevant is a subjective decision. 
However, there are previous examples of medication optimisation due to the 
application of STOPP/START and other variations of SPRMs [209, 232].  
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Furthermore, the single study site also increases the potential for cross-over learning 
between healthcare professionals within the hospital environment. Ideally, this study 
would be conducted on a larger scale involving multiple hospital sites however this 
was not possible due to limited resources available to implement this RCT.  
 
Zermansky and Silcock have suggested a gold-standard method for economic 
evaluation for medication review [211]. Ideally, evaluation should be conducted with 
a 1 year follow-up period from a health service perspective. Health related quality of 
life should be the effectiveness measure of choice, facilitating comparison with 
established societal values.  The ideal comprehensive evaluation would be a cost-
benefit evaluation over a 5-year period from a societal perspective. It would be 
valuable to compare a number of alternative medication review strategies using these 
suggested methods.  
 
5.6 Conclusion 
Based on the information available from the corresponding RCT, a software-supported 
structured pharmacist intervention is likely to be cost-effective even if the healthcare 
payer is unwilling to assign any additional finance for the prevention of ADR. 
However, as the authors are unaware of decisions previously made based on the cost 
per ADR prevented, there is some degree of uncertainty regarding the cost-
effectiveness status of the intervention from a policy perspective. In addition, the 
difference in incremental costs and effects on an individual basis did not demonstrate 
statistical significance.  To date, medication reviews conducted by pharmacists have 
primarily received funding at a primary care level [204]. At a minimum, this study 
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further adds to the growing body of evidence that a structured form of medication 
review and reconciliation incorporating STOPP/START criteria is superior to current 
medication review based on a pharmacist’s individual clinical knowledge.  
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6 - Chapter 6: Clinical and economic 
benefits of a community pharmacy 
vaccination strategy 
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6.1 Abstract 
Introduction  
Influenza places a significant burden on healthcare systems worldwide. Seasonal 
influenza vaccination is the most effective method of preventing or reducing the 
symptoms of influenza. However, vaccination uptake rates remain below targeted 
levels, especially amongst high-risk population groups. Legislation was implemented 
in Ireland to allow pharmacists to partake in the Seasonal Influenza Vaccination 
Programme at a national level. The aim of this research is to evaluate the impact of 
introducing a pharmacist-led vaccination campaign on the Irish healthcare system. The 
clinical and economic benefit obtained by a cohort of patients who obtained an 
influenza vaccination in a pharmacy setting will be estimated. 
Method 
Data was collected from patients who availed of an influenza vaccination service 
offered by a community pharmacy chain at multiple locations in the Republic of 
Ireland during the 2013/14 influenza season. Demographic information from sample 
data was applied to national population levels. A method described by Preaud et al. 
was adapted to estimate the clinical and economic benefit gained from vaccination of 
patients by a community pharmacist in Ireland in 2013/14 [233].  
Results 
Implementation of pharmacist-led influenza vaccination has resulted in substantial 
clinical and economic benefits to the healthcare system. The majority of patients 
(64.9%) who availed of this service had identifiable influenza-related risk factors. Of 
patients with influenza-related risk factors, age ≥65 year was the most commonly cited 
risk factor. Pharmacist vaccination services averted a total of  848 influenza cases 
across all age groups during the 2013/2014 influenza season. Due to receipt of 
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vaccination in a pharmacy setting, 444 influenza-related GP visits were prevented. In 
terms of more serious influenza-associated events, 11 hospitalisations and five 
influenza-related deaths were averted. Costs averted were approximately €305,000. 
These were principally wider societal-related costs associated with lost productivity 
Conclusion 
Community pharmacy vaccination has proved to be a successful addition to the Irish 
society. Vaccination services are being predominantly utilised by patients who are 
classified as being ‘at-risk’ for influenza. The number of influenza-related events 
averted due to vaccination in a pharmacy setting is a welcome benefit to the Irish 
healthcare system, especially in winter months where services are already 
overburdened. 
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6.2 Introduction 
Influenza places a significant burden on the Irish health system. Internationally, annual 
rates of influenza illness vary between 5 – 10% in adults and 20 – 30% in children 
[234]. Irish specific data presented by the Health Protection Surveillance Centre 
indicates that during the 2013/14 influenza season 693 patients were hospitalised with 
a confirmed case of influenza [235]. In addition, 43 people were considered to have 
an influenza associated death during the same time period [235]. Similar event rates 
are replicated at a European and global level [236]. Influenza also imposes a 
substantial burden on society, in terms of loss of productive working days and overall 
increased use of healthcare resources [237].  
 
Seasonal influenza vaccination is the most effective method of preventing or reducing 
the symptoms of influenza. Influenza vaccination has been linked with a reduction in 
hospital admission by as much as 60% and a reduction in mortality of 50% [238, 239]. 
However, vaccination effectiveness varies substantially depending on circulating 
strains and host characteristics [240].  
 
The potential positive influence of seasonal vaccines is further tempered by poor 
uptake levels. It is estimated that 180 million people across the 27 EU countries are 
considered members of influenza vaccination target groups [233]. However, only 44% 
of the eligible target population is vaccinated annually [233]. Ireland is amongst the 
group of countries with suboptimal vaccination uptake levels [241]. Despite the best 
efforts of policy makers, influenza vaccination uptake rates have remained steadfastly 
below the EU recommended level of 75% [242]. Influenza vaccination uptake rates 
are currently at 59% in population over 65 years of age [243]. Vaccination coverage 
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among those with chronic medical disease is approximately 30%, one of the lowest 
uptake rates in Western Europe [244]. 
 
Comprehensive evidence is available to advocate the utility and success of pharmacist 
administered vaccination services. The service was initially provided in California in 
the early 1990s [245]. Since 2009, it has been implemented in fifty US states and other 
health systems including England, Scotland, Portugal and Canada [246]. Evidence 
supporting provision of vaccination services has been generated based on clinical data, 
economic evaluations and patient preference [247-249]. 
 
In 2011, legislation was implemented in Ireland to allow pharmacists to partake in the 
“Seasonal Influenza Vaccination Programme” at a national level [250]. Numbers of 
patients availing of this service have been steadily growing since its establishment 
[251]. While the feasibility of the system is established, limited evidence is available 
regarding whether the service is reaching patients in relevant risk groups. In addition, 
the overall benefit of the service to the health service and society in general has not 
been quantified.  
 
The aim of this research is to evaluate the impact of introducing a pharmacist-led 
vaccination campaign on the Irish healthcare system. The clinical and economic 
benefit obtained by a cohort of patients who obtained an influenza vaccination in a 
pharmacy setting will be estimated. In addition, analysis will be performed on the 
demographic details of a sample of patients who availed of community pharmacy 
vaccination services. These outcomes will provide a quantitative estimate of the 
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impact of an important community pharmacy service and will also help inform future 
public health policy decisions in the area.  
6.3 Methods 
6.3.1 Sample Data collection 
Data was collected from patients who availed of an influenza vaccination service 
offered by a community pharmacy chain at multiple locations in the Republic of 
Ireland during the 2013/14 influenza season. Pharmacists performing vaccination 
completed externally accredited training, in addition to education on internal 
operational procedures. All participating pharmacists were assessed as competent in 
undertaking the service prior to receiving authorisation. Procedures were also in place 
for dealing with potential adverse reactions to the vaccinations. 
Vaccination service had been especially targeted through various media campaigns at 
patients with the following risk factors:  
• Aged 65 and over. 
• Long-term medical condition such as diabetes, heart or lung disease. 
• Impaired immune system due to disease or treatment. 
• Body Mass Index (BMI) over 40. 
• Pregnancy (the vaccine can be given at any stage of pregnancy). 
• Residency of a nursing homes or another long-stay institution. 
• A healthcare worker. 
• A carer and  
• Regular close contact with poultry, waterfowl or pigs. 
Influenza vaccination is available free of charge in the pharmacy to patients who are 
eligible for General Medical Services (GMS) scheme or GP visit scheme. GMS 
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scheme entitles patients to free medical care (e.g. GP visits, supply of medications 
with a small patient co-payment). GP visit scheme has similar entitlements but patient 
will have greater out of pocket payments for medications. In 2013, approximately 40% 
of the population were eligible for the GMS scheme [252]. A further 3% of the 
population qualified for GP visit cards. Private patients (those not eligible for GMS or 
GP Visit schemes) are required to pay an out of pocket payment of approximately €20.  
 
Only patients who had agreed to have their information analysed by external bodies 
had their data included in this study. No patient identifiable information is presented 
in this study or was transferred to any external parties.  
6.3.2 Estimate of influenza related clinical burden 
The following formula was used to calculate the number of influenza-like events 
prevented: 
𝑁𝑁𝑜𝑜𝑁𝑁𝑃𝑃𝑁𝑁𝑃𝑃 𝑣𝑣𝑃𝑃𝑜𝑜𝑜𝑜𝑃𝑃𝑜𝑜𝑃𝑃𝑃𝑃𝑁𝑁𝑣𝑣 × 𝑅𝑅𝑃𝑃𝑃𝑃𝑁𝑁 𝑃𝑃𝑜𝑜 𝑃𝑃𝑜𝑜𝑜𝑜𝑃𝑃𝑜𝑜𝑁𝑁𝑜𝑜𝑖𝑖𝑃𝑃 𝑃𝑃𝑃𝑃𝑃𝑃𝑜𝑜𝑁𝑁𝐶𝐶𝐶𝐶 𝑥𝑥 𝑉𝑉𝑃𝑃𝑜𝑜𝑜𝑜𝑃𝑃𝑜𝑜𝑁𝑁 𝑁𝑁𝑜𝑜𝑜𝑜𝑁𝑁𝑜𝑜𝑃𝑃𝑃𝑃𝑣𝑣𝑁𝑁𝑜𝑜𝑁𝑁𝐶𝐶𝐶𝐶 
This formula was varied to account for age and risk factors. Health related outcomes 
such as GP visits, lost days at work, hospitalizations and death were then calculated 
by applying the probability of experiencing these influenza related events to the 
overall number of cases of influenza prevented. Age and risk status were accounted 
for in transition probabilities. Input data is presented in Table 6.1.  
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Table 6.1 Age specific data used to estimate clinical and economic burden 
Model Input 18 - 64 18 - 64, risk ≥65 Ref 
Patients vaccinated in 
pharmacy setting 
14154 10975 15270 Study sample 
data / PSI 
[253] 
Influenza attack rate 3.64% 3.64% 4.91% Preaud et al. 
[233] 
Probability of influenza 
related GP visit 
0.31 0.62 0.62 Prosser et 
al.[248] 
Probability of lost work 
days 
0.90 0.90 - Carrat et al. 
[254] 
Mean number of days off 
work 
4 4 - Carrat et al. 
[254] 
Annual Influenza related 
hospitalisations per 100,000 
population  
4.9 17.9 130 Preaud et al. 
[233] 
Annual influenza related 
mortality per 100,000 
population 
0 3.87 66.9 Preaud et 
al.[233]  
Vaccine effectiveness (%) 51%% 51%% 51%% CDC [255] 
Lower vaccine effectiveness 
– 95% CI (%) 
43% 43% 43% CDC [255] 
Upper vaccine effectiveness 
– 95% CI (%) 
58%% 58% 58% CDC  [255] 
 
140 
 
 
6.3.3 Economic analysis 
A method described by Preaud et al. was adapted to estimate the clinical and economic 
benefit gained from vaccination of patients by a community pharmacist in Ireland in 
2013/14 [233].  
Analysis was performed from a wider societal perspective to capture the considerable 
burden associated with influenza related work absences. Estimates for the number of 
days taken off work due to influenza were informed by a study conducted by Carrat et 
al [256]. All unit cost data were obtained from Irish sources, references are provided 
in Table 6.2. All costs are expressed in euros (€) at 2013 levels.  
Table 6.2  Influenza related unit resource use 
Resource Variable Unit  Reference 
GP Visit €50.00 ORC 
OTC Treatment €7.00 
Investigator 
estimate 
Prescription medicine €15.00 
Investigator 
estimate 
Inpatient hospitalisation for acute upper 
respiratory tract infection and influenza 
(age specific) 
- Adult, 18 – 64 
- Adult, ≥65 
€2056.80 
€3599.40 HPO 
Average wage (per day) €138 CSO Q3 2015 
ORC - Office of the Revenue Commissioners, HSE - Health Service Executive, HPSC - Health Protection 
Surveillance Centre, HPO – Healthcare Pricing Office, CSO - Central Statistics Office 
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6.3.4 Ethical Approval 
Ethics approval for the research was received from the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals and University College Cork, Ireland. All 
patient information was managed in accordance with established data protection 
procedures.  
6.4 Results 
Overall, 40,443 patients were vaccinated in a community pharmacy setting during the 
2013/2014 influenza vaccination season [253]. Demographic analysis was performed 
on a sample of 3,949 patients. This sample represented 10% of national pharmacy 
based vaccinations during the 2013/2014 influenza vaccination season. All of these 
patients had obtained vaccinations from source outlined in methods section. Figure 
6.1 provides detailed breakdown of patient demographics. Based on sample analysed, 
females, over 65 years of age, who had previously received an influenza vaccination 
were the most frequent type of user of this scheme.  
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Figure 6.1  Demographic details of sample patients accessing pharmacy 
vaccination services (n=3,949) 
 
The majority of patients (64.9%) who availed of this service had identifiable influenza-related 
risk factors. Of patients with influenza-related risk factors, age ≥65 year was the most 
commonly cited risk factor; followed by history of respiratory illness or diabetes (Figure 
6.2). A combination of risks (e.g. over 65 and concurrent respiratory illness) were recorded 
for 148 patients.  
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Figure 6.2  Risk factors analysis of pharmacist vaccinated patients (n=2561) 
 
Pharmacist vaccination services averted a total of 848 influenza cases across all age 
groups during the 2013/2014 influenza season, as described in Table 6.3. 
Unsurprisingly, patients who are over 65 years of age represented the group of patients 
who were responsible for the largest number of cases averted (n=382). A total of 1679 
days of lost productivity were averted in patients aged 18 – 64. Patients aged ≥ 65 
years of age were not included in this productivity analysis, as they were deemed 
unlikely to be in full time employment. Due to receipt of vaccination in a pharmacy 
setting, 444 influenza-related GP visits were prevented. In terms of more serious 
influenza-associated events, 11 hospitalisations and five influenza-related deaths were 
averted. 
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Table 6.3 Clinical / economic benefits of pharmacist influenza vaccination  
Category of influenza- 
related events averted 
(Based on total 
pharmacist vaccinated 
population in Ireland, 
n = 40,433) 
 18 – 64 years 
(Range) 
18 – 64 years, 
Risk (Range) 
≥ 65 years 
(Range) 
Total 
economic 
burden 
Influenza-like illness 263 (222 –299)  203 (172 – 232) 382 (322 – 435) - 
OTC Treatment  -  -  -  €5,942 
Lost days of work 946 733 - €231,346 
Influenza-related GP 
visit 
81 126 237 €22,242 
Prescription medicine 
treatment 
- - - €6,673 
Influenza-related 
hospitalisation 
0 1 10 €38,501 
Influenza-related  
mortality 
0 0 5 - 
Overall influenza 
related costs (Range) 
 €304,703 
(€256,907 - 
€343,630) 
 
Costs averted were approximately €304,000. These were principally composed of 
wider societal-related costs associated with lost productivity. Therefore, the majority 
of economic benefits were driven by patients in the 18 – 64 years age category. Elderly 
patients were responsible for the bulk of direct healthcare costs (€51,849). Due to the 
inter-seasonal variation in vaccination effectiveness, a range of averted events and 
other associated impacts is presented in Table 6.3.  
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6.5 Discussion 
Based on the study sample pharmacist-led vaccination services are being 
predominantly used by patients in ‘at-risk’ categories for influenza. Uptake of 
influenza vaccination by any patient group is to be welcomed; however engagement 
of patients in at risk categories is maximizing the benefit of the vaccination service as 
these patients are more vulnerable and more likely to have outcomes which require 
use of higher levels of healthcare resources. It is also assisting with Ireland’s aims of 
reaching EU and WHO recommended levels of vaccination for patients with risk 
factors for influenza [242].   
 
The fact that the majority of users being identified are classified as at-risk to influenza 
has been replicated elsewhere. A similar study conducted in the Isle of Wight primary 
care trust (PCT), also demonstrated that a majority of users availing of a pharmacist 
administered influenza vaccination were in an at-risk category[257]. Pharmacist 
vaccinations increased the overall patient numbers receiving vaccination in the Isle of 
Wight PCT. However, there is no evidence that availability of a pharmacist service 
has improved overeall influenza vaccination uptake levels.   
 
Pharmacist-delivered influenza vaccination numbers have increased annually since 
initiation of the scheme [251]. However, overall uptake of influenza vaccination has 
not increased in terms of percentage of patients over 65 years who are being 
vaccinated. Ireland remains below recommended vaccination levels [242]. As 
described in Figure 6.1, the majority of the patients availing of influenza vaccination 
have previously received it. While it is a positive development that evidence indicates 
a large number of patients are convinced of the benefit of vaccination and avail of 
service on a regular basis, there remains a substantial number of patients who are not 
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engaging with the service either at a pharmacy or GP level. More targeted initiatives 
need to be utilised in order to identify patients reluctant to avail of vaccination services 
and to convince them of their benefit.   
 
To date, health policy has relied on general media campaigns to attempt to increase 
influenza vaccination uptake. However, it appears that their influence has plateaued. 
The time may have come to take a different approach to patient recruitment. Utilisation 
of the proposed electronic healthcare record may offer a means to identify reluctant 
patients and consolidate resources on improving uptake rates amongst these patients. 
Electronic healthcare records have demonstrated utility amongst other populations 
reluctant to engage with vaccination [258].  
 
Considering government funding for pharmacist vaccination programme in 2013 was 
in region of €250,000 [252], the overall economic benefit to society of €305,000 is a 
satisfactory return on this investment. The majority of the economic benefit is 
composed of indirect costs benefitting the working adult population. This finding 
supports the argument that greater support should be directed towards encouraging 
vaccination amongst this category of patients. Absenteeism has been estimated to cost 
the Irish economy up to €1.5 billion annually so any reduction will be a welcome 
development to the state [259]. 
 
While direct healthcare costs may appear insignificant considering overall expenditure 
on healthcare in Ireland, these benefits should not be appraised in isolation. Influenza 
tends to reach peak levels during December / January period. This period is generally 
one where demands on the Irish healthcare system reach crisis levels [260]. The 
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prevention of influenza-like events reduces demand on hospital services at a time 
when they do not have capacity to deal with additional strains associated with 
vulnerable patients. Increased demand due to influenza-related events can affect other 
areas of the healthcare system due to cancellation of routine procedures in order to 
deal with crises events. Moreover, vaccination outcome measures evaluated in this 
study are an under estimate of the overall benefit to society as the additional benefit 
of herd immunity associated with vaccination has not been captured. 
 
Research is on-going to develop more targeted vaccinations but the continued 
antigenic drift associated with influenza strains complicates the process [261]. Both 
clinical and economic benefits are highly dependent on the effectiveness of the 
influenza vaccination, which is reflected in the large range of economic costs averted 
(€257,000 – €344,000). While awaiting developments in vaccine technology, 
increasing influenza vaccination coverage remains the best method of reducing the 
impact of influenza.  
 
While the economic and clinical benefit derived from pharmacist-led vaccination is 
currently a satisfactory addition to the Irish healthcare system, it is a resource which 
could be further developed. Currently, vaccination in pharmacies is limited to 
patients over 18 years of age. Legislation allows for pharmacist vaccination of 
patients less than 18 years of age [250]. However, healthcare payer does not 
currently provide funding for the provision of the service to cohort of patients less 
than 18 years of age. 
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The large number of patients under 65 years of age (62%) indicates that pharmacy 
could be a good location for enabling vaccination of the children of time pressurised 
working parents. Convenience of location and opening hours were the two most 
cited reasons for utilisation of pharmacy vaccination services from recent research in 
the UK [249]. Evidence also indicates that it is a cost-effective public health 
intervention [262]. In addition to reducing clinical burden of illness amongst the 
childhood population, increased vaccination of this cohort has potential to reduce 
school absenteeism and parental industrial absenteeism [263].   
 
One policy which could be considered to increase overall vaccination uptake is the 
additional provision of government funding to reduce out of pocket payments for 
patients who want to avail of influenza vaccination. Any increase in overall national 
vaccination uptake will help provide additional indirect protection to unvaccinated 
sectors, due to a reduction in risk of transmission. Research at a EU-27 level has 
indicated that if influenza vaccination was utilised by all at-risk patients versus 
current uptake levels, an additional 1.6 to 1.7 million cases would be prevented, with 
influenza-related costs averted increasing by an additional €190 -226 million 
annually [233].   
 
The success of pharmacist-provided influenza vaccinations has highlighted the 
possibility of extending the range of vaccinations which can be provided in a 
community pharmacy setting in the future. Pneumococcal and various travel 
vaccinations have been provided in a community pharmacy setting in other 
jurisdictions [264, 265]. Potential barriers to the implementation of vaccination 
services have been identified in a previous literature review [266]. The recognized 
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challenges include competent response to adverse reactions, record keeping, liability, 
legal regulations and quality of service. The clinical governance standards enacted 
during the establishment of influenza vaccination services largely overcomes these 
barriers. In addition, the evolved powers of both the Pharmaceutical Society of 
Ireland and the Health Information and Quality Authority ensure that the appropriate 
regulators are in place to assist with the development of potential future vaccination 
programmes.   
 
There is a potential for sample bias in the data collection phase. Patients were all 
attendees of the same pharmacy chain. While pharmacies were located in both urban 
and rural locations, throughout the country, sample demographic data may not be 
representative of the entire Irish population. 
 
Input data used in estimates of the clinical and economic burden averted, is sourced 
from various international sources. Influenza rates and vaccine effectiveness vary 
annually, therefore broad estimates were thought to be more appropriate to use and 
similar methodology had been employed in similar previously published studies.  
A further limitation is the exclusion of potential adverse drug reactions (ADR) 
associated with influenza vaccination from overall analysis. ADRs would not be 
expected to have a major impact on overall benefits associated with influenza 
vaccination provision. PSI evaluation of service for 2013/2014 vaccination season 
indicated 12 ADRs were reported by pharmacists [253]. None of these related to 
serious events such as anaphylaxis.  
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6.6 Conclusions 
Community pharmacy vaccination has proved to be a successful addition to the Irish 
society. Vaccination services are being predominantly utilised by patients who are 
classified as being ‘at-risk’ for influenza. The number of influenza-related events 
averted due to vaccination in a pharmacy setting is a welcome benefit to the Irish 
healthcare system, especially in winter months where services are already 
overburdened. While clinical benefit of the vaccination scheme is primarily 
experienced by older patients, working adults obtain the majority of economic 
benefit in the form of reduced out of pocket expenses and averted absenteeism from 
work. Expansion of government funding for this scheme to support additional patient 
groups and disease campaigns would result in further substantial benefits to society. 
The successful establishment of influenza vaccination services within a community 
pharmacy setting highlights that pharmacies are still a relatively untapped potential 
source within the Irish healthcare system for implementation of public health policy 
initiatives.  
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7 - Chapter 7: Systematic Review 
Update 
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7.1 Objective 
A systematic review entitled “Economic evaluation of clinical pharmacist 
interventions on hospital inpatients: a systemic review of recent literature” was 
conducted in April 2013 and published in February 2014. The objective of this 
chapter is to re-conduct the search in order to update the thesis.  
7.2 Methods 
The search used the same search terms and databases as the original searches and 
was conducted in January 2016. The publication dates of articles included in the 
search strategy ranged from January 2013 to December 2015. Eligible studies 
underwent the same quality assessments outlined in chapter 2.  
7.3 Results  
The updated search results are outlined in the below flowchart (Figure 7.1). Of 2695 
potential articles, 16 studies were eligible for inclusion. Table 7.1 provides details 
on the included studies.  
 
Antibiotic specific interventions were the most common type of clinical pharmacy 
service identified following systematic review. A total of six studies were identified, 
which highlighted various degrees of cost savings and cost avoidance, which can be 
gained from implementation of targeted antibiotic interventions [107, 267-270]. 
Specific details are given in Table 7.1. 
 
General medication optimisation interventions were identified in two studies [176, 
271].  Benefits associated with these interventions were impressive but were judged 
to be of poor quality due to the lack of available comparators.  
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Inappropriate prescribing of stress ulcer prophylaxis is a considerable burden on 
healthcare payers, Buckleyet al. and Mosavi et al  have separately described 
interventions where hospital pharmacists can lead efforts to reduce unnecessary 
expenditure in this area [272, 273].  
 
A number of more innovative speciality areas were identified. Pharmacists have 
identified niche roles for themselves in surgery[274], paediatric cystic fibrosis [275], 
intensive care[276] , infectious diseases [136], organ transplants [277] and heart 
failure[278].  
 
General IV to oral conversions, are a long established area of potential influence for 
hospital pharmacists, additional evidence relating to the topic was described by 
Hohlfelder et al [279].  
 
From a quality perspective, only two studies could be labelled as “good-quality” 
studies. Lack of comparators and disregard for costs associated with providing the 
service were once again an issue with majority of studies.  
7.4 Conclusion  
The findings of the updated systematic review were broadly in line with the 
conclusions of chapter 2 (Chapter 2, section 2.5). The majority of clinical pharmacy 
interventions provide direct cost savings or generate positive outcomes in relation to 
cost avoidance. This thesis update adds to the growing body of evidence which 
highlights the issue of poor study design from a health economic perspective. The 
vast majority of studies do not address simple but important issues such as 
quantifying the cost of providing the service.  
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A positive development is new evidence indicating that pharmacist involvement is 
improving economic outcomes in specialized care areas such as cystic fibrosis [275]. 
These studies have potential to improve chances of establishing pharmacist positions 
on specialist multidisciplinary teams.  
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Figure 7.1 Literature search method and screening results 
 
 
 
 
 
64 papers underwent full text review 
At full text review stage, 48 articles 
were excluded. Reasons for exclusion:  
- 17, non-hospital inpatient 
-11, Review / model / commentary 
-13, non-pharmacist 
-4, Non-peer reviewed journal  
-3, no economic outcome 
 
16 papers were considered eligible for 
inclusion in systematic review.  
At title review stage 
2631 results were 
reviewed.  
 
 
 
 
 
After searching databases and removal 
of duplicates, 2,695 articles were 
reviewed 
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Table 7.1  Description of studies eligible for inclusion in updated review 
 
  
First Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of study 
Maldonado et 
al. (2013) 
[277] 
Changing 
transplant 
recipient 
education and 
inpatient 
transplant 
pharmacy 
practices: Single 
centre 
perspective 
Medication 
management, 
reconciliation, 
discharge 
planning and 
patient 
education.  
USA. 628 bed 
tertiary care 
hospital with 
focus of study 
on 
interdisciplinary 
transplant care 
team 
Intervention 
group = 54 
patients. Control 
group = 60 
patients 
Cost analysis 3 years LOS, 
readmission 
rates.  
Annual cost 
savings of 
$279,180 
Fair (Missing 
cost of service) 
Retrospective 
database 
analysis 
Neville et al. 
(2013) 
[274] 
Clinical benefits 
and economic 
impact of post-
surgical care 
provided by 
pharmacists in a 
Canadian 
hospital  
Addition of 
clinical pharmacy 
services to 
general surgery 
wards. 
Medication 
management of 
surgical patients. 
Canada. 950 bed 
adult tertiary 
care hospital.  
Prospective 
observational 
study. 1097 
interventions 
evaluated.  
Cost 
avoidance 
6 months Cost avoidance 
per intervention 
$0.68–1.36 million Poor (No 
comparator) 
Prospective 
observational 
study 
Cies et al. 
(2014) [275] 
Clinical 
pharmacist 
impact on care, 
length of stay, 
and cost in 
pediatric CF 
patients 
Clinical 
pharamcist is 
responsible for 
aminoglycoside 
dosing, 
adjustments and 
monitoring.  
USA. 189 bed 
tertiary care 
childrens 
teaching 
hospital. 
Intervention 
group = 29 
patients. Control 
group = 22 
patients 
Cost analysis Intervention 
period, 
September 
2008 to May 
2009. 
Comparator 
period, 
January 2007 
to August 
2008.  
Compare the 
number of 
pediatric CF 
patients 
achieving AG 
PK/PD targets 
when therapy is 
managed by a 
clinical 
pharmacist (CP) 
versus usual 
care (UC) 
Cost saving of 
$287,877 
Fair (Missing 
cost of service) 
Retrospective 
cohort study. 
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Table 7.1  Description of studies eligible for inclusion in updated review 
 
First Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economi
c Method 
Period Outcome 
Measures 
Results Quality Type of study 
Khalili et al. 
(2013) [136] 
Evaluation of clinical 
pharmacist's 
interventions in an 
infectious diseases 
ward and impact on 
patient's direct 
medication cost 
Patient medical 
chart review and 
direct 
interventions.  
Iran. 60 bed 
infectious 
diseases 
ward.  
Post-
intervention 
group = 956. 
Pre-intervention 
group = 1040.  
Cost 
analysis 
1 year pre 
and post 
intervention. 
Direct medication 
cost for patients.  
direct 
medication cost 
per patient was 
decreased about 
3.8%. Decrease 
was non-
significant.  
Fair (Missing 
cost of service) 
Prospective, 
interventional 
study 
 
Claus et al. 
(2014) [276] 
Expected net benefit 
of clinical pharmacy 
in intensive care 
medicine: a 
randomized 
interventional 
comparative trial with 
matched before and 
after groups 
Clinical 
pharmacist 
provided 
recommendation 
on drug therapy 
and follow up 
from clinical 
pharmacist 
Belgium. 22 
bed surgical 
ICU.  
Intervention 
group =  
75patients. 
Control group = 
60 patients 
Cost-
benefit 
analysis 
April to mid 
June 2012 
Comparison of 
mean daily drug 
costs between 
patients with or 
without a clinical 
pharmacy service.  
Excluding 
outlier drugs 
mean daily cost 
per patient was 
decreased from 
€184.4 to €90.5 
(P<0.001). 
Good  Randomized 
interventional 
comparative 
trial.  
Buckley et al. 
(2015) [272] 
Impact of a Clinical 
Pharmacist Stress 
Ulcer Prophylaxis 
Management Program 
on Innappropriate Use 
in Hospitalized 
Patients. 
Clinical 
pharmacists 
initiate, modify, or 
discontinue stress 
ulcer prophylaxis.  
USA. 700 bed 
major 
academic 
medical 
centre. 
Post-
implementation 
period = 371. 
Pre-
implementation 
period = 763.  
Cost-
analysis 
October 2011 
to January 31 
2012.  
Total inpatient 
costs associated 
with acid 
suppression 
therapy.  
Pre-
implementation 
inpatient costs 
$20,052. Post-
implementation 
costs $3280. 
Estimated 
annual savings 
of >€200,000.  
Fair (Missing 
cost of service) 
Retrospective 
pre- and post- 
implementation 
study.  
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Table 7.1  Description of studies eligible for inclusion in updated review 
First Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of study 
Mousavi et al. 
(2013) [273] 
Impact of clinical 
pharmacy 
services on stress 
ulcer prophylaxis 
prescribing and 
related cost in 
patients with 
renal 
insufficiency 
Stress ulcer 
prophylaxis 
developed by 
clinical 
pharmacists.  
Iran. 60 bed 
infectious 
diseases ward.  
Post-test phase 
= 236 patients. 
Pre-test phase = 
375 patients.  
Cost 
analysis 
6 month pre-
intervention 
stage. 6 month 
post-
intervention 
stage.  
Costs due to 
innappropriate 
acid suppression 
therapy.  
67% reduction 
in cost per 
patietns of 
inappropriate 
stress ulcer 
prophylaxis.  
Fair (Missing 
cost of service) 
Pre- and post- 
intervention 
study.  
Wang et al. 
(2015) [267] 
Impact of 
pharmacist 
interventions on 
rational 
prophylactic 
antibiotic use and 
cost saving in 
elective cesarean 
section 
Pharmacists made 
recommendations 
on prophylactic 
antibiotic 
prescribing, in 
addition to 
physician 
education and 
monitoring of 
clinical records.  
China. Patients 
who underwent 
elective cesarean 
section in a 
tertiary hospital.  
197 patients 
were enrolled in 
both pre- and 
post- 
intervention 
period.  
Cost 
analysis 
 Antibiotic cost 
reduction 
Antibiotic cost 
reduction = 
$68,024. 
Cost:Benefit 
ratio = 27.23 : 1. 
Good  Pre- and post- 
intervention 
study.  
Bartlett et al. 
(2014) [268] 
Implementation 
and first-year 
results of an 
antimicrobial 
stewardship 
program at a 
community 
hospital.  
Implementation of 
an antimicrobial 
stewardship 
program by a team 
of pharmacists.  
USA. 155 bed 
hospital.  
797 
interventions 
during study 
period.  
Cost 
analysis 
Intervention 
period January - 
December 
2011.  
Antimicrobial 
acquisition costs.  
Cost savings of 
$145,353.  
Poor (Quasi-
experimental). 
Pre- and post- 
intervention 
study.  
Sallach-Ruma 
et al. (2015) 
[269] 
Correlates and 
Economic and 
Clinical 
Outcomes of an 
Adult IV to PO 
antimicrobial 
conversion 
program at an 
academic 
medical centre in 
Midwest United 
States 
Pharmacist 
initiated IV to PO 
conversions.  
USA. 635 bed 
tertiary teaching 
care center. 
237 patients Cost 
analysis  
40513 Cost savings due 
to iv to po switch.  
$5242 in 
December 2010.  
Poor (Multiple 
flaws) 
Retrospective 
observational 
study. 
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Table 7.1  Description of studies eligible for inclusion in updated review 
First Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of study 
Szkiladz et al. 
(2013) [278]  
Impact of 
pharmacy 
student and 
resident-led 
discharge 
counseling on 
heart failure 
patients 
Discharge 
counselling to 
patients provided 
by students and 
residents to patients 
with heart failure 
related symptoms 
USA. 659 bed 
tertiary care 
academic 
teaching 
hospital.  
Intervention 
group =  86 
atients. Control 
group = 94 
patients 
Cost 
avoidance  
Oct 2011 to 
March 2012 
Cost avoidance of 
medication errors 
likely to be 
prevented.  
$4241 per 
intervention 
period.  
Fair (Missing 
cost of service) 
Retrospective, 
non-randomized 
intervention 
study.  
Zhang et al. 
(2014) [107] 
Pharmacist 
interventions for 
prophylactic 
antibiotic use in 
orological 
inpatietns 
undergoing 
clean or clean-
contaminated 
operations in a 
Chinese 
Hospital  
Pharmacist 
interventions 
included real-time 
monitoring of 
medical records and 
controlling of the 
prescriptions of 
prophylactic 
antibiotics 
China. 
Tertiary 
hosptial.  
Post-
intervention 
group = 174 
patients. Pre-
intervention 
group = 196 
patients 
Cost-benefit 
analysis 
Pre-
intervention 
January 2011 
- June 2011. 
Post-
intervention 
January 2012 
- June 2012.  
Mean antibiotic 
cost savings 
$239.64 for 
intervention 
period. Benefit 
to cost ratio 
18.79 : 1 
Good Retrospective, 
pre- / post- 
interventions 
study.  
Shogbon et 
al. (2014) 
[271] 
Student 
pharmacists' 
clinical 
interventions in 
advanced 
pharmacy 
practice 
experiences at a 
community 
nonteaching 
hospital 
Interventions on 
following areas: 
Therapuetic, safety, 
quality assurance 
and education.  
USA.  2107 
interventions 
Cost analysis June 2009 - 
December 
2012 
Cost savings to 
institution 
$280297 Poor Retrospective 
database 
analysis 
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First 
Author 
(Year) 
Title Pharmacist 
Intervention 
Setting No of patients / 
Interventions 
Economic 
Method 
Period Outcome 
Measures 
Results Quality Type of study 
Gallagher 
et al. 
(2014) 
[176] 
Cost-outcome 
description of 
clinical 
pharmacist 
interventions in 
a university 
teaching 
hospital 
Clinical 
interventions 
identified 
during 
pharmacist 
chart review 
Ireland. 850 bed 
hospital site.  
4257 
interventions 
Cost 
description 
January 2012 - 
December 2012 
Cost 
avoidance 
Cost avoidance due to 
prevention of ADEs - 
€708221. Cost-benefit 
ratio 8.64 : 1.  
Poor (No 
comparator) 
Retrospective 
database 
analysis 
Tachi et al. 
(2013) 
[270] 
Impact of 
levofloxacin 
dose 
adjustments by 
dispensing 
pharmacists on 
adverse 
reactions and 
costs in the 
treatment of 
elderly patients 
Pharmacists 
evaluated 
patient kidney 
function and 
suggested 
approprieate 
doses of 
levofloxacin. 
Japan. 609 bed 
acute-care 
general hospital.  
Intervention 
group =  142 
patients. 
Control group = 
98 patients 
Cost analysis March 2011 to 
August 2011 
Cost savings 
to institution 
Intergroup difference in 
total cost per patient 
was ¥465.60.  
Fair (Missing 
cost of service) 
Retrospective 
comparative 
study.  
Hohlfelder 
et al. 
(2015) 
[279] 
Improvements 
in a program to 
convert i.v. to 
oral 
medications at 
an academic 
medical center 
Addition of 
targeted 
interventions to 
a pharmacist 
initiated iv to po 
oral conversion 
program 
USA. 793 bed 
academic acute 
tertiary hospital.  
Mean number 
of interventions: 
post 
intervention = 
57, pre-
intervention = 
25.  
Cost analysis  Post-
intervention = 
October 2014 - 
January 2015. 
Pre-intervention 
= January 2014 
- August 2014.  
Cost saving No significant 
difference in overall 
cost savings. Mean 
monthly (±SD) cost 
savings, post 
intervention = 
$2068.49±143.32 versus 
pre-intervention = 
$1276.75±1217.43 
(P=0.12). 
Fair (Missing 
cost of service) 
Before- and 
after- 
intervention 
analysis.  
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8 - Chapter 8: Thesis Discussion 
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8.1 Discussion Summary 
This thesis primarily examined the health economic impact of a series of 
interventions by pharmacists within the Irish healthcare system.  
This chapter will assess the overall implications of the evidence presented earlier in 
this thesis. Discussion will focus on the following areas: 
• Key findings from each of the research chapters, 
• Overall findings of thesis, 
• Potential impact of evidence on national policy, 
• Strengths and limitations of the evidence presented, 
• Future research and 
• Conclusion 
8.2 Summary of chapter 2 
A systematic review was conducted at the early stage of the research to provide an 
overall evidence base and structured background on the topic of health economic 
evaluations of clinical pharmacy services at a global level.  
The principal finding from the systematic review indicated that clinical pharmacist 
interventions are associated with positive economic outcomes within healthcare 
systems, a finding also reported in previous systematic reviews and in the new 
evidence produced in chapter 3 – 6 of this thesis. 
 
The second key finding related to the overall quality issues with much of health 
economic research produced in relation to pharmacy services.  This had been 
previously highlighted but it is an aspect that has not been improved upon in recent 
studies. Even with a robust study design, there is always likely to be some 
uncertainty associated with decisions on the cost-effectiveness of interventions. 
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However, greater input of health economists at an earlier point in the research 
process would assist in reducing some of the quality issues and subsequently 
increase the generalizability of the findings. Health economic expertise needs to be 
included from an early stage of the study design, rather than being seen as a ‘bolt-on’ 
after the main clinical study has been published. Greater adherence to guidance 
documents such as the ‘CHEERS’ statement utilised in this study may be beneficial. 
Similar guidance documents are commonly used in other areas of research but have 
perhaps been underutilised or under promoted in the field of health economics 
research (Chapter 2, page 60). 
 
While, similar systematic reviews have been published in the past, the current review 
does provide a timely update on the recent developments within clinical pharmacy 
services at a hospital level.  On commencement of this systematic review, the time 
period covered had not been included in a formal published review focusing on 
health economic evaluations. Subsequent reviews covering a similar time period 
have been published [96]. An ACCP-led collaborative study had a slightly wider 
remit and alternative means of assessment but came to similar conclusions relating to 
the paucity of studies which could be considered high quality in terms of health 
economic methodology [96]. Findings such as these have been discussed for over 20 
years and in multiple jurisdictions [80, 95, 96, 280]. However, based on evidence 
from chapter 2, clinical pharmacy orientated researchers have not really engaged 
with previous advice.  
 
Chapter 2 was an example of research which successfully adopted the use of 
‘CHEERS’ statement within a systematic review. This approach has been 
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subsequently used by authors of other systematic reviews [281-283] , further 
endorsing the utility of this approach. The use of the CHEERS approach enabled 
definite recommendations on research methodologies which required greater 
consideration in future clinical pharmacy studies.   
 
An update on the published systematic review has identified 16 studies of relevance 
published between 2013 and 2015. Quality assessment outcomes were similar to 
original systematic review.  
 
8.3 Summary of chapter 3 
Chapter 3 of the thesis provides detail on an article titled ‘Cost-outcome description 
of clinical pharmacist interventions in a university teaching hospital’ published in 
BMC Health Services Research [176]. 
 
This research offers an insight into the impact of pharmacist ward rounds, a 
fundamental component of a clinical pharmacy service. As they have already been 
established, to a variable degree within the Irish health system, an established data 
source was available for analysis. The most stimulating finding of the hospital 
intervention study was the sheer volume of interventions implemented by a single 
pharmacy team and the significant level of cost avoidance estimated to be generated 
as a result of their clinical interventions. While the costs averted from the study were 
based on a subjective method, the cost : benefit ratio of 8.64 : 1 indicates that this 
service would likely to be considered to be value for money even in the event that an 
ultra-conservative approach is taken to assigning ratings to various interventions 
(Chapter 3, Table 3.3) 
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Another major highlight of this study was that the impact was measured over a full 
calendar year. Other studies have attempted to measure the benefit of clinical 
pharmacist interventions over a short period and extrapolate finding over a longer 
period of time [88, 90, 147]. However, evidence provided in this study provided a 
more realistic evaluation of the impact over an entire year within a hospital 
environment.  
 
In addition, the large amount of data evaluated and Irish setting of the study has 
meant that this research has been used by multiple hospital departments in internal 
submissions for additional funding for hospital pharmacy staff.  Appendix 7 and 
Appendix 8 also outline the application of this research methodology in two other 
hospitals. Similar levels of cost avoidance were highlighted in both a national major 
paediatric tertiary referral hospital and an additional University Teaching Hospital.  
 
A limitation of Chapter 3 was the large element of unknown acceptance rates 
associated with the interventions (68.81%) (Chapter 3, Table 3.2). At an Irish 
hospital level, ward reviews conducted by pharmacists have become an established 
practice. However, evidence indicates that it can be intermittent or confined to 
certain wards or areas of the hospital [16]. As pharmacists may not get a chance to 
perform a follow-up review on the patient, it can be difficult to determine whether 
the suggested intervention was implemented. Furthermore, lack of pharmacist 
integration on core medical teams may limit the acceptance rates of suggested 
interventions.  
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Drug omissions were the most frequent intervention highlighted in chapter 3 
(Chapter 3, Table 3.5). Drug omissions have been continuously highlighted as an 
issue within the Irish hospital system. Examples have been highlighted in various 
hospitals, ranging from omissions at admission to discharge [157, 203]. The 
targeting of dedicated pharmacist staff members towards completion of medicines 
reconciliation at both entry and exit from care institutions would help to reduce this 
problem.  Establishment of similar roles in other jurisdictions have been associated 
with improved outcomes [284].   
8.4 Summary of chapter 4 
Health policy in Ireland is shifting towards a strategy promoting management of 
chronic diseases at a primary care level [39]. While it is anticipated that the majority 
of these services will be provided by GPs in purpose-built primary care centres, it is 
well documented that GPs are overworked and in short supply and the purpose-built 
centres have not yet been built. Pharmacist involvement in the management of 
chronic illness offers a partial solution to these ongoing resource issues. Chapter 4 
outlines one such example where pharmacists can have a positive impact on chronic 
disease management. Earlier research conducted by academics within the UCC 
School of Pharmacy and wider Southern Hospital Group had demonstrated the 
clinical promise of a novel form of pharmacist-led patient self-management of INR 
therapy. However, establishment of a service requires local economic data to attract 
new funding or force a revision of established funds or resources.   
 
Results outlined in chapter 4 indicate that for a marginal increase in expenditure, a 
clinically significant improvement in management of warfarin therapy is achieved. 
On a per-patient basis over a 6 month period, PST resulted in an incremental cost of 
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€59.08 in comparison to routine care. The intervention arm of care resulted in a 
significantly increased mean TTR in comparison with routine care (72% ± 19.7% vs 
59 ± 13.5%) (Chapter 4, Table 4.2). This conclusion is supported by similar results 
in all scenarios evaluated.  Research outlined in chapter 4 is the first economic 
evaluation of a pharmacist-supervised direct to patient system of INR management. 
 
A recent publication by the HSE Medicines Management Program has indicated that 
at a >70% level of TTR [285]; warfarin is the preferred method of management for 
atrial fibrillation, even in comparison to the new oral anti-coagulant agents. TTR 
level in the usual care control group evaluated in this research was 59%. The overall 
mean level of care in the community in Ireland is unknown, however evidence in this 
study indicates that care may be sub-optimal. Supporting pharmacist-led 
management of warfarin therapy would be a potential method of ensuring that 
patients receiving warfarin receive optimal care.  
 
Cost of management of a patient using PST strategy for a six month period was €226 
(Chapter 4, Table 4.2). In comparison, the net ingredient cost of six months of 
therapy with a NOAC agent ranges from €384.66 to €456.06 [193]. Previous studies 
have indicated that NOACs are cost-effective in comparison to warfarin [194]. 
However, the level of anticoagulation control demonstrated through pharmacist-
supervised patient self-testing of warfarin therapy may force a re-appraisal of these 
conclusions. 
 
Examples of variations of this service have been provided in a number of locations 
around the country. Appendix 9 of this outlines research conducted in a community 
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pharmacy which is providing a similar system of pharmacist-led anticoagulation 
control. However, the successful establishment of this service without any support 
from the HSE / DoH indicates there is a demand and capacity to deliver the service 
at a community pharmacy level.  
 
It has also formed part of various submissions by the IPU to government 
departments as an example of a service which could be provided at a community 
pharmacy level [286]. To date, the service has remained isolated to private provision 
in a handful of community pharmacies. Government funding has not yet been 
provided for either pharmacy fees or to support patient with cost of test strips or 
medical devices. Evidence described in this chapter will help ensure that informed 
decisions are made regarding the provision of the service.  
 
8.5 Summary of Chapter 5 
STOPP/START is a prescribing guideline which has generated quite a deal of 
interest at an international level in the field of geriatric pharmacotherapy research. 
The main contribution of Chapter 5 is that it is the first time the practical application 
of a structured pharmacist review of medication incorporating STOPP/START has 
been adequately examined in a cost-effectiveness analysis. Chapter 5 indicates that 
application of SPRM/CDSS is dominant in comparison to usual pharmaceutical care 
(Chapter 5, Table 5.3).  
 
Evidence provided in this thesis combined with the previous work presented by 
O’Sullivan et al [203], demonstrates that revision of service provision within Irish 
hospitals to include the intervention in Chapter 5 will not alone improve clinical 
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outcomes but also result in cost-savings directly to the healthcare payer. Compared 
to usual care, the intervention arm was associated with a reduction of €807 in mean 
healthcare costs, in conjunction with a reduction in the mean number of adverse 
events. Even at a threshold of €0, the probability of the intervention being cost-
effective was 0.707 (Chapter 5, Table 5.3). The single site nature of the study 
warrants caution when the above results are interpreted.  
 
Research presented in this chapter outlining the cost-effectiveness of a pharmacist 
medication review in a hospital setting is in concordance with a number of other 
similar pharmacist-led medication review interventions. Two Swedish-based studies 
support our findings, concluding that a structured pharmacist medication review was 
a cost-effective intervention [228, 287].  
 
Irish hospitals have moved towards a policy of activity based funding. Incorporation 
of a pharmacist-led SPRM/CDSS could have further benefits to hospital groups. 
Previously, reducing the length of stay of patients offered no financial reward 
however, new funding mechanisms will remedy that problem. If hospitals can reduce 
the incidence of adverse drug events, and thereby reduce the overall length of stay of 
patients they will improve their score in an important metric which will assist in their 
overall funding level.  It may also facilitate efficiency improvements and enable 
hospital trusts overcome capacity issues. Commencement of activity based funding 
is an opportunity to enable implementation of the interventions proposed in this 
thesis.  
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The application of this structured intervention, along with the unstructured 
interventions highlighted in Chapter 3, demonstrate the important role that 
pharmacists can have on a patient’s transition in a hospital setting from admission to 
discharge. The cost-saving nature of this intervention in comparison to ad-hoc 
pharmaceutical care, which itself is likely to be beneficial to the overall hospital 
budget based on the level of cost-avoidance generated in chapter 3, further supports 
the value of employing a large number of hospital pharmacists dedicated to 
medication optimisation.   
 
The abolition of the recruitment moratorium and move towards greater use of 
electronic health records and electronic discharge may mean that it is an opportune 
time to redesign systems to include SPRM/ CDSS as a crucial component of hospital 
medication management strategy.  
 
8.6 Summary of Chapter 6 
The final research chapter describes a relatively new community pharmacy service 
and the benefits being derived from it within the Irish health system while also 
highlighting the unfulfilled potential which could be realised if further financial 
support was forthcoming from healthcare payers.  
 
The main contribution of Chapter 6 relates to the clinical and economic benefits of a 
community pharmacy vaccination service following evaluation at a national level. 
Previous papers have provided general estimates of more broad vaccination 
strategies rather than the focusing on a pharmacist-specific vaccination campaign 
[233].  
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While previous chapters have focused on pharmacists’ skills being applied in an 
elderly or chronically ill population, this chapter is an example of the pharmacist 
offering a more public health-orientated intervention. Even with modest vaccination 
numbers, significant illness burden is prevented at higher and more expensive levels 
of care. The other notable aspect was the worthwhile contribution of pharmacist 
vaccination to the economy due to the prevention of influenza-related absences from 
employment. While clinical benefit associated with the vaccination scheme is 
primarily experience by older patients, working adults derive the majority of the 
economic benefits in the form of reduced out-of-pocket expenses and averted 
absenteeism from work (Chapter 6, Table 6.3).  
 
Another important element of the vaccination process was the effectiveness rate of 
the annual vaccination. Both clinical and economic benefits are highly dependent on 
the effectiveness of the influenza vaccination, which is reflected in the large range of 
economic costs averted, €193374 – €533,218 (chapter 6, Table 6.3). While awaiting 
developments in vaccine technology, increasing influenza vaccination coverage 
remains the best method of reducing the impact of influenza.  
 
This service has been successfully provided at a community pharmacy level for a 
number of years, demonstrating steady growth in terms of patient uptake. However, 
without further investment from healthcare payers to support vaccination in a 
broader population, the value of this service may quickly reach its limit in terms of 
numbers of patients who will avail of service. Pharmacist vaccination has much 
greater potential to help Ireland reach its overall goals of vaccination of 70% of at-
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risk patients. A recent welcome development for this service has been the 
introduction of new legislation for pharmacists to vaccinate patients against 
pneumococcal infection and shingles [288]. It remains to be seen what kind of 
assisted access patients will be provided by the state to avail of this service.  
 
8.7 Overall summary of research findings 
 A common identifiable trend across the research chapters was the level of economic 
benefit these services are / can provide to society in comparison with the investment 
cost required to provide them. The level of savings and averted costs that could be 
generated through a national application of various services evaluated or increased 
funding to provide additional support for existing services is considerable and at the 
very least this research will highlight the interventions for consideration.  
 
The burden of ADEs and the potential for pharmacists to have a positive impact in 
the area is highlighted initially in the systematic review and further developed in 
Chapters 3 and 5. The combination of ageing demographics, increased co-morbidity 
and polypharmacy ensures that greater consideration will have to be given to patient 
care pathways to ensure the negative burden of ADEs is minimized. This has been 
previously highlighted as a unique area of expertise for pharmacists and research 
provided in this thesis further documents the potential (Chapter 3, page 85) (Chapter 
5, page 128). 
 
Another trend identified across the research chapters is the minimal cost associated 
with set-up of these services. Chapter 3 requires no additional costs other than 
pharmacist time. Chapter 4 does require some initial funding for purchase of the PST 
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software and meters but once the project has been established further expenditure 
was confined to payment for pharmacy services. Chapter 5 apart from some training 
costs is reliant on pharmacist experience and availability. Flu vaccination by 
pharmacists simply requires a fee for provision of the service. The network of 
established community pharmacies provides the readymade location and willing 
workforce to implement the scheme. Expansion or implementation of these four 
services outlined in this thesis would be expected to have a minimal budget impact 
with substantial medium to long term benefits anticipated. In terms of balance, it 
should be noted that other healthcare professionals are capable of offering some of 
the services outlined. However, this thesis is focused on whether clinical pharmacy 
services are providing value for money to Irish society and will thus remain focused 
on this particular topic.  
 
Another learning element apparent from all research chapters is the urgent 
requirement for investment in IT at all levels of the healthcare system. While 
evidence presented in this thesis indicates that pharmacists having greater 
involvement in patient care is a positive development, steps must be taken to 
maintain GP oversight of the overall patient care pathway.  To ensure clinical 
governance is maintained the establishment of a functioning patient electronic health 
record is vital. As previously mentioned the application of SPRM/CDSS type 
intervention would be enhanced through the establishment of an e-prescribing 
system at all levels of care.  
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8.8 Strengths and limitations of the evidence presented 
All of the research chapters (2 – 6) outlined have generated full publications in peer-
reviewed academic publications or is currently under assessment for future 
publication. Additionally, research has been presented at multiple conferences in 
both poster and oral format (Appendix 10.1). While publication is not the definitive 
goal for investigating a problem, it is an outcome which reflects the impact of this 
thesis overall and the interest in the topic from the wider academic community.  The 
author adopted a pro-active approach to ensuring that a wider audience was made 
aware of any work undertaken (Appendix 10.1).   
 
This PhD thesis utilised a variety of rich data sources to inform the overall outcomes 
of this thesis. The findings from the influenza vaccination analysis (Chapter 6) in 
particular are based on a national based sample of the patients, facilitating an 
accurate reflection of the influenza patients who availed of the service. Cost-
effectiveness analyses (Chapters 4 and 5) were based on primary data collected from 
two randomised controlled trials. This enabled the accurate identification of resource 
use associated with both intervention and control arms. Chapter 3, an evaluation of 
the economic impact of pharmacists’ interventions was informed by direct access to 
a database outlining all recorded pharmacist interventions conducted in a major 
tertiary care centre over a 12 month period. This facilitated an appraisal of the long-
term value of the service, in comparison to previously published shorter term 
evaluations.  
 
Chapter 5 is perhaps the most comprehensive economic evaluation of a proposed 
pharmacist intervention provided in this thesis. CHEERS guidelines were adopted as 
guidance for the generation of the paper. In addition the methodologies used are 
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highly suitable for use alongside cluster RCTs. The use of multi-level mixed effect 
models are becoming a prominent method of evaluating data which may be clustered 
in nature. 
 
Individual chapters elaborate on the specific limitations of each study. On a more 
general level, while the trial-based economic evaluations (chapters 4 and 5) are an 
established and relevant form of assessment. They do give rise to their own 
methodological challenges. While datasets utilised were considered trustworthy and 
generally complete, all manually generated datasets will have some degree of 
missing data. Moreover, in the case of both the patient self-testing and medication 
review research, trial follow-up period was shorter than the period during which 
differences in health effects and use of healthcare resources between interventions 
persist; increasing the uncertainty surrounding whether investing in these 
intervention programmes would be a good use of healthcare resources over a longer 
period of time.  
 
Ireland is a country which has a health technology assessment system that favours an 
emphasis on cost-utility analysis [185]. While the primacy of QALY-based 
assessments is not universally recognised [134], the main advantage of QALY-based 
assessments is the fact that they enable comparison across different areas of the 
healthcare system. While the cost-effectiveness of the majority of services outlined 
in this thesis appear to be positive, broader decision on allocation of healthcare 
budget may be better informed by QALY-based methodology.   
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Recommendations outlined previously to incorporate health economic research early 
in a study design were not adhered to during the course of this thesis. The research 
was predominantly incorporated around retrospective evaluation of data sources or 
as an add-on to previously completed clinical trials. While chapters presented in this 
thesis were not majorly impacted by this issue, reductions in uncertainty surrounding 
some of the input data could have been reduced through earlier engagement with 
primary researchers.  
 
8.9 Impact of evidence on national policy  
This principal contribution of this thesis has been the identification of new strategies 
by which pharmacists can have a more influential role in patient care; and evidence 
which indicates that these services may have added value for the health system at 
both a clinical and economic level. The interventions evaluated in this thesis can 
have a significant impact on national health policy if implemented.  
 
Evidence generated in this thesis is being published at an opportune time. The 
current Minister of Health (at time of writing – February 2016) has indicated a desire 
to expand community pharmacy services [289]. However, any expansion of services 
will not be met with universal agreement. Other healthcare practitioners will have 
their own views on whether any expansion to the role of pharmacists should occur 
similar to the debate globally. Just because a service has been delivered elsewhere 
does not automatically mean that it will be the correct fit for a very unique healthcare 
system. The robust economic evidence generated over the course of this thesis will 
assist healthcare payers determine in an objective manner whether it is worth 
pursuing a policy of expanded clinical pharmacy care.  
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Interventions described in this thesis will influence healthcare policy decisions, 
through conference publication nationally and internationally and through peer 
reviewed publications. Fortunately, implementation of the proposed interventions 
will not require a substantial capital investment. The reallocation of funds for 
additional employment or additional payment of services, in addition to agreement of 
all stakeholders involved in the provision of care to the relevant patient group, may 
be challenging.  
 
While dissemination of research through the medium of academic journals and 
conferences is an important aspect of any research thesis, communication through 
these channels may not be reaching the correct audience if we want to see the 
research influencing policy at a national level. It is just as vital that if this research is 
to make an impact, it is brought to the attention of key decision makers within the 
healthcare system.  The author of this thesis has ensured that throughout the course 
of his research he has attempted to engage the wider pharmacy and healthcare 
community. This thesis resulted in collaboration with three major teaching hospitals, 
a national independent community pharmacy representative group and a large 
community pharmacy chain. Moreover it is the intention to submit a policy briefing 
document to the Department of Health in order to make them fully aware of the Irish 
specific evidence generated over the course of this thesis, see Appendix 12. 
 
The Pharmacy 2020 report has been cited on numerous occasions throughout this 
thesis. However, it is a document which is losing its relevance since its publication 
in 2008[9]. This has been recognised by the Pharmaceutical Society of Ireland, who 
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are in the process of commissioning a new policy document on the future of 
pharmacy in Ireland [290]. To ensure that the research can be incorporated into a 
wider pharmacy development framework, a draft copy of this thesis has been 
submitted to the working group.  For communication to a non-clinical audience, 
incorporation of health economic evidence such as  that produced in this thesis will 
assist in the decision-making process surrounding any recommendation that are 
made from report.  
 
8.10 Barriers to implementation of research  
High quality evidence alone is not sufficient to enable change of pharmacy system. 
Zellmer described a number of external barriers to the development of clinical 
pharmacy services [291]. We will now discuss these in an Irish context.  
 
The national economy in Ireland is currently in a recovery phase and any new health 
initiatives will be heavily reliant on the continued recovery of our economy [292]. It 
is possible to implement through redistribution of resources [293], but development 
of clinical pharmacy services will be much more likely to prosper with specific 
designated funding for new initiatives. Recent examples from Belgium have 
described how development of clinical pharmacy services within a hospital should 
not be predicated on receipt of new funding and can be established through 
realignment of staff within a pharmacy department [293].   
 
As outlined in the introductory chapter and in research in other jurisdictions, 
pharmacist influence on major policy decisions is arguably under-represented given  
their involvement in the overall process of medicine and health policy [294, 295]. 
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Pharmacy groups at both hospital and community level need to become better 
advocates for their profession. A coherent and realistic policy on pharmacy services 
needs to be developed and presented to wider stakeholders within the health system. 
Evidence presented in this thesis is a step in the right direction to achieve this.  
 
Any service expansion needs to incorporate the correct skill mix. It is quite easy to 
recommend that additional pharmacists should be employed in hospitals to 
implement the services outlined in chapter 3. However, the recruitment embargo 
within the healthcare system in recent years has meant that senior staff with hospital 
experience may not be available within the system to facilitate the roll out of 
additional services. The residency type training programs offered in the United 
States ensures that there is an ongoing stream of highly qualified staff available to 
take up highly skilled hospital-based roles. The redesign of pharmacist curriculum to 
include greater focus on hospital placements at an undergraduate level is a positive 
step in overcoming this problem [296]. At a community level it may be easier to 
implement services such as pharmacist vaccinations and absorb them into everyday 
workload. More complex services such as the New Medicines Service offered in the 
NHS have also being implemented without any provision of additional resources or 
reduction in other responsibilities [53].  
 
Alteration of work practices may also be required. Currently pharmacy services in 
Irish hospitals are largely confined to office hours. If pharmacy services are to become 
integral to hospital care in Ireland, negotiation with hospital pharmacists will be 
required. Significant capital investment is also needed to update pharmacy sites within 
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hospitals. They are very much antiquated environments, which do not offer sufficient 
space to facilitate even the current services provided [16].   
Whilst not necessarily a problem confined to the pharmacy department within the Irish 
healthcare system, the lack of access to IT resources or an integrated IT strategy is 
nonetheless a barrier to the development of pharmacy services and an on-going source 
of waste within the system. The on-going reliance on paper based documentation is 
responsible for a major waste of healthcare resources [297].  
8.11 Recommendations for policy implementation 
The following section proposes a five point plan which is a potential mechanism to 
develop the pharmacy profession in Ireland, incorporating evidence presented in this 
thesis and from other sources.  
1. Finalisation of Future Pharmacy Practice Project – Completion of 
evidenced based review of potential future pharmacy contribution to Irish 
healthcare system. Formal conference launch with invites sent to key 
stakeholders from a wide range of healthcare, political and public arenas. 
Public engagement plan to generate wider awareness of the potential for both 
community and hospital pharmacists to maximize health outcomes in the 
population.   
2. Implementation plan – Following an example from Northern Ireland [42]. 
Establish an implementation advisory group with members drawn from 
community, hospital, industry, academia, regulatory bodies and experts on 
implementing change at a national level. Also ensure that pharmacy 
representative groups are in alignment with overall strategy to develop 
pharmacy. Agree on timelines for achieving strategic goals.  
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3. Task force – Source seed funding from PSI to ensure that adequate resources 
can be made available to allow for a viable attempt at implementation of 
‘Pharmacy Futures’ plan. Consider employment of a team whose sole focus 
is successfully achieving objectives outlined in implementation plan. 
Continue to fund external public relations firm to assist in keeping media and 
public focus on potential for pharmacy to improve public health. This will 
increase pressure on Department of Health to engage in meaningful 
discussions with pharmacy task force regarding the future direction of 
pharmacy in Ireland.  
4. Framework agreement – This type of negotiated agreement has been in 
place for many years between the Irish Pharmaceutical Healthcare 
Association (IPHA) and the Department of Health.  IPHA agreement allows 
for projections on drug spending and savings to be made and specific budgets 
for new therapies to be made available.  Proposed pharmacy framework 
agreement would seek agreement on funding for provision of new services 
over a period 3 – 5 years. Similar initiatives have been implemented 
successfully in Australia[58]. A coherent long term strategy for pharmacy 
would reduce the possibility of disputes between DoH and community 
pharmacies, which could potentially put safety supply at risk.  
5. Multi-annual pharmacy budget – To ensure commitments made in 
framework agreement are adhered to, it is important to have guaranteed 
funding for the duration of agreement.  As payments to pharmacy are not a 
fixed expense, they have traditionally been an easy target for budgetary cuts 
[298]. Pharmacy task force should engage early with other healthcare 
professional representative groups and indeed the HSE senior leadership 
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team. All of these parties would mutually benefit from establishment of 
multi-annual budgets to allow for proper planning and implementation of 
gradual healthcare reform.  
 
8.12 Future work 
Research presented in this thesis gives rise to a number of questions which could be 
adequately addressed through future research.  
i) Qualitative interviews with senior healthcare payers to determine the 
utility of local health economic data.  
ii) Application of SPRM/CDSS intervention in a community setting. 
iii) Longer term outcomes associated with SPRM/CDSS intervention. 
iv) Economic evaluation of pharmacist-led warfarin management in 
comparison to NOACs. 
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8.13 Conclusion 
Overall, clinical pharmacy services are adding value to the Irish healthcare system, 
but provision of additional funding for new services would enable them to offer a 
great deal more.  
 
This thesis has added substantially to the overall evidence surrounding the impact of 
pharmacists within the Irish healthcare system. In the past, much of the valuable 
research produced in relation to pharmacist innovations had focused on the clinical 
elements of an intervention. This thesis has overcome a large element of the 
knowledge deficit associated with the cost analysis and cost-effectiveness of 
implementing a viable clinical pharmacy service at community and hospital level in 
Ireland.  
 
However, the scarce resources available for development within the Irish healthcare 
system will potentially be a major barrier to any further development of the 
profession. Consideration should be given to development of a framework agreement 
between pharmacist representative groups and healthcare providers to enable 
development of a coherent medium to long term development plan.  
Research and evidence presented will assist decision makers make informed decision 
about the future direction and engagement of pharmacists within the Irish healthcare 
system.  
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Clinical Pharmacists in 
an Irish Hospital Setting 
All Ireland Schools of 
Pharmacy Research 
Conference, Belfast.  
2013 Categorisation of 
Interventions made by 
Clinical Pharmacists in 
an Irish Hospital Setting 
Prescribing and research 
in medicines management 
(PRIMM), London.  
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10.1.5 Peer-reviewed conference abstract publications 
Year Title Conference 
2015 A cost-effectiveness 
analysis of hospital 
pharmacist review in 
older patients. 
ISPOR Milan – Value in 
Health 
2015 Economic evaluation of a  
randomized controlled 
trial of pharmacist-
supervised patient self-
testing of warfarin   
therapy 
ISPOR Philadelphia – 
Value in Health 
2015 Economic evaluation of a 
software-supported 
structured pharmacist 
medication review in 
hospitalised older 
patients 
HSRPP – International 
Journal of Pharmacy 
Practice 
2015 Economic evaluation of a 
randomized controlled 
trial of pharmacist-
supervised patient self-
testing of warfarin 
therapy 
HSRPP – International 
Journal of Pharmacy 
Practice 
2013 Cost-outcome description 
of clinical pharmacist 
interventions in a 
university teaching 
hospital 
ISPOR Dublin – Value in 
Health 
2013 Categorisation of 
Interventions made by 
Clinical Pharmacists in 
an Irish Hospital Setting 
PRIMM – 
Pharmacoepidimiology 
and Drug Safety 
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10.1.6 Funding awards for doctoral training 
Year Award Amount 
2015 ISPOR Student Travel Bursary €2000 
2013 Roche Diagnostics €10000 
2013 Graduate School of the College of 
Medicine and Health, University College 
Cork travel bursary to attend health 
economics training course at . 
€1000 
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10.2 Appendix 2: PHD Education and Training 
10.2.1 UCC PhD Modules 
Module title Completed Credits 
PG6001 - Scientific 
Training for Enhanced 
Postgraduate Study 
August 2013 5 credits 
PG7016 - Systematic 
review for health service 
research  
September 2013 5 credits 
ST6013 - Statistics and 
Data Analysis for 
Postgraduate Research 
Students 
July 2014 10 credits 
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10.2.2 Other short training courses  
Course title Institute / Body Completed 
Advanced cost-
effectiveness analysis  
University of York July 2013 
Discrete Event Simulation 
for Economic Analyses – 
Applications 
ISPOR Amsterdam November 2014 
Pharmacoeconomic 
Modeling - Applications 
ISPOR Amsterdam November 2014 
Introduction To Modeling ISPOR Amsterdam November 2014 
Bayesian Analysis ISPOR Philadelphia May 2015 
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10.3 Appendix 3: Systematic review search strategy 
 
Search strategy for systematic reviews 
Title: Pharmacoeconomic studies of Clinical Pharmacy Intervention: Systematic 
review (2008 – 2012) 
Time period: 01/01/2008 – 31/12/2012 
Language: English (only) 
Search completed: 25/04/2013 
Pub Med strategy: Mesh terminology was employed.  
(Drug Information Services OR Medication Therapy Management OR Drug 
toxicity OR Prescriptions OR Drug Therapy or Pharmacy Services, Hospital) 
AND 
(Cost and Cost Analysis or Economics, Pharmaceutical) 
Academic Search Complete 
((Pharmaceutical Services with following narrow terms ticked, Hospital Pharmacies, 
Medication Therapy management, Pharmacy – Information services, speciality 
Pharmacies) OR Drugs – Toxicology OR (Drug Therapy with following narrower 
items ticked, drug utilization, drugs – administration, drugs – prescribing, medication 
errors, polypharmacy, premedication.)) 
AND 
Cost effectiveness 
NHS Economic Evaluation Database:  
Used strategy described for PubMed.  
Cochrane Library: 
Used strategy described for PubMed.  
Embase 
(Drug Information OR Medication Therapy Management OR Drug toxicity OR 
Prescription OR Drug Therapy or Pharmacy Services, Hospital) 
AND 
(Economic Evaluation or Pharmacoeconomics) 
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ECONLIT 
Did not allow searching using Mesh terms and mapping was impractical. “Pharmacy” 
was only search term used. 
SOCINDEX 
(Pharmacy* or Pharmacist*) AND (Cost* or Hospital*) 
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10.4 Appendix 4: Data collection form for systematic review  
 
Trial Name: 
 
First author: 
Year of Publication: Journal Reference: 
Intervention: 
 
 
Setting of study: Sample size: 
Study period: Input costs: 
Outcome measures: 
 
 
Results: 
 
 
 
Economic method: Perspective: 
Quality of study (Reason): Type of study: 
Comparator: Characterising uncertainty: 
Population demographics: Discount rate: 
Time Horizon: Estimating resources 
and costs: 
Currency price date  
and conversion rate: 
Study parameters: 
Incremental costs and outcomes: 
Eligible for Inclusion: Reason for exclusion: 
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10.5 Appendix 5:  CHEERS Checklist  
CHEERS checklist—Items to include when reporting economic evaluations of 
health interventions.  
Section/item 
Item 
No Recommendation 
Reported on page No/ 
line No 
Title and 
abstract    
Title 1 
Identify the study as an 
economic evaluation or use 
more specific terms such as 
“cost-effectiveness 
analysis”, and describe the 
interventions compared. ___________________ 
Abstract 2 
Provide a structured 
summary of objectives, 
perspective, setting, methods 
(including study design and 
inputs), results (including 
base case and uncertainty 
analyses), and conclusions. ___________________ 
Introduction 
Background and 
objectives 3 
Provide an explicit statement 
of the broader context for the 
study.  
  
Present the study question 
and its relevance for health 
policy or practice decisions. ___________________ 
Methods 
Target 
population and 
subgroups 4 
Describe characteristics of 
the base case population and 
subgroups analysed, 
including why they were 
chosen. ___________________ 
Setting and 
location 5 
State relevant aspects of the 
system(s) in which the ___________________ 
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CHEERS checklist—Items to include when reporting economic evaluations of 
health interventions.  
Section/item 
Item 
No Recommendation 
Reported on page No/ 
line No 
decision(s) need(s) to be 
made. 
Study 
perspective 6 
Describe the perspective of 
the study and relate this to 
the costs being evaluated. ___________________ 
Comparators 7 
Describe the interventions or 
strategies being compared 
and state why they were 
chosen. ___________________ 
Time horizon 8 
State the time horizon(s) 
over which costs and 
consequences are being 
evaluated and say why 
appropriate. ___________________ 
Discount rate 9 
Report the choice of 
discount rate(s) used for 
costs and outcomes and say 
why appropriate. ___________________ 
Choice of health 
outcomes 10 
Describe what outcomes 
were used as the measure(s) 
of benefit in the evaluation 
and their relevance for the 
type of analysis performed. ___________________ 
Measurement of 
effectiveness 11a 
Single study-based 
estimates: Describe fully the 
design features of the single 
effectiveness study and why 
the single study was a 
sufficient source of clinical 
effectiveness data. ___________________ 
 11b 
Synthesis-based 
estimates: Describe fully the 
methods used for 
identification of included ___________________ 
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CHEERS checklist—Items to include when reporting economic evaluations of 
health interventions.  
Section/item 
Item 
No Recommendation 
Reported on page No/ 
line No 
studies and synthesis of 
clinical effectiveness data. 
Measurement 
and valuation of 
preference based 
outcomes 12 
If applicable, describe the 
population and methods used 
to elicit preferences for 
outcomes. ___________________ 
Estimating 
resources and 
costs 13a 
Single study-based economic 
evaluation: Describe 
approaches used to estimate 
resource use associated with 
the alternative interventions. 
Describe primary or 
secondary research methods 
for valuing each resource 
item in terms of its unit cost. 
Describe any adjustments 
made to approximate to 
opportunity costs. ___________________ 
 13b 
Model-based economic 
evaluation: Describe 
approaches and data sources 
used to estimate resource use 
associated with model health 
states. Describe primary or 
secondary research methods 
for valuing each resource 
item in terms of its unit cost. 
Describe any adjustments 
made to approximate to 
opportunity costs. ___________________ 
Currency, price 
date, and 
conversion 14 
Report the dates of the 
estimated resource quantities 
and unit costs. Describe 
methods for adjusting 
estimated unit costs to the 
year of reported costs if 
necessary. Describe methods 
for converting costs into a ___________________ 
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CHEERS checklist—Items to include when reporting economic evaluations of 
health interventions.  
Section/item 
Item 
No Recommendation 
Reported on page No/ 
line No 
common currency base and 
the exchange rate. 
Choice of model 15 
Describe and give reasons 
for the specific type of 
decision-analytical model 
used. Providing a figure to 
show model structure is 
strongly recommended. ___________________ 
Assumptions 16 
Describe all structural or 
other assumptions 
underpinning the decision-
analytical model. ___________________ 
Analytical 
methods 17 
Describe all analytical 
methods supporting the 
evaluation. This could 
include methods for dealing 
with skewed, missing, or 
censored data; extrapolation 
methods; methods for 
pooling data; approaches to 
validate or make adjustments 
(such as half cycle 
corrections) to a model; and 
methods for handling 
population heterogeneity and 
uncertainty. _______________ 
Results 
Study parameters 18 
Report the values, ranges, 
references, and, if used, 
probability distributions for 
all parameters. Report 
reasons or sources for 
distributions used to 
represent uncertainty where 
appropriate. Providing a 
table to show the input ___________________ 
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CHEERS checklist—Items to include when reporting economic evaluations of 
health interventions.  
Section/item 
Item 
No Recommendation 
Reported on page No/ 
line No 
values is strongly 
recommended. 
Incremental 
costs and 
outcomes 19 
For each intervention, report 
mean values for the main 
categories of estimated costs 
and outcomes of interest, as 
well as mean differences 
between the comparator 
groups. If applicable, report 
incremental cost-
effectiveness ratios. ___________________ 
Characterising 
uncertainty 20a 
Single study-based economic 
evaluation: Describe the 
effects of sampling 
uncertainty for the estimated 
incremental cost and 
incremental effectiveness 
parameters, together with the 
impact of methodological 
assumptions (such as 
discount rate, study 
perspective). ___________________ 
 20b 
Model-based economic 
evaluation: Describe the 
effects on the results of 
uncertainty for all input 
parameters, and uncertainty 
related to the structure of the 
model and assumptions. ___________________ 
Characterising 
heterogeneity 21 
If applicable, report 
differences in costs, 
outcomes, or cost-
effectiveness that can be 
explained by variations 
between subgroups of 
patients with different 
baseline characteristics or 
other observed variability in ___________________ 
242 
 
CHEERS checklist—Items to include when reporting economic evaluations of 
health interventions.  
Section/item 
Item 
No Recommendation 
Reported on page No/ 
line No 
effects that are not reducible 
by more information. 
Discussion 
Study findings, 
limitations, 
generalisability, 
and current 
knowledge 22 
Summarise key study 
findings and describe how 
they support the conclusions 
reached. Discuss limitations 
and the generalisability of 
the findings and how the 
findings fit with current 
knowledge. ___________________ 
Other 
Source of 
funding 23 
Describe how the study was 
funded and the role of the 
funder in the identification, 
design, conduct, and 
reporting of the analysis. 
Describe other non-monetary 
sources of support. ___________________ 
Conflicts of 
interest 24 
Describe any potential for 
conflict of interest of study 
contributors in accordance 
with journal policy. In the 
absence of a journal policy, 
we recommend authors 
comply with International 
Committee of Medical 
Journal Editors 
recommendations. ___________________ 
 
* Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value 
in health : the journal of the International Society for Pharmacoeconomics and Outcomes 
Research. 2013 Mar-Apr;16(2):e1-5. PubMed PMID: 23538200. Epub 2013/03/30. eng. 
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10.6 Appendix 6: Cheers checklist for SPRM in older hospitalized 
patients 
 
Section Item 
No 
Recommendation Completed 
Title 1 Identify the study as an 
economic evaluation or use 
more specific terms such as 
“cost-effectiveness analysis”, 
and describe the interventions 
compared 
Yes 
Abstract 2 Provide a structured summary 
of objectives, perspective, 
setting, methods (including 
study design and inputs), 
results (including base case 
and uncertainty analyses), and 
conclusions. 
 
Yes 
Introduction 
Background and objectives 3 Provide an explicit statement 
of the broader context for the 
study. 
 
Yes 
Background and objectives  Present the study 
question and its 
relevance for health 
policy or practice 
decisions. 
 
 
Methods 
Target population and subgroups 
 
4 Describe characteristics of the 
base case population and 
subgroups analysed, including 
why they were chosen. 
No 
Setting and location 5 State relevant aspects of the 
system(s) in which the 
decision(s) need(s) to be made. 
Yes 
Study perspective 6 Describe the perspective of the 
study and relate this to the 
costs being evaluated. 
Yes 
Comparators 7 Describe the interventions or 
strategies being compared and 
state why they were chosen. 
Yes 
Time horizon 8 State the time horizon(s) over 
which costs and consequences 
are being evaluated and say 
why appropriate. 
Yes 
Discount rate 9 Report the choice of discount 
rate(s) used for costs and 
Yes 
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outcomes and say why 
appropriate. 
Outcomes 10 Describe what outcomes were 
used as the measure(s) of benefit 
in the evaluation and their 
relevance for the type of analysis 
performed. 
Yes 
Measurement of effectiveness 11 a Single study-based estimates: 
Describe fully the design features 
of the single effectiveness study 
and why the single study was a 
sufficient source of clinical 
effectiveness data. 
Yes 
Measurement and valuation of 
preference based outcomes 
12 If applicable, describe the 
population and methods used 
to elicit preferences for 
outcomes. 
 
 
N/A 
Estimating resources and costs 
 
 
 
13 Single study-based economic 
evaluation: Describe 
approaches used to estimate 
resource use associated with 
the alternative interventions. 
Describe primary or secondary 
research methods for valuing 
each resource item in terms of 
its unit cost. 
Describe any adjustments 
made to approximate to 
opportunity costs. 
 
Yes 
Currency, price, date and conversion 14 Report the dates of the 
estimated resource quantities 
and unit costs. Describe 
methods for adjusting estimated 
unit costs to the year of reported 
costs if necessary. Describe 
methods for converting costs 
into a common currency base 
and the exchange rate. 
 
Yes 
Choice of model 15 Describe and give reasons for 
the specific type of decision-
analytical model used. 
Providing a figure to show 
model structure is strongly 
recommended. 
 
N/A 
Assumptions 16 Describe all structural or other 
assumptions underpinning the 
decision-analytical model. 
N/A 
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Analytical methods 17 Describe all analytical methods 
supporting the evaluation. This 
could include methods for 
dealing with skewed, missing, 
or censored data; extrapolation 
methods; methods for pooling 
data; approaches to validate or 
make adjustments (such as half 
cycle corrections) to a model; 
and methods for handling 
population heterogeneity and 
uncertainty. 
Yes 
Results 
Study parameters 18 Report the values, ranges, 
references, and, if used, 
probability 
distributions for all parameters. 
Report reasons or sources for 
distributions used to represent 
uncertainty where appropriate. 
Providing a table to show the 
input values is strongly 
recommended. 
No 
Incremental costs and outcomes 
 
19 For each intervention, report 
mean values for the main 
categories of estimated costs 
and outcomes of interest, as 
well as mean differences 
between the comparator 
groups. If applicable, report 
incremental cost-effectiveness 
ratios. 
Yes 
Characterising uncertainty 20 Single study-based economic 
evaluation: Describe the 
effects of sampling uncertainty 
for the estimated incremental 
cost and incremental 
effectiveness parameters, 
together with the impact of 
methodological assumptions 
(such as discount rate, study 
perspective). 
Yes 
Characterising heterogeneity 21 If applicable, report differences 
in costs, outcomes, or cost-
effectiveness that can be 
explained by variations 
between subgroups of patients 
with different baseline 
characteristics or other 
observed variability in effects 
that are not reducible by more 
information. 
N/A 
Discussion  
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Study findings, limitations, 
generalisability, and current knowledge 
22 Summarise key study findings 
and describe how they support 
the conclusions reached. 
Discuss limitations and the 
generalisability of the findings 
and how the findings fit with 
current knowledge.  
Yes 
Other 
Source of funding 23 Describe how the study was 
funded and the role of the 
funder in the identification, 
design, conduct, and reporting 
of the analysis. Describe other 
non-monetary sources of 
support. 
Yes 
Conflicts of interest 24 Describe any potential for 
conflict of interest of study 
contributors in accordance 
with journal policy. In the 
absence of a journal policy, we 
recommend authors comply 
with International Committee 
of Medical Journal Editors 
recommendations. 
Yes 
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10.7 Appendix 7: Economic impact of pharmacist interventions in 
University Hospital Waterford 
Background 
An analysis was conducted of the cost avoidance generated by clinical pharmacist 
interventions in University Hospital Waterford. 
Methods 
Interventions were documented by four pharmacists over a nine week period 
(13/10/2014 – 12/12/2014). The eClinical Pharmacy Suite was used to document the 
interventions. Interventions were assigned a rating, depending on the probability that 
an ADE would have occurred in the absence of the intervention. These ratings were 
then multiplied by the cost of an ADE in order to estimate cost avoidance. 
Results 
 Cost avoidance of €407,958 was generated. Cost of service was found to be 
€49,129, resulting in a net cost-benefit of €358,829 and a cost-benefit ratio of 7.3:1. 
Interventions involving dose alterations, drug omissions and requests to review 
therapy were most common.  
Cost Definition Value 
Cost Avoidance €407,958 
Cost of Service €49,129 
Net Cost-Benefit  €358,829 
Cost-Benefit Ratio  7.3 
 
Conclusion 
In this study pharmacist interventions generated substantial cost avoidance. Clinical 
pharmacist interventions are seen as a valuable service which improves medication 
safety in hospitals and reduces the number of ADEs. 
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10.8 Appendix 8: Cost avoidance generated through pharmacist 
interventions in a paediatric hospital 
 
Background 
An analysis was conducted of the cost avoidance generated through clinical 
pharmacy interventions in terms of adverse drug event (ADE) avoidance. 
Methods 
Pharmacist intervention data was gathered from 01/01/13 to 31/12/13 from a 
paediatric hospital. A cost-descriptive analysis was carried out from the data 
gathered. 
Results 
A total of 688 interventions were documented. Interventions involving dosage 
adjustments (300) were the most common. The most common drugs involved in 
interventions during the study were gentamicin sulphate and ranitidine. The majority 
of the interventions were in the areas of respiratory (149) and cardiology (127) 
medicine. Total cost avoidance was found to be €116,488.11. A cost of service of 
€10,955.82 was calculated. The study resulted in a net cost-benefit of €105,492.29. 
A cost-benefit ratio of 9.6:1 was obtained. 
Conclusions 
Substantial cost-avoidance is generated through clinical pharmacy interventions in a 
paediatric hospital. 
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10.9 Appendix 9: Evaluation of anti-coagulation services in Cloyne 
Pharmacy and a cost analysis between primary and secondary 
care anti-coagulation clinics.  
 
Aims 
To evaluate anticoagulation management services in Cloyne Pharmacy and to 
conduct a cost analysis of primary and secondary care anticoagulation clinics. 
Methods 
A two year retrospective analysis of all INR results for patients attending the 
warfarin clinic at Cloyne Pharmacy between January 2012 and January 2014 was 
conducted. Mean percentage Therapeutic Time in Range(TTR) was calculated using 
the Rosendaal method. A cost analysis was conducted to compare patient and clinic 
cost between Cloyne Pharmacy warfarin clinic and Cork University Hospital. Patient 
knowledge, satisfaction and quality of life were assessed in Cloyne Pharmacy by a 
patient questionnaire. 
Results 
Mean percentage (TTR) was calculated for 61 patients and found to be 
72.16%±15.76. Using the expert dosing system at Cloyne Pharmacy, RAID 
‘Express’ CDSS, a mean % TTR was calculated to be 76.81% for 64 patients. 
Table 1 Descriptive data from the patient questionnaire 
 Cloyne CUH 
Mean distance 
travelled(km) 
11.17 35.5 
Time for travel and 
clinic(mins) 
26.17 65.5 
Retired (%) 86.4 86.4 
Carer required (%) 33.3 33.3 
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Table 2 Clinic cost comparison between Cloyne Pharmacy and Cork 
University Hospital – Healthcare payer perspective 
 Cloyne Pharmacy Cork University 
Hospital 
Pharmacist per 15 
minutes (clinic) 
€8 - 
INR Test (Lancets and 
test strips) 
€5 €2* 
Mean number of tests 
in 6 months per 
patient 
8.48 10.7* 
Mean test cost in 6 
months 
€110.24 €21.40* 
Salary costs Included in pharmacist 
time 
€145.98* 
Total cost for 
managing a patients in 
6 months 
€110.24 €167.37 
 * - Costs calculated based on internal CUH data and expert guidance 
 
Table 3  Patient cost comparison between Cloyne Pharmacy and CUH – 
Societal perspective 
 Cloyne  CUH 
Mean TTR for 6 
months 
76.34% 59% 
Mean costs per patient 
per visit  
€33.68 €37.69 
Cost per test Included above €2 
Mean no of test per 
patient per 6 month 
8.48 10.7 
Total patient test cost 
per 6 months 
€285.62 €424.68 
Salary cost - €145.98 
Total patient cost for 6 
months 
€285.62 €570.66 
 
 
Conclusion 
Cloyne Pharmacy is adhering to anticoagulation international standards and maybe 
cost-effective in comparison with hospital-based care.  
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10.10  Appendix 10: Ethical Approval 
 
Ethics addendums were sought from and approved by the Clinical Research and 
Ethics Committee of the Cork Teaching Hospitals for chapter 3 – 5.  
Full ethical approval for chapter 6 is detailed below.  
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10.11 Appendix 11: Thesis publications 
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10.12 Appendix 12: Policy brief 
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Clinical Pharmacy Services in Ireland – A solution to our healthcare 
problems?  
Author: James Gallagher 
Affiliation: School of Pharmacy, University College Cork 
Contact: j.e.gallagher@umail.ucc.ie 
Date of issue: March 2016 
Issue 
Clinical pharmacy services have the potential to have a positive impact within the 
Irish healthcare system. However, due to budgetary constraints in recent years they 
have been the target of reduced expenditure rather than any . Healthcare systems in 
other countries have demonstrated greater use of the skills and knowledge of 
pharmacists.  
Policy implications 
The established network of community pharmacies and highly experienced and 
educated pharmacy workforce is a resource which can be utilised to greater effect.   
Pharmacists in the community pharmacy have the capacity to provide solutions to 
planned transfer of responsibility from hospitals to community settings.  
 
However, any increase in service provision by pharmacist will likely require 
additional funding. Traditionally, pharmacy services at both community and hospital 
level have been an easy place to make savings in times of budgetary crisis.  
In the short to medium term all healthcare groups are likely to seek additional 
funding. Facilitating new pharmacy staff at hospital level or additional clinical 
pharmacy services in the community will increase pressure coming from other 
groups of healthcare professional to accede to their requests. 
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Key findings 
Recently, researchers at the School of Pharmacy, University College Cork have 
conducted a series of economic evaluation of clinical pharmacy services . This 
research provides a comprehensive analysis of the clinical and economic benefits 
associated with these services. It also provides an accurate description of the costs 
associated with the provision of the described services.  
• Pharmacist interventions at a major university teaching hospital prevented 
€710,000 additional spending over a 1 year period. The cost of providing this 
service was €82,000. 
• A pharmacist-led anticoagulation management service in the community 
provides a clinically significant increase in anticoagulant control for a 
minimal increase in cost. It will cost the state an additional €60 for six 
months care using the pharmacist-supervised method in comparison to nurse-
led management in a hospital setting. Greater anticoagulation control results 
in a reduction in strokes and mortality. Implementation of this service would 
enable transfer of patient care from an outpatient hospital setting to a local 
community pharmacy.  
• A structured pharmacist review of medication in older hospitalised patients 
was shown to result in better patient outcomes at a decreased cost to the state.  
• Pharmacist vaccination services averted a total of 848 influenza cases across 
all age groups during the 2013/2014 influenza season. Due to receipt of 
vaccination in a pharmacy setting, 444 influenza-related GP visits were 
prevented. In terms of more serious influenza-associated events, 11 
hospitalisations and five influenza-related deaths were averted. Costs averted 
were approximately €305,000. 
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Recommendations 
Short term 
• Employment of chief pharmacist who will become an integral part of the 
HSE senior leadership team. 
• Engagement with HPAI / IPU representatives to development a 5 year 
framework agreement outlining plans for expenditure and service 
development. This will facilitate improved pharmacy service delivery and 
maximise patient health outcomes. 
• Explore budgetary capacity to employ a number of pharmacy specialist 
positions at hospital level to facilitate medicines optimisation for targeted 
complex patient groups (e.g. geriatric patients).  
• Increase funding of community pharmacy vaccination scheme to support 
additional at-risk groups for influenza vaccination.  
• Support pilot schemes for pharmacist-led management of anti-coagulation in 
rural areas. Provide funding for scheme to run for 3 years in order for patient 
outcomes under this form of management to be adequately assessed.  
Long term 
• Working in conjunction with IPU and the Schools of Pharmacy and within 
framework agreements, transform community pharmacies from “retail” 
orientated to the established first line choice of medicine and health 
management in a community setting. This will be a long term goal and one 
likely to necessitate repeated framework agreements in order to establish, 
implement and revise clinical pharmacy services in the community.  
Further reading 
Gallagher J., Economic evaluations of clinical pharmacy services in Ireland, PhD 
Thesis. https://cora.ucc.ie/handle/10468/140 
